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ABSTRACT

Roles of GABAB, Muscarinic and Nicotinic Receptor Signaling in the Acquisition and
Expression of Fructose and Fat-Conditioned Flavor Preferences and Acquisition of
Quinine-Conditioned Flavor Avoidances in Rats.
by
Francis M. Rotella

Advisor: Professor Richard J. Bodnar, Ph.D.

In addition to increased intake of sweet solutions by mammals, learning,
particularly classically-conditioned “Pavlovian-like” learning, also plays an important
role. An orosensory conditioned flavor preference (CFP) can be elicited by pairing one
novel flavor (conditioned stimulus, CS+) with a fructose solution and a second novel
flavor (CS-) with a saccharin solution. Rats will prefer the CS+ flavor in a subsequent 2bottle choice test with both flavors mixed in saccharin. Previous pharmacological
analyses revealed that systemic administration of dopamine (DA) D1 and D2 as well as
NMDA, but not opioid, receptor antagonists eliminated the acquisition (learning) of
fructose-CFP. Further, expression of an already-acquired fructose-CFP was significantly
reduced by systemic DA D1 or D2, but not NMDA or opioid receptor antagonists. This
dissertation research extended the pharmacological substrates of fructose-CFP by
examining whether systemic administration of muscarinic (scopolamine: SCOP) and
nicotinic (mecamylamine: MEC) cholinergic receptor antagonists, or a GABAB receptor
agonist (baclofen: BAC) affected the learning and maintenance of fructose-CFP.
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Whereas fructose-CFP acquisition was eliminated by SCOP, but not MEC or BAC,
fructose-CFP expression was only marginally reduced by SCOP, MEC and BAC.
In addition to sugars, fats can also elicit CFP by pairing two novel flavors with
different concentrations (e.g., 3.5% and 0.9%) of corn oil (CO). Previous studies
indicated that acquisition of CO-CFP was eliminated by NMDA recptor antagonistm, it
was significantly reduced by DA D1 and D2, but not opioid receptor antagonists.
Expression of CO-CFP was mildly reduced by DA D1, DA D2, NMDA or opioid
receptor antagonists. In similar fashion, the effects of SCOP, MEC and BAC were
evaluated upon acquisition and expression of CO-CFP. Interestingly, a similar pattern of
results emerged for fat-CFP as was found for fructose-CFP. Thus, whereas CO-CFP
acquisition was eliminated by SCOP, but not MEC or BAC, CO-CFP expression was
significantly but marginally reduced by SCOP, MEC and BAC.
In addition to learned preferences, a conditioned flavor avoidance (CFA) can be
produced by pairing a CS+ flavor with the bitter taste of quinine. The present studies
evaluated whether fructose-CFP, CO-CFP and quinine-CFA share common
neurochemical substrates by determining the systemic effects of DA D1 (SCH23390:
SCH), DA D2 (raclopride: RAC), NMDA (MK-801), opioid (naltrexone: NTX),
muscarinic (mAch: SCOP) or nicotinic (nAch: MEC) receptor antagonists as well as
GABAB (BAC) agonists on the acquisition of quinine-CFA. We first demonstrated that
DA D1, NMDA and opioid, but not DA D2 receptor antagonism enhanced the CFA
produced by the bitter taste of quinine, and then subsequently found that whereas MEC
and BAC enhanced this avoidance, SCOP failed to alter quinine-CFA.

vi
Therefore, this dissertation demonstrated the differential involvement of major
neurotransmitter systems in two forms of preference-based and one form of avoidancebased learning. Accordingly, whereas the acquisition of sugar- and fat-preferences is
primarily mediated by DA D1, DA D2, NMDA and mAch receptors, and their expression
is primarily mediated by DA D1, DA D2, mAch and nAch receptors, the acquisition of
quinine-avoidance is primarily mediated by DA D1, NMDA, opioid, nAch and GABAB
receptors.
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Chapter 1: Introduction
Significance and Specific Aims:
Humans and animals learn to use orosensory cues (e.g., taste, odor, texture) to signal
approach to energy-dense and nutritious substances (Capaldi, 1996; Sclafani, 1995), and
avoidance to toxic substances (Dwyer, 2011; Fanselow and Birk, 1982; Freeman and Riley,
2009). Associative learning influences food-related preferences and avoidances, dissociating
behavioral, neurochemical and neuroanatomical differences among four forms of food-related
learning: conditioned flavor preferences (CFP) promoted by either the orosensory (flavor-flavor
CFP (Sclafani and Ackroff, 1994)) or post-ingestive (flavor-nutrient CFP (Sclafani et al., 1999;
Sclafani et al., 1999)) qualities of sugars and fats, conditioned taste-aversions (CTA), elicited by
post-ingestive gastrointestinal malaise (Chambers and Bernstein, 1995; Garcia et al., 1974), or
conditioned flavor avoidances (CFA) elicited by the negative orosensory qualities of quinine
(flavor-flavor CFA (Dwyer, 2011).
One primary focus of this dissertation examines whether the pharmacological effects
affecting orosensory-mediated flavor-flavor CFP produce similar patterns of effects upon flavorflavor CFA in adult male Sprague-Dawley rats. The behavioral pharmacology mediating the
acquisition and expression of sugar (fructose) and/or fat (corn oil) flavor-flavor CFP has been
investigated using antagonists of dopamine (DA) DA D1 (SCH23390), DA D2 (raclopride), Nmethyl-D-aspartate (NMDA: MK-801), or opioid (naltrexone: NTX) receptors (Baker et al.,
2003; 2004; Dela Cruz et al., 2012a; 2012b; Golden and Houpt, 2007). The major forebrain
targets (nucleus accumbens (NAc), amygdala (AMY) and medial prefrontal cortex (mPFC) of
the meso-limbic and meso-cortical DA system originating in the ventral tegmental area (VTA)
(Swanson, 1982) have been implicated in the mediation of the orosensory and post-ingestive
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substrates of sugar-CFP (Amador et al., 2014; Bernal et al., 2008; 2009; 2010; Khaimova et al.,
2004; Malkusz et al., 2012; 2014; 2015; Touzani et al., 2008; 2009a; 2009b; 2010b). However,
the abilities of these receptor antagonists to alter the acquisition of quinine-CFA are unknown,
and are examined in the present specific aims.
A second primary focus of this dissertation examines two additional neurotransmitter
receptor systems in the acquisition and expression of fructose-CFP and fat-CFP and in the
acquisition of quinine-CFA: the cholinergic muscarinic and nicotinic receptor systems and the
GABAB receptor system. The cholinergic system, acting through muscarinic (mAch) and
nicotinic (nAch) receptor signaling, has been implicated both directly and as a modulator of
overlapping limbic and cortical DA circuits previously assessed in these flavor-flavor CFP
studies (see review: Avena and Rada, 2012). The γ-Aminobutyric acid (GABA) system, and
particularly its GABAB receptor, mediates both primary stimulatory (e.g., Ebenezer, 1995; Echo
et al., 2002; Khaimova et al., 2004; Miner et al., 2010) and inhibitory (Buda-Levin et al., 2005;
Wojnicki et al., 2006; Wong et al., 2009) behavioral effects upon food and palatable intake, and
has also been shown to mediate responses within this same limbic DA circuit (Johnson and
North, 1992).

Therefore, additional specific aims examine the pharmacodynamic roles of

GABAB, mAch and nAch receptors in mediating the associative learning processes conditioned
by either primary appetitive stimuli (e.g., sugar or fat, CFP) or primary avoidant stimuli (e.g.,
quinine: CFA) in rats.
Specific Aim 1: Will muscarinic or nicotinic cholinergic receptor antagonism mediate the
acquisition and expression of sugar (fructose)-CFP?
Previous pharmacological analyses have evaluated the neurochemical substrates of the
acquisition (learning) and expression (maintenance) of the flavor-flavor component of sugar-
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CFP. Systemic administration of either DA D1 (SCH23390) or D2 (raclopride) receptor
antagonists eliminated both acquisition and expression of fructose-CFP in real-feeding, foodrestricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker et al., 2003; Hsiao
and Smith, 1995; Yu et al., 2000a; 2000b). Subsequent studies revealed that systemic
administration of the non-competitive NMDA receptor antagonist (MK- 801) eliminated
acquisition, but not expression of fructose-CFP (Golden and Houpt, 2007). In contrast, systemic
administration of NTX, a general opioid receptor antagonist, reduced sweet intake, but failed to
alter flavor-flavor-mediated sugar-CFP (Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999).
Therefore, DA D1, DA D2, and NMDA, but not opioid receptor signaling is required for the full
learning (acquisition) and maintenance (expression) of fructose-CFP.
Evidence implicating cholinergic involvement in complex aspects of food intake appears
to be due to activity in a limbic circuit (specifically the VTA and NAc) in which cholinergic
signaling can act directly upon preferences and avoidances either in and of itself, or through
interactions with brain DA (see review: Avena and Rada, 2012). Therefore, Specific Aim 1
investigates the role of muscarinic and nicotinic cholinergic receptor signaling in mediating the
expression and acquisition of flavor preferences conditioned by fructose in rats by examining the
ability of muscarinic (scopolamine: SCOP) and nicotinic (mecamylamine: MEC) receptor
antagonists to block the expression and acquisition of fructose-CFP.
In addition to sugars, rodents are attracted to the flavor of fats (e.g., corn oil: CO) which
may be partly mediated by taste receptors for fatty acids (Ackroff and Sclafani, 2007; 2009;
Passilly-Degrace et al., 2009), as well as rewarding post-ingestive and orosensory properties, and
can condition a flavor preference (Ackroff and Sclafani, 2009; Sclafani, 1999; 2004). The second
Specific Aim addresses this corollary.
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Specific Aim 2: Will muscarinic or nicotinic cholinergic receptor antagonism mediate the
acquisition and expression of fat (corn oil)-CFP?
In contrast to fructose-CFP, systemic administration of DA D1 and D2 receptor
antagonists produced marginal reductions in the expression of fat (CO)-CFP, and DA D2, but not
DA D1 receptor antagonism hastened the extinction of fat-CFP acquisition (Dela Cruz et al.,
2012a). Further, systemic administration of NMDA receptor antagonists significantly reduced
the acquisition, but not the expression of fat-CFP. Finally, opioid receptor antagonism was
ineffective in altering this fat preference similar to that observed for fructose-CFP (Dela Cruz et
al., 2012b). Consequently, Specific Aim 2 addresses the potential involvement of muscarinic or
nicotinic cholinergic receptor signaling in a parallel paradigm employed for the assessment of
DA D1, DA D2, NMDA and opioid receptor signaling in the mediation of fat-CFP elicited by the
ingestion of a flavor (e.g., cherry) paired with a higher (3.5%) CO concentration relative to a
flavor (e.g., grape) paired with a lower (0.9%) CO concentration. This aim expands on the
behavioral pharmacological relationships of the above neurochemical substrates beyond sugar
preferences to that of fat preferences and thereby making a unifying statement about preferences
in general. Thus, it is hypothesized that both subtypes of cholinergic receptor antagonists will
influence the expression of fructose-CFP (Specific Aim 1) and fat-CFP (Specific Aim 2).
However, only antagonism of the muscarinic subtype will modulate the acquisition of fructose(Specific Aim 1) or fat- (Specific Aim 2) CFP.
The first two Specific Aims examine cholinergic receptor involvement in fructose- and
fat-CFP. The next two Specific Aims evaluate GABAB receptor involvement.
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Specific Aim 3: Does systemic pharmacological stimulation of GABAB receptors influence
the acquisition and expression of sugar (fructose)-CFP?
Studies of reward- or aversive-related learning revealed that regions within the
mesolimbic DA system (e.g., VTA) are in turn modulated by and receive inputs from a number
of other neurotransmitter systems including GABA using receptor activation rather than
inhibition in influencing reward- and/or aversive-related learning (Johnson and North, 1992; Tan
et al., 2012; van Zessen et al., 2012). Therefore, this specific aim addresses the specific effects
of GABAB receptor stimulation rather than inhibition.
There are two major receptor families for GABA: GABAA and GABAB. Systemic
administration of the GABAA receptor agonist, muscimol, interferes with memory consolidation
processes in forms of inhibitory avoidance learning (Castellano and McGaugh, 1990) and
conditioned taste aversions (DiSorbo et al., 2009). However, the timing of these effects suggests
that the effects were due to retrograde amnesic effects (Salinas and McGaugh, 1995). In these
studies, muscimol was most effective in interfering with learning when administered after the
conditioning procedures (Castellano and McGaugh, 1990; DiSorbo et al., 2009). This approach is
fundamentally different from the procedure employed in CFP studies. Further, the systemic
effects of GABAA agonism initially produce profound behavioral inhibitory effects associated
with a cataleptic state followed by periods of hyperactivity (Vyazovskiy et al., 2007), which
could potentially confound the learning effects of interest, similar to the reward-confounding
behavioral effects of DA antagonists (Wise and Schwartz, 1981). The mechanism of action of
such GABAA agonists as muscimol occurs through stimulation of ionotropic GABA receptors,
leading to a relatively quick hyperpolarization of the neuron and resulting in general depression
of neuronal activity (see review: Johnston, 2014). Moreover, central muscimol is very
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commonly used as a tool in producing generalized depression in addition to its GABAA actions.
On the other hand, GABAB agonists such as baclofen act via stimulation of metabotropic GABA
receptors, leading to a longer term cellular cascade of events resulting in a much slower
depression and modulation of neuronal (particularly DA) activity (Kuba et al., 2000).
In addition, central stimulation of both subtypes of the GABA receptor (e.g., muscimol:
GABAA and baclofen: GABAB) stimulate food intake in a receptor-specific manner (Miner et al.,
2010). However, each seem to be expressed on different clusters of neurons (Sugita et al., 1992).
Accordingly, GABAA receptors are located mainly on non-DA-containing neurons (Churchill et
al., 1992), while GABAB receptors are located mainly on DA-containing neurons (MargretaMitrovic et al., 1999; Wirtshafter and Sheppard, 2001). Given the proposed interactions between
GABA and DA in the modulation of CFP and CFA, this specific aim focuses on GABAB
signaling via systemic agonism of these receptors.
Another rationale for limiting our investigation to GABAB receptors is their specific
involvement in animal psychopathological models of food intake dysregulation (e.g., bingeeating: Berner et al., 2009; Broft et al., 2007; Buda-Levin et al., 2005; Corwin et al., 2012; de
Beaurepatre et al., 2015; Wojnicki et al., 2006). However, the effects of peripheral GABAB
receptor activation (via baclofen: BAC) on food intake vary. In non-deprived rats, increases in
food intake depend on time of consumption (Ebenezer and Patel, 2011), route of administration
(Ebenezer and Prabhaker, 2007; Patel and Ebenezer, 2008a; 2008b), and acute tolerance (Bains
and Ebenezer, 2013). In contrast, BAC can also decrease food intake in diabetic and dietinduced obese mice (Sato et al., 2007), as well as reduce intake of pure fat emulsions relative to
chow under normal, limited-access and “binge-type” conditions in rats (Buda-Levin et al., 2005;
Rao et al., 2008; Wang et al., 2011; Wojnicki et al., 2014; but see: Bains and Ebenezer, 2013)
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and suppress intake of either a pure fat or a sugar-fat mixture (Avena et al., 2014; Berner et al.,
2009; Corwin et al., 2009; Wojnicki et al., 2013; Wong et al., 2009).
Evidence implicating GABAB receptor involvement in complex aspects of food intake
appears to be due to activity in a previously mentioned limbic circuit (specifically the VTA and
NAc). Additional research suggests GABAB signaling mediates both medium spiny NAc GABA
and VTA DA outputs, possibly interacting with DA-Ach activity here (Avena and Rada, 2012;
Hoebel et al., 2007). Behavioral evidence also suggests the interaction of GABAB stimulation
and DA-Ach involvement through baclofen’s ability to reduce nicotine self-administration in
rats, in addition to being extended to glutamate (mGluR5) signaling (Markou et al. 2004).
Therefore, Specific Aim 3 examines the roles of GABAB receptor signaling by determining
whether the systemic GABAB (baclofen) receptor agonist will alter the acquisition and/or
expression of fructose-CFP in an identical paradigm employed for the assessment of Specific
Aim 1. As with the evaluation of the cholinergic system, the next Specific Aim examines
GABAB receptor involvement in fat-CFP.
Specific Aim 4: Does systemic pharmacological stimulation of GABAB receptors influence
the acquisition and expression of fat (corn oil)-CFP?
GABAB receptor stimulation has also been implicated in the mediation of fat intake. BAC
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et al., 1979;
Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993), and
was reported to be mediated through GABA receptor interactions between the VTA and NAc
(Miner et al., 2010). Systemic BAC increased fat intake under normal conditions (e.g., Bains and
Ebenezer, 2013; Ebenezer and Patel, 2011), but suppressed fat intake under “binge-type”
conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 2005; Corwin and
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Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 2009). Furthermore, the
reinforcing effects of rewards as well as cues associated with those rewards mediated by
mesolimbic circuitry is modulated by GABAB receptor stimulation in optogenetic studies of food
intake (van Zessen et al., 2012). Indeed, given that many of the animal psychopathological
studies were mimicking binge-eating with strong effects on diets containing fat, it would be
expected that BAC effects should exert more powerful effects on acquisition and expression of
fat-CFP if these learning processes are intimately related to the psychopathological model.
The first four Specific Aims relate to the second primary focus of the research. The first
primary focus addresses the question as to whether CFA might utilize the same pharmacological
systems and patterns of effects as CFP. Thus, the fifth and sixth Specific Aims examine this
possibility.
Specific Aim 5: Can DA D1, DA D2, opioid and NMDA receptors, involved in mediating
appetitive associative learning processes (e.g., sugar- and fat-CFP), similarly modulate
underlying associative processes contributing to the behavioral effects of conditioned flavor
avoidance (CFA) associative learning processes induced by primary avoidant stimuli (e.g.,
quinine, CFA)?
Flavor–taste avoidance learning occurs when an arbitrary flavor (CS, conditioned
stimulus) is paired with a naturally non-preferred taste (US, unconditioned stimulus, e.g., bitter:
quinine), and similar distinctions between flavor-flavor and flavor-nutrient processes with
respect to avoidance and aversive conditioning have been assessed. Former studies elucidating
the taste-specific (US: quinine) rather than post-ingestive (US: lithium chloride) effects of
avoidance and aversive conditioning, respectively, have suggested that it is possible for rats to
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learn to associate negative orosensory qualities (e.g., bitter) with that of neutral flavors
(Fanselow and Birk, 1982; Dwyer, 2011).
Although there is much literature elucidating the pharmacology of flavor-toxin CTA
elicited by the pairing of a neutral flavor (CS) with that of gastrointestinal malaise (US), flavor–
taste CFA learning conditioned via non-visceral US’s (e.g., taste) has not been the subject of
pharmacological analysis. Thus, Specific Aim 5 addresses this gap by examining the roles of
those pharmacological substrates assessed previously for other forms of primarily taste-mediated
learning (e.g., fructose- and fat-CFP), including DA D1, DA D2, NMDA and opioid receptor
signaling in flavor avoidance conditioned by the bitter taste of quinine. One simple hypothesis is
that pharmacological effects on CFP and CFA produce parallel effects. In this model, given that
DA D1, DA D2 and NMDA, but not opioid receptor antagonism effectively block fructose-CFP
acquisition (Baker et al., 2003; 2004; Golden and Houpt, 2007), it would be hypothesized that
blockade of DA D1, DA D2 and NMDA, but not opioid receptors would systematically reduce
the magnitude of quinine-CFA acquisition. An alternate hypothesis is that pharmacological
antagonist effects would drive CFP and CFA in the same direction. In this model, given that DA
D1, DA D2 and NMDA, but not opioid receptor antagonism effectively block fructose-CFP
acquisition, it would be hypothesized that blockade of DA D1, DA D2 and NMDA, but not
opioid receptors would systematically enhance the magnitude of quinine-CFA acquisition.
Specific Aim 6: Extending on the previous pharmacological assessments of fructose- and
fat- CFP, will muscarinic or nicotinic cholinergic as well as GABAB receptors also mediate
avoidance learning?
A.

Cholinergic receptors have also been previously implicated in certain forms of CFA such

as in lithium chloride-(LiCl) induced CFA (Coil et al., 1978; Ossenkopp and Giugno, 1990;
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Ossenkopp et al., 1986). With respect to flavor-taste CFA, avoidant tastants such as quinine
have been demonstrated to modulate Ach activity in itself (Ballestero et al., 2005) and influence
adrenal catecholamine release stimulated by Ach (Jang et al., 2001). Further, nicotine depressed
quinine-evoked responses in the nucleus tractus solitarius that were blocked by MEC (Simons et
al., 2006). Nicotine and quinine CFA generalized to each other in three mouse strains (Gyekis et
al., 2012), with MEC blocking this ability in behavioral and electrophysiological assays
(Oliveira-Maia et al., 2009).
These data appear to implicate cholinergic receptor signaling in flavor–taste CFA and
therefore Specific Aim 6 addresses the pharmacological roles of muscarinic (SCOP) and
nicotinic (MEC) receptor signaling in mediating the acquisition of quinine-induced CFA. Due to
much behavioral evidence implicating muscarinic receptor signaling in the formation of learned
associations conditioned by primary appetitive stimuli (Nisanov et al., 2016; Sharf et al., 2006;
Sharf and Ranaldi, 2006), it is hypothesized that only manipulation of the muscarinic subtype
will modulate the acquisition of quinine-CFA and that these effects will oppose those seen in
fructose-CFP studies such that muscarinic cholinergic receptor blockade will enhance the
magnitude of quinine-CFA.
B.

Furthermore, given the inconsistent effects of GABAB receptor agonism on various forms

of food-related approach type learning (Berner et al., 2009; Broft et al., 2007; Buda-Levin et al.,
2005; Corwin et al., 2012; de Beaurepatre et al., 2015; Wojnicki et al., 2006), we assess the roles
of GABAB receptor signaling in food-related avoidance type learning, thereby shedding some
light on these inconsistencies. As such, Specific Aim 6 also tests hypotheses as to the roles of
GABAB receptor signaling in the acquisition of quinine-CFA. Similar to the rationale noted in
Specific Aims 3 and 5, if GABAB receptor signaling is interacting with DA and/or muscarinic
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Ach at integral limbic sites, it is hypothesized that agonism of GABAB receptors will modulate
quinine-CFA in a manner opposite to that of DA and/or muscarinic receptor antagonism for
fructose-CFP, thereby enhancing the magnitude of quinine-CFA.
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Chapter 2: Background and Rationale
General Background:
To promote normal growth and development, humans require the intake of a multitude of
substances including carbohydrates, fats, proteins, vitamins, minerals, fiber, and water. However,
government data in 2015 indicated that the average diet was high in calories, added sugars, and
saturated fats, but low in essential nutrients such as vitamin D, calcium, potassium, and fiber
thereby posing health risks for a majority of the population (Dietary Guidelines Advisory
Committee, 2015). This factor has contributed to increases in diet-related nutrition and metabolic
disorders and diseases including obesity, type II diabetes, cardiovascular diseases and certain
cancers (Dietary Guidelines Advisory Committee, 2015).
As an example, although obesity may be due partially to genetic factors (Choquet and
Mayre, 2011), the presence of unlearned preferences and aversions (Menella and Beauchamp,
2005; Roitman et al., 2008; Sclafani, 2004), as well as the abundance of processed, energy dense
and cost-efficient, yet nutrient-sparse foods (Dietary Guidelines Advisory Committee, 2015;
Drenowski and Specter, 2004), another significant contributing factor to non-compliance with
dietary guidelines and the development of diet-based nutrition and metabolic disorders is
learning (Gibson and Brunstrom, 2007; Roitman et al., 2008; Scalfani, 2004; Yeomans, 2008). In
addition to these factors, substantial animal research has shown that fats and sugars are both
recognized as contributing to the palatability of foods, overeating, and diet-induced obesity
through their inherent positive hedonic properties as well as learning processes associated with
the preferences for fat- and sugar-rich foods (Sclafani, 1999). It has also been proposed that
sugars, much like other substances of abuse such as alcohol, are able to elicit several components
of addiction such as bingeing, withdrawal and craving in animal models (Avena et al., 2008a),
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possibly contributing to the development of diet-induced obesity. Evidence supporting the
inherent negative hedonic qualities and learning processes associated with the unpalatability and
avoidance of bitter substances is far less conclusive (Dwyer, 2011; Fanselow and Birk, 1982).
These preferences, and to a lesser extent, avoidances (Dwyer, 2011; Fanselow and Birk, 1982;
Rotella et al., 2014; 2015), are based, in part, on learned associations between the various flavor
elements in foods (e.g., flavor–flavor conditioning), and between flavor cues and post-ingestive
consequences (e.g., flavor–nutrient/flavor-toxin conditioning).
Elucidating the neurochemical substrates of orosensory associative processes with an
array of primary appetitive as well as aversive stimuli is critical to our understanding of
dysregulations both in brain and bodily nutritional homeostatic mechanisms as well as
conditioned goal-directed and consummatory behaviors associated with preventable nutritional
and metabolic disorders. This research provides further insight as to alternate potential
neurochemical substrates modulating traditional neurotransmitter systems (such as DA) in
addition to mediating the activity of reward-related and/or limbic structures within the brain in
and of themselves during orosensory associative processes. The series of Specific Aims were
addressed by incorporating systemic pharmacological manipulations on our well-established
flavor-flavor paradigms.
The remainder of the Background section is organized to cover the following topics: 1)
conditioned flavor preferences (CFP) for sugars and fats and 2) pharmacological and
neuroanatomical substrates of CFP. Based on these preliminary findings, the rationale for the
studies of the dissertation research is then presented: 3) potential roles of cholinergic receptor
systems in mediating CFP; 4) potential roles of GABAB receptors in mediating CFP; and 5)
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conditioned flavor avoidances (CFA) and their potential pharmacology. This will be followed by
Section 6 describing how these six specific aims are organized into the series of research studies.
1. Conditioned Flavor-Flavor Preferences (CFP):
1A. Sugar-CFP (Flavor-Flavor vs. Flavor-Nutrient Conditioning)
Rats use flavor cues (taste, odor, texture) to guide their selection of nutritious foods
(Capaldi, 1996). Sugar-induced conditioned flavor preferences (CFP) occur when a novel flavor
(CS+) is paired with a more-preferred sucrose (16%) or fructose (8%) and saccharin (0.2%)
solution relative to a flavor (CS-) paired with a less-preferred saccharin (0.2%) solution. These
sugar-CFPs are based on learned associations between food flavor elements (flavor-flavor
conditioning) as well as between flavor and post-ingestive consequences (flavor-nutrient
conditioning) (Sclafani, 1995). Flavor-flavor conditioning has been studied for sucrose in sham
feeding rats (Yu et al., 1999; 2000a; 2000b), and for fructose in real-feeding rats (Baker al.,
2003; 2004), given the inability of fructose to condition preferences after intragastric (IG)
administration (Sclafani and Ackroff, 1994; Sclafani et al., 1993; 1999). In contrast, glucose is
capable of producing CFP following oral and IG administration (Dela Cruz et al., 2014; Sclafani
and Ackroff, 1994; Sclafani et al., 1993; 1999). Specific Aims 1 and 3 will expand our
knowledge of the pharmacological substrates of sugar (e.g., fructose) flavor-flavor conditioning.
Conditioned flavor preferences (and subsequent description of conditioned flavor
avoidance) is described throughout this dissertation as “Pavlovian-like” conditioning rather than
true Pavlovian conditioning. For all studies, multiple UCSs were paired with a neutral stimulus
(NS) as opposed to a single US and NS pairing in traditional Pavlovian conditioning studies.
Thus, in sugar-CFP studies, the CS+ was operationally defined as the more preferred solution
containing one NS (e.g. cherry Kool Aid) paired with two UCSs (fructose + saccharin: having
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both orosensory and post-ingestive consequences) and the CS- was operationally defined as the
less preferred solution containing a different NS (e.g. grape Kool Aid) paired with one UCS
(saccharin: having only orosensory consequences). Thus, the “CS-” is not a negative stimulus,
but rather a “less-preferred” stimulus. In fat-CFP studies, the CS+ was operationally defined as
the more preferred solution containing one NS (e.g. cherry Kool Aid) paired with one UCS with
a higher (3.5%) concentration of corn oil and the CS- was operationally defined as the less
preferred solution containing a different NS (e.g. grape Kool Aid) paired with one UCS with a
lower (0.9%) concentration of corn oil. Previous studies (Dela Cruz et al., 2012a, 2012b) show
that rats consume less of the 0.9% concentration relative to the 3.5% concentration of corn oil.
In quinine-CFA studies the CS+ was operationally defined as the less preferred solution
containing one NS (e.g. cherry Kool Aid) paired with three UCSs (quinine + fructose +
saccharin) and the CS- was operationally defined as the more preferred solution containing a
different NS (e.g. grape Kool Aid) paired with two UCSs (fructose + saccharin). Therefore, we
operationally define the CS+ as the more preferred solution and the CS- as the less preferred
solution in CFP studies, while we operationally define the CS+ as the less preferred solution and
CS- as the more preferred solution in CFA studies.
The primary purpose of the present series of studies was to analyze the pharmacology of
CFP and CFA. Therefore, given the short-term (~2 h) effects of the drugs, it was imperative that
we utilized a conditioning procedure in which rats were exposed to solutions for multiple
sessions of short durations (~1h). It should be noted that for the development of fat and
carbohydrate flavor preferences, paradigms using short-term (30min) or long-term (22h) training
session lengths have been done (Lucas & Sclafani, 1999). They found that intake and/or
preference could vary depending on the duration of the subsequent choice tests (either 30min or
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22h), and that this influenced the extent to which carbohydrates were preferred over fats, and
vice versa (Lucas & Sclafani, 1999). Thus, short-term choice tests do not always predict the
long-term intakes and preferences for fats and carbohydrates, thereby limiting our
pharmacological findings to only short-term tests.
1B. Fat-CFP
Rodents are also attracted to the flavor of fat (e.g., corn oil) which may be partly
mediated by taste receptors for fatty acids (Ackroff and Sclafani, 2007; Ackroff and Sclafani,
2009; Passilly-Degrace et al., 2009), as well as rewarding post-ingestive and orosensory
properties (Ackroff and Sclafani, 2009; Sclafani, 1999; Sclafani, 2004). Prior studies have
shown that in addition to carbohydrates such as sugars, fats are also capable of eliciting robust
and stable flavor-flavor and flavor-nutrient CFPs in rats (Dela Cruz et al., 2012a; 2012b; Lucas
and Sclafani, 1989; Lucas and Sclafani, 1999). With respect to fat “Pavlovian-like” associative
processes, similar distinctions between the capability of certain sugars (e.g., fructose vs. glucose)
to condition flavor preferences via either orosensory or post-ingestive processes have been
demonstrated utilizing varying methodologies, fats as unconditioned stimuli, and CS-US delay
intervals (Ackroff and Sclafani, 2009). Accordingly, sham-feeding studies comparing nutritive
and nonnutritive oil (corn oil and mineral oil, respectively) intake and preferences suggest that
while both oils are capable of eliciting intake via their palatable orosensory properties, intake of
nutritive oils are preferred during oil-oil choice testing (Mindell et al., 1990) and are preferred
during separate oil emulsion-saccharin choice testing in food-restricted rats (Elizade and
Sclafani, 1990). Accordingly, Specific Aims 2 and 4 expand our knowledge of the
pharmacological substrates of fat (e.g., corn oil) flavor-flavor conditioning.
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2. Pharmacological and Neuroanatomical Substrates of CFP:
2A. Acquisition and Expression of Fructose-CFP
The pharmacological substrates of conditioned flavor preferences (CFP) initially focused
on brain DA and opioid systems (see reviews: Sclafani et al., 2011; Touzani et al., 2010a). Sweet
taste activated mesolimbic and mesocortical DA circuits involved in the mediation of natural as
well as drug rewards (e.g., Genn et al., 2004; Hajnal et al., 2003). DA receptor antagonism also
suppressed the intake of sweet solutions in rats (Geary and Smith, 1985; Muscat and Willner,
1989; Xenakis and Sclafani, 1981).
As previously mentioned, flavor-flavor conditioning has been studied for sucrose in
sham-feeding rats (Yu et al. 1999; 2000a; 2000b), and for fructose in real-feeding rats (Baker et
al., 2003; 2004), given the inability of fructose to condition preferences after IG administration
(Sclafani and Ackroff, 1994; Sclafani et al., 1993; 1999). Research was then aimed to assess the
underlying pharmacological and neuroanatomical substrates moderating these distinct behavioral
phenomena. Accordingly, systemic administration of DA D1 (SCH23390) or D2 (raclopride)
receptor antagonists eliminated both acquisition and expression of fructose-CFP in real-feeding,
food-restricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker et al., 2003;
Hsiao and Smith, 1995; Yu et al., 2000a; 2000b).
A critical role of the mesocorticolimbic DA system has been identified in reward
processes and reward-related learning (Berridge and Robinson, 1998; Salamone and Correa,
2012; Smith, 2004; Wise, 2008). In this system, DA neurons located in the VTA project to
cortical and limbic structures including the NAc, AMY and the mPFC (Swanson, 1982). Another
brain DA system implicated in flavor learning (Caulliez et al., 1996) includes the A13 DA
neurons located in the zona incerta that innervate the lateral hypothalamus (LH) (Wagner et al.,
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1995). Central DA receptor mediation of the acquisition of fructose-CFP is controlled by the
AMY and mPFC (Bernal et al., 2009; Malkusz et al., 2012). Central DA receptor mediation of
the expression of fructose-CFP is controlled by the NAc, AMY, medial orbital frontal cortex
(mOFC) and LH (Amador et al., 2014; Bernal et al., 2008; Bernal et al., 2009; Malkusz et al.,
2015).
In addition to DA, the roles of other neurotransmitter systems in mediating forms of CFP
have been evaluated. For example, although it has been demonstrated that naloxone, a general
opioid receptor antagonist, treatment during a flavor and glucose training session prevented rats
from acquiring a preference for a glucose-paired flavor (Mehiel, 1996), subsequent studies
demonstrated that systemic administration of NTX reduced sweet intake, but failed to alter
acquisition or expression of flavor-flavor-mediated sugar-CFP induced by sucrose in shamfeeding rats or fructose in real-feeding rats (Baker et al., 2004; Yu et al., 1999). Central
injections of NTX into the NAc, mPFC, AMY or LH also failed to affect fructose-CFP
expression (Bernal et al., 2010; Malkusz et al., 2014). Systemic administration of NMDA
receptor antagonists (MK-801) eliminated acquisition, but not expression of fructose-CFP
(Golden and Houpt, 2007). Further, systemic administration of cannabinoid (CB1) receptor
inverse agonists (AM251) reduced expression, but not acquisition of fructose-CFP (Miner et al.,
2008). Therefore, DA D1, DA D2, NMDA and CB1, but not opioid receptor signaling is required
for the full learning (acquisition) and maintenance (expression) of fructose-CFP, apparently in
limbic sites associated with reward.
2B. Acquisition and Expression of Corn Oil-CFP
DA mediation of the rewarding effect of fat flavor is suggested by the findings that corn
oil sham-feeding promotes NAc DA release (Liang et al., 2006), and DA D1 and D2 antagonists
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suppress the sham feeding response to corn oil and real-feeding of fats in rats (Baker et al., 2001;
Davis et al., 2006; Rao et al., 2008; Weatherford et al., 1988; 1990). DA D2, but not D1
antagonism also suppressed operant responding for corn oil in mice (Yoneda et al., 2007). In
inbred mice, strain differences were observed in the ability of the D1 antagonist, SCH23390 to
significantly reduce fat intake whereas the D2 antagonist, raclopride, had minimal effects on fat
intake (Dym et al., 2010).
The opioid system has been implicated in the mediation of fat appetite and intake. In
particular, there are many reports of opioid receptor antagonists suppressing fat intake in rats and
mice (Cole et al., 1995; Dym et al., 2010; Glass et al., 2000; Higgs and Cooper, 1998; Islam and
Bodnar, 1990; Marks-Kaufman et al., 1985; Naleid et al., 2007; Sahr et al., 2008). In addition,
administration of the mu-selective opioid agonist, D-Ala2-NMe-Phe4-Glyol5-enkephalin
(DAMGO) into the NAc stimulated high-fat intake in rats (Zhang et al., 1998). Place preferences
conditioned by oral intake of corn oil or a high-fat snack food are also attenuated by NTX
administration (Jarosz et al., 2006; Shide and Blass, 1991). Finally, it was demonstrated that the
opioid system contributes to the acquisition for dietary fat but is not required for its maintenance
and the reinforcement for fat intake and quantity consumed are differentially moderated by this
system (Sakamoto, 2015).
Glutamate signaling has been shown to play a crucial role in learning and memory and
the underlying synaptic plasticity (Rezvani, 2006). More specifically, glutamate receptor
activation is required for food-related incentive learning. That is, glutamate antagonism within
the AMY and NAc impaired appetitive instrumental learning (Hernandez et al., 2005; Kelley et
al., 1997). Glutamate antagonism within the AMY also impaired both the acquisition and
expression of conditioned taste avoidance (Yasoshima et al., 2000). Within the VTA, glutamate
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antagonists impaired cue-sucrose learning and DA release in the NAc elicited by the sucrosepredictive cue (Stuber et al., 2008; Zellner et al., 2009; Zweifel et al., 2009). Interestingly,
glutamate receptor antagonism by systemic administration of MK-801 blocked the acquisition of
fructose-CFP (Golden and Houpt, 2007).
In contrast to the pronounced pharmacological effects observed on the acquisition and
expression of fructose-CFP, the acquisition and expression of CO-CFP was only attenuated by
DA D1 and D2 (Dela Cruz et al., 2012a), but not opioid receptor antagonism (Dela Cruz et al.,
2012b), while the non-competitive NMDA receptor antagonist (MK-801) eliminated only the
acquisition of CO-CFP (Dela Cruz et al., 2012b).
3. Potential Roles of Cholinergic Receptor Systems in Mediating CFP:
3A. Cholinergic Systems and Fructose-CFP (Specific Aim 1)
Ach has been implicated in food intake, particularly the “addictive” aspects of excessive
sugar intake, by its interactions with brain DA systems (Avena and Rada 2012).
Neuroanatomical interactions presumably occur through Ach inputs from the pedunculopontine
and laterodorsal tegmental (PPT/LDT) nuclei to VTA DA cells (Holmstrand and Sesack, 2011;
Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et al., 1990) or through Ach or DA
terminal innervation of Ach-containing interneurons in the NAc (Dautan et al., 2014; de Rover et
al., 2002; Witten et al., 2010; Zhou et al., 2002). These interactions are integral in the
formulation of central mechanisms involved in food reward (see reviews: Avena and Rada, 2012;
Kelley et al., 2005; Laurent et al., 2014; Mark et al., 2011; McFadden et al., 2014; Nunes et al.,
2013). Additionally, food intake increases Ach release in the AMY (Hajnal et al., 1998) and
NAc (Avena et al., 2006; 2008a; 2008b; 2008c; Mark et al., 1992; Mark et al., 1995). Moreover,
central studies of food and drug reward suggests that these brain DA-Ach systems interact to

21
modulate medium spiny GABAergic output within the NAc (Hoebel et al., 2007) as well as
DAergic output within the VTA (Mark et al., 2011; Mifsud et al., 1989; Schilstrom et al., 1998;
Schmidt et al., 2011). Additionally, muscarinic receptor antagonism with SCOP in the NAc
reduced both deprivation-induced feeding (Pratt and Blackstone, 2009) and NAc DAMGOinduced feeding (Perry et al., 2009), and NAc sites at which SCOP suppressed feeding and
DAMGO-induced feeding overlapped (Perry et al., 2014). DAMGO-induced increases in highfat feeding were blocked by NTX and SCOP, but not by antagonists of DA, glutamate or
nicotinic receptors (Will et al., 2006). VTA muscarinic receptor blockade also mediated cuerelated responses to feeding such that SCOP administered into the VTA disrupted free-feeding
and acquisition, but not the maintenance of food-related learning (Sharf and Ranaldi, 2006).
SCOP administered into the NAc core induced avoidance to flavor and spatial cues (Pratt et al.,
2007). SCOP administered into the ventral hippocampus impaired memories for sociallytransmitted food preferences (Carballo-Marquez et al., 2009). To determine cholinergic
involvement in the development of sugar preferences, one of our preliminary studies (Rotella et
al., 2015) demonstrated that SCOP, but not MEC completely blocked the acquisition of fructoseCFP. Also, both SCOP and MEC significantly reduced, but failed to block the expression of
fructose-CFP.
3B. Cholinergic Systems and Corn Oil-CFP (Specific Aim 2)
Cholinergic receptor signaling have been implicated in the mediation of fat intake.
Consumption of a high-fat diet for one week reduced acetylcholinesterase activity in the frontal
cortex, hypothalamus and midbrain, as well as increased both β2-nAchR binding in the medial
prefrontal cortex and substantia nigra, in addition to α7-nAchR binding in the lateral and
ventromedial hypothalamus. MEC blocked the enhancements in exploratory and novelty-seeking
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behaviors induced by high-fat consumption (Morganstern et al., 2012). Chronic nicotine reduced
body weight in mice, particularly those maintained on a high-fat diet, an effect blocked by MEC
co-treatment (Mangubat et al., 2012). Accumbal microinjections of SCOP markedly reduced fat
intake elicited by accumbal administration of the mu-opioid receptor agonist, DAMGO, and also
reduced food intake in food-deprived rats (Perry et al., 2009; Will et al., 2006). However,
accumbal SCOP failed to affect fat intake itself (Will et al., 2006).
4. Potential Roles of the GABAB System in Mediating CFP:
4A. GABAB Systems and Fructose-CFP (Specific Aim 3)
Given the involvement of the DA or Ach systems in mediating fructose-CFP as well as
other forms of NAc GABA-mediated food and drug related learning, another potential candidate
neurotransmitter system which has not been evaluated in the modulation fructose-CFP is the
GABAergic system. As previously mentioned in Specific Aim 3 we chose to limit our
investigation to GABAB receptors given evidence supporting the potential confounding
behavioral, pharmacological and cognitive effects of systemic administration of GABAA receptor
agonists (e.g., muscimol) in similar learning paradigms (Salinas and McGaugh, 1995; Castellano
and McGaugh, 1990; DiSorbo et al., 2009; Kuba et al., 2000; see review: Johnston, 2014), as
well as research suggesting the possible lack of GABAA involvement in the DA system (Miner et
al., 2010; Sugita et al. 1992; Churchill et al., 1992; Margreta-Mitrovic et al., 1999; Wirtshafter
and Sheppard, 2001) and evidence supporting the specific involvement of GABAB signaling in
animal psychopathological models of food intake dysregulation (e.g., binge-eating: Berner et al.,
2009; Broft et al., 2007; Buda-Levin et al., 2005; Corwin et al., 2012; de Beaurepatre et al.,
2015; Wojnicki et al., 2006).
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Correspondingly, systemic administration of the GABAB agonist, baclofen, has been
shown to influence the intake of both solid and liquid diets (Ebenezer, 1995), fats and sugars
(Avena et al., 2014; Berner et al., 2009; Ebenezer and Pringle, 1992), and modulate short-term
food intake (Patel and Ebenezer, 2010) as a function of texture (Wojnicki et al., 2013).
Additionally, a systemic study comparing GABAB mediated alterations of food intake supported
a primarily central role in baclofen’s effects, as 3-aminopropylphosphinic acid (3-APA), also a
GABAB agonist but is impermeable to the blood-brain barrier, failed to alter food intake
(Ebenezer and Patel, 2004). Moreover, central studies implicate GABA receptor involvement at
limbic and hypothalamic structures in increasing food intake (Echo et al., 2002; Khaimova et al.,
2004; Miner et al., 2010; Stratford and Kelley, 1997). As mentioned, however, it should be
noted that BAC-induced modulations to food, sugar, and fat intake vary widely as a function of
time of feeding (Ebenezer and Patel, 2011), route of administration (Bains and Ebenezer, 2013;
Ebenezer and Prabhaker, 2007; Patel and Ebenezer, 2008a; 2008b), homeostatic state (BudnaLevin et al., 2005; Rao et al., 2008; Sato et al., 2007; Wang et al., 2011; Wojnicki et al., 2014),
and acute tolerance (Bains and Ebenezer, 2013) rendering it’s exact effects inconclusive. Given
the evidence describing the mixed effects of BAC on intake per se, it is hypothesized that
systemic GABAB agonist administration will alter the acquisition and expression of fructoseCFP.
4B. GABAB Systems and Corn Oil-CFP (Specific Aim 4)
GABAB receptor signaling has also been implicated in the mediation of fat intake. BAC
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt and ScheelKruger, 1979; Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al.,
1993), and was reported to be mediated through GABA receptor interactions between the ventral
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tegmental area and nucleus accumbens (Miner et al., 2010). Systemic BAC increased fat intake
under normal conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), but
suppressed fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009;
Buda-Levin et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014;
Wong et al., 2009). Additionally, the reinforcing effects of primary rewarding and conditioned
stimuli mediated by mesolimbic circuitry was found to be modulated by GABAB receptor
activation in optogenetic studies of food intake (van Zessen et al., 2012).
5. Conditioned Flavor-Flavor Avoidances (CFA):
5A. Quinine-CFA: Parallels of Fructose-CFP
Flavor–taste avoidance learning, occurs when an arbitrary flavor (CS) is paired with a
naturally non-preferred taste (US, e.g., bitter, quinine). Fanselow and Birk (1982) originally
reported that rats learned to avoid a flavor (e.g., almond) mixed into a quinine solution although
their study was not a pure CFA because the animals had a second flavor (e.g., vanilla) mixed into
a preferred saccharin solution. More recently, Dwyer (2011) trained rats to drink a CS+ flavor
(e.g., cherry) added to a quinine solution and a CS− flavor (e.g., grape) added to water in
separate sessions. In a subsequent two-bottle choice test, the rats avoided the CS+ when both CS
flavors were presented in plain water.
Previous studies elicited quinine-CFA by employing a paradigm in which thirsty rats
were trained to drink flavored water adulterated with quinine (Dwyer, 2011; Harris and
Westbrook, 1998). Specific Aim 5 utilizes a different design to match that used in our flavor–
taste preference conditioning studies in which hungry rats were trained with a flavored fructose
and saccharin solution and a less preferred flavored saccharin solution (Baker et al., 2003). In
this case, hungry rats are trained with two differently flavored fructose and saccharin (FS)
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solutions with one adulterated with quinine. We examine a range of quinine concentrations to
determine a concentration that is able to condition a flavor avoidance comparable in magnitude
to the preference obtained in earlier fructose-CFP studies (Baker et al., 2003; 2004; Bernal et al.,
2008; 2009; 2010; Golden and Houpt, 2007; Malkusz et al., 2012).
5B. Potential Pharmacological Substrates of Quinine-CFA (Specific Aim 5)
Conditioned flavor avoidances (CFA) can be induced by either ingested toxins that
induce gastrointestinal distress (flavor–toxin learning; see review: Freeman and Riley, 2009) or
by aversive tastes (flavor-taste learning; e.g., Dwyer, 2011; Fanselow and Birk, 1982).
Pharmacological analyses have examined DA D1, DA D2, NMDA and opioid
antagonists in flavor-toxin CFA learning. DA D1, but not D2 antagonism disrupted the
acquisition of a LiCl-induced CFA following systemic administration, and following central
administration into the LH or NAc shell (Caulliez et al., 1996; Fenu et al., 2001; 2005; 2009).
Blockade of NMDA, α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA (Yasoshima et al.,
2000). Naloxone enhanced taste aversions elicited by LiCl (Davis et al., 2009; Miceli et al.,
1979; Smurthwaite et al., 1992). Given this as well as the differential effects of DA D1, DA D2,
NMDA and opioid receptor signaling on flavor-flavor learning elicited by the palatability of
fructose and corn oil, Specific Aim 5 assesses the potential role of these receptor candidates in
modulating the acquisition and expression of flavor-flavor CFP elicited by the unpalatability of
quinine.
5C. Cholinergic Systems and Quinine-CFA (Specific Aim 6A)
Cholinergic receptors have also been previously implicated in certain forms of CFA. In
flavor-toxin CFA learning, SCOP attenuated LiCl-induced CFA without altering aversion to
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quinine (Coil et al., 1978). SCOP and nicotine are capable of eliciting flavor-taste CFAs with the
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et
al., 1986; Ossenkopp and Gugno, 1990). A possible role for cholinergic receptors in flavor-taste
CFA is supported by the ability of quinine to inhibit Ach currents in alpha-9-alpha-10-containing
nicotinic Ach receptors in Xenopus oocytes (Ballestero et al., 2005), and adrenal catecholamine
secretion evoked by Ach stimulation of muscarinic and nicotinic receptors (Jang et al., 2001). In
turn, nicotine depressed quinine-evoked responses in the nucleus tractus solitarius that were
blocked by MEC (Simons et al., 2006). Nicotine and quinine CFA generalized to each other in
three mouse strains (Gyekis et al., 2012), with MEC blocking this ability in behavioral and
electrophysiological assays (Oliveira-Maia et al., 2009). Thus, these data appear to implicate
cholinergic receptor signaling in flavor-taste CFA and as a result, Specific Aim 6A addresses the
roles of muscarinic and nicotinic cholinergic receptor signaling in mediating quinine-induced
CFA.
5D. GABA Systems and Quinine-CFA (Aim 6B)
A role for GABAB receptor systems in conditioned aversions is supported by the ability
of the GABAB agonist, BAC, but not the GABAB antagonist, saclofen, to suppress saccharininduced drinking following pairing (Echo et al., 2002; Wilson et al., 2011). However, another
study using a similar dose range found that systemic BAC failed to induce an aversion or affect
ethanol-induced aversions (Chester and Cunningham, 1999). Further, although systemic BAC
failed to alter operant responding to quinine-adulterated solutions (Petry and Heyman, 1997), it
did enhance the discriminative abilities of D-amphetamine in a conditioned taste aversion
procedure (Miranda et al., 2009). Accordingly, Specific Aim 6B tests the involvement of
GABAB receptor signaling in quinine-CFA.
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6. Organization of the Studies:
The six specific aims of this dissertation research are systematically examined in four
major documents that have successfully undergone peer review and have indeed been published.
For ease of presentation, Chapters 3-6 present the four papers in the order that they were
published. Thus, Dissertation Research Paper 1 (Chapter 3) addresses Specific Aim 5,
Dissertation Research Paper 2 (Chapter 4) addresses Specific Aims 1 and 6A, Dissertation
Research Paper 3 (Chapter 5) addresses Specific Aims 3 and 6B, and Dissertation Research
Paper 4 (Chapter 6) addresses Specific Aims 2 and 4.
Dissertation Research Paper 1: The goals of Specific Aim 5 were to determine whether
DA D1, DA D2, opioid and NMDA receptors, involved in mediating appetitive associative
learning processes (e.g., sugar- and fat-CFP), would similarly moderate underlying associative
processes contributing to the behavioral effects of CFA associative learning processes induced
by primary aversive stimuli (e.g., quinine). Thus, we addressed the pharmacology of flavor-taste
CFA by examining the roles of DA D1, DA D2, NMDA and opioid receptor signaling in flavor
avoidance conditioned by the bitter taste of quinine. This paper, entitled “Role of NMDA, opioid
and dopamine D1 and D2 receptor signaling in the acquisition of a quinine-conditioned flavor
avoidance in rats”, was published in Physiology and Behavior (128, 133-140, 2014) (Chapter 3).
Dissertation Research Paper 2: The goals of Specific Aim 1 were to determine whether
muscarinic or nicotinic cholinergic receptor antagonism mediates the acquisition and expression
of sugar (fructose)-CFP. Further, one goal of Specific Aim 6 determines whether muscarinic or
nicotinic receptor antagonism mediate quinine-CFA. Therefore, we evaluate the ability of SCOP
and MEC for their effects upon the acquisition and expression of fructose-CFP (Specific Aim 1)
and acquisition of quinine-CFA (Specific Aim 6A). This paper, entitled “Muscarinic and
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nicotinic cholinergic receptor antagonists differentially mediation acquisition of fructoseconditioned flavor preference and quinine-conditioned flavor avoidance in rats”, was published
in Neurobiology of Learning and Memory (123, 239-249, 2015) (Chapter 4).
Dissertation Research Paper 3: The goal of Specific Aim 3 was to determine whether
systemic pharmacological stimulation of GABAB receptors influence the acquisition and
expression of sugar (fructose)-CFP. Further, a second goal of Specific Aim 6 determines whether
stimulation of GABAB receptors mediate quinine-CFA. Therefore, we evaluate the ability of
BAC for its effects upon the acquisition and expression of fructose-CFP (Specific Aim 3) and
acquisition of quinine-CFA (Specific Aim 6B). This paper, entitled “Baclofen differentially
mediates fructose-conditioned flavor preference and quinine-conditioned flavor avoidance in
rats”, was published in European Journal of Pharmacology (775, 15-21, 2016a) (Chapter 5).
Dissertation Research Paper 4: The goals of Specific Aim 2 were to determine whether
muscarinic or nicotinic cholinergic receptor antagonism mediates the acquisition and expression
of fat (corn oil)-CFP. Similarly, the goal of Specific Aim 4 determines whether stimulation of
GABAB receptors antagonism mediate the acquisition and expression of fat-CFP. Therefore, we
evaluate the ability of SCOP and MEC (Specific Aim 2) as well as BAC (Specific Aim 4) for
their effects upon the acquisition and expression of fat-CFP. This paper, entitled “Muscarinic,
nicotinic and GABAergic receptor signaling differentially mediate fat-conditioned flavor
preference in rats”, was published in Pharmacology, Biochemistry, and Behavior (150-151, 1421, 2016b) (Chapter 6).
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Chapter 3: Role of NMDA, opioid and dopamine D1 and D2 receptor signaling in the
acquisition of a quinine-conditioned flavor avoidance in rats
1. Introduction:
Animals use flavor cues (taste, odor, texture) to guide their selection of nutritious foods
and avoidance of toxic foods (or fluids) with learning shaping this selection (Capaldi, 1996;
Sclafani, 1995). Four common types of food learning have been identified: CFP induced by the
orosensory (flavor-taste learning; e.g., (Baker et al., 2004; Baker et al., 2003, Holman, 1975,
Sclafani, 1995; Sclafani & Ackroff, 1994; Sclafani et al., 1993; Sclafani et al., 1999; Yu et al.,
1999; 2000a; 2000b)) and/or the post-oral (flavor-nutrient learning; e.g., (Azzara et al., 2000;
2001; Touzani et al., 2008)) reinforcing properties of foods such as sugars, and CFA induced by
either ingested toxins that induce gastrointestinal distress (flavor-toxin learning; see review:
(Freeman & Riley, 2009)) or an aversive taste (flavor-taste learning; e.g., (Dwyer, 2011;
Fanselow & Birk, 1982)). This paper is using the term, avoidance rather than aversion, as we did
not measure taste reactivity following CFA and to allow consistency throughout the text. The
fourth and least studied type of food learning, flavor-taste avoidance learning, occurs when an
arbitrary flavor (CS) is paired with a naturally unpreferred taste (US, e.g., bitter quinine).
Fanselow and Birk (1982) originally reported that rats learned to avoid a flavor (e.g., almond)
mixed into a quinine solution although their study was not a pure CFA because the animals had a
second flavor (e.g., vanilla) mixed into a preferred saccharin solution. More recently, Dwyer
(2011) trained rats to drink a CS+ flavor (e.g., cherry) added to a quinine solution and a CSflavor (e.g., grape) added to water in separate sessions. In a subsequent two-bottle choice test, the
rats avoided the CS+ when both CS flavors were presented in plain water.
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Numerous studies have investigated the neurochemical substrates of flavor-taste and
flavor-nutrient CFP as well as flavor-toxin CFA using DA, NMDA and opioid receptor
antagonists. In CFP studies, systemic treatment with DA D1 and D2 receptor antagonists
attenuated the acquisition and expression of a flavor-taste CFP produced by the sweet taste of
sucrose or fructose (Baker et al., 2003; Yu et al., 2000a; 2000b). In contrast, systemic DA D1 but
not D2 antagonism blocked the acquisition, and to a lesser degree the expression of a flavornutrient CFP elicited by IG sucrose infusions (Azzara et al., 2001). Brain sites involved in DA
modulation of flavor-taste and flavor-nutrient CFP by sugar include the NAc (Bernal et al., 2008;
Touzani et al., 2008), AMY (Bernal et al., 2009; Touzani et al., 2009) and mPFC (Malkusz et al.,
2012; Touzani et al., 2010). In flavor-toxin CFA studies, systemic DA D1, but not D2
antagonism disrupted the acquisition of a LiCl-induced CFA (Fenu et al., 2005; 2009). Central
drug studies revealed that DA D1 receptor antagonists administered into either the LH (Caulliez
et al., 1996) or shell of the NAc (Fenu et al., 2001) disrupted the acquisition of a LiCl-induced
CFA.
In NMDA receptor signaling studies, the acquisition, but not the expression of flavortaste mediated fructose-CFP was blocked by systemic treatment with the non-competitive
NMDA antagonist, MK-801 (Golden & Houpt, 2007). Blockade of NMDA, AMPA and
metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA (Yasoshima et al.,
2000), and blockade of NMDA receptors in the AMY eliminated the acquisition of flavornutrient- CFP (Touzani et al., 2013). In contrast to DA and glutamate involvement, systemic or
central administration of the general opioid antagonist, NTX had little or no effect on flavor
preference conditioning by the taste or nutritive actions of sugar (Azzara et al., 2000; Baker et
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al., 2004; Bernal et al., 2010; Yu et al., 1999). However, naloxone enhanced taste aversions
elicited by LiCl (Davis et al., 2009; Miceli et al., 1979; Smurthwaite et al., 1992).
Flavor-taste CFA learning has not been the subject of pharmacological analysis, and the
present study addressed this gap by examining the roles of DA D1, DA D2, NMDA and opioid
receptor signaling in flavor avoidance conditioned by the bitter taste of quinine. In two prior
studies, CFA was produced by training thirsty rats to drink flavored water adulterated with
quinine (Dwyer, 2011; Harris & Westbrook, 1998). Here we used a different design to match that
used in our flavor-taste preference conditioning studies in which hungry rats were trained with a
flavored fructose + saccharin solution and a less preferred flavored saccharin solution (Baker et
al., 2003). In this case, hungry rats were trained with two differently flavored fructose +
saccharin (FS) solutions with one adulterated with quinine. The first experiment examined a
range of quinine concentrations to determine a concentration that conditioned a flavor avoidance
comparable in magnitude to the preference obtained in earlier fructose-CFP studies (Baker et al.,
2004; 2003; Bernal et al., 2008; 2009; 2010; Golden & Houpt, 2007; Malkusz et al., 2012). The
second experiment examined the systemic effects of DA D1 (SCH23390), D2 (raclopride),
NMDA (MK-801) and opioid (naltrexone) receptor antagonists on the acquisition of the quinineinduced CFA. In these experiments, the avoidance of the quinine-paired CS+ flavor was
evaluated in two-bottle tests with both flavored FS solutions presented without quinine. To
determine if the high palatability of the FS solutions used in the choice tests may weaken the
expression of the quinine conditioned avoidance, a third experiment was conducted in which the
rats were given two-bottle tests using flavored saccharin solutions without fructose.
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2. Methods:
2.1. Subjects: Male Sprague-Dawley rats (n=138, 250-275 g), obtained from Charles
River Laboratories (Wilmington, MA), were housed individually in wire mesh cages and
maintained on a 12:12 h light/dark cycle with chow (5001, PMI Nutrition International,
Brentwood, MO) and water available ad libitum for the first week. All animals were then foodrestricted to 85-90% of their body weight throughout behavioral testing. Food rations were
provided 1 h after the end of daily training and testing sessions. The experimental protocols in
the three experiments were approved by the Queens College Institutional Animal Care and Use
Committee certifying that all subjects and procedures are in compliance with the National
Institutes of Health Guide for Care and Use of Laboratory Animals.
2.2. Test Solutions and Initial Training: The training solutions contained 8% fructose
(Sigma Chemical Co., St. Louis, MO) and 0.2% sodium saccharin (Sigma Chemical Co.) with or
without quinine (0.001-0.06%: Sigma Chemical Co.), each flavored with 0.05% unsweetened
grape or cherry Kool-Aid (General Foods, White Plains, NY). Fructose rather than sucrose or
glucose was used because, unlike these other sugars, fructose has minimal post-oral flavor
conditioning effects (Sclafani & Ackroff, 1994; Sclafani et al., 1993; 1999). Half of the rats in
each group had the cherry flavor added to the FS solution and the grape flavor added to the
fructose + saccharin + quinine (FSQ) solution; the flavors were reversed for the remaining rats.
In the two-bottle choice tests, the cherry and grape flavors were presented in either 8% fructose +
0.2% saccharin (Experiments 1 and 2) or 0.2% saccharin (Experiment 3) solutions. The flavored
fructose + saccharin + quinine solution is referred to as the CS+/FSQ, and the flavored fructose +
saccharin solution as the CS-/FS; and the same flavors used in the two-bottle tests are referred to
as CS+ and CS-, respectively. All testing took place in the rat’s home cage during the mid-light
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phase of the light:dark cycle. The food-restricted rats were initially trained to drink an unflavored
8% fructose and 0.2% saccharin solution from sipper tubes during five daily 1-h sessions. The
sipper tube was mounted on the front of the cage held by a taut steel spring, and was positioned
3-6 cm above the cage floor.
2.3. Procedure: Rats were trained over eight one-bottle training sessions (1 h) to drink
the CS-/FS solution on odd-numbered days, and the CS+/FSQ solution on even-numbered days.
The eight training trials were divided into four pairs of sessions with a one-day break between
each pair. In the first three training pairs, only one bottle was presented. In the fourth pair of
training sessions (days 7 and 8), a second sipper tube containing water was also presented to
acclimate the rats to the presence of two sipper tubes used during the choice tests; water intake
was negligible in these training trials. The left-right position of the CS and water sipper tubes
was counterbalanced over the two days. Training intakes were limited to 16 ml/session to
correspond with the training procedure used in our prior fructose-CFP studies (Baker et al., 2003;
2004; Bernal et al., 2008; 2009; 2010; Malkusz et al., 2012). Following training, the rats were
given six two-bottle choice test sessions (1 h) with unlimited access to the CS+ and CSsolutions. The position of the two bottles were left (L)-right (R)-R-L-L-R in half of the animals,
and R-L-L-R-R-L in the remaining half. Solution intakes during the training and testing were
measured by weighing (0.1 g) the bottles before and after the 1 h sessions.
2.4. Experiment 1: Quinine Concentration and CFA: Seven groups (n=6/7 each) of foodrestricted rats, matched for unflavored fructose+ saccharin intakes, were tested in the
conditioning procedure described above in which one of the following quinine concentrations
was included in the CS+FSQ solution during one-bottle training: 0.001%, 0.002%, 0.004%,
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0.008%, 0.012%, 0.016% and 0.030%. The animals then received six two-bottle tests with the
CS+ and CS- flavors mixed in 8% fructose + 0.2% saccharin solutions.
2.5. Experiment 2: Pharmacological Effects on Acquisition of Quinine-CFA: Five groups
of food-restricted rats received systemic injections of a) vehicle (VEH group, n=13; 1 ml 0.9%
normal saline/kg body weight, ip), b) MK-801 (MK801 group, n=11; 100 ug/kg, ip, Sigma
Chemical Co.), c) SCH23390 (SCH group, n=12; 200 nmol/kg, ip, Sigma Chemical Co.), d)
raclopride (RAC group, n=11; 200 nmol/kg, ip, Sigma Chemical Co.) or naltrexone (NTX group,
n=12; 1 mg/kg, ip, Sigma Chemical Co.) 30 min prior to each of eight one-bottle training
sessions with the CS-/FS solution on odd-numbered days and CS+/FSQ (0.030% concentration)
on even-numbered days. The doses of MK-801, SCH, RAC and NTX were chosen based on their
use in prior studies investigating the acquisition of fructose-CFP (Baker et al., 2003; 2004;
Golden & Houpt, 2007). To assess whether drug effects were functionally equivalent to
increasing the quinine concentration, a sixth group of rats (VEH.06% group, n=12) received
vehicle injections followed 30 min later with the CS-/FS solution or a CS+/FSQ solution
containing 0.06% quinine. Following training, all groups received six two-bottle sessions with
the CS+and CS- flavors mixed in 8% fructose + 0.2% saccharin solutions.
2.6. Experiment 3: To assess whether the highly palatable 8% fructose + 0.2% saccharin
solution used in two-bottle testing in Experiments 1 and 2 influenced the expression of the
quinine conditioned flavor avoidance, two groups of rats received either vehicle or SCH (200
nmol/kg) 30 min prior to each of eight one-bottle training sessions with the CS-/FS and
CS+/FSQ (0.030% concentration). However, in the six two-bottle choice sessions, the CS+ and
CS- flavors were presented in 0.2% saccharin solutions.
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2.7. Data analysis: In each experiment, training intakes were averaged over the four
CS+/FSQ and four CS-/FS sessions and were analyzed with a two-way randomized-blocks
ANOVA (CS conditions x Groups). Intakes during the preference tests were averaged over
sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A
three-way randomized-blocks ANOVA compared the CS intakes of the concentration groups in
Experiment 1 (Group x CS x Test), and the CS intakes of the drug groups in Experiments 2 and 3
(Group x CS x Test). Separate two-way ANOVAs evaluated total CS intakes and percent CS+/s
intakes of the different groups in the three experiments. When main or interaction effects were
found, Bonferroni corrected comparisons (p<0.05) detected significant effects.
3. Results:
3.1. Quinine Concentration and CFA: During one-bottle training, the mean intake of the
CS-/FS solution significantly exceeded that of the CS+/FSQ solution (14.7 vs. 11.9 g/1 h,
F(1,36)= 111.82, p<0.0001), and significant differences were also observed across the seven
quinine concentrations (F(6,36)= 15.99, p<0.0001) and for the interaction between CS and
concentration (F(6,36)= 22.63, p<0.0001). As indicated in Figure 1A, one-bottle training intakes
of the CS-/FS and CS+/FSQ solutions failed to differ at quinine concentrations 0.001%, 0.002%,
004% and 0.008%. CS+/FSQ intakes were significantly lower than CS-/FS intakes with the
0.012%, 0.016% and 0.03% quinine concentrations (Figure 1A).
In the two-bottle choice tests, overall, CS+ intakes (13.9 g) failed to differ from CSintakes (14.5 g). However, significant differences were observed among tests (F(2,72)= 5.68,
p<0.018) and for the interaction between quinine concentration and tests (F(12,72)= 6.16,
p<0.047). Figure 1B depicts CS- and CS+ intakes in Test 1 across the seven training quinine
concentrations. Whereas the six lower quinine concentrations elicited similar CS- and CS+
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Figure 1. Elicitation of Quinine-conditioned flavor avoidance (CFA) is dependent on quinine
concentration. Panel A: One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and
CS-/FS solutions in separate groups of animals given CS+/FSQ solutions containing 0.001%,
0.002%, 0.004%, 0.008%, 0.012%, 0.016% or 0.030% quinine. Panel B. Two-bottle choice Test
1 intakes (mean +SEM, g/60 min) of the CS+ flavor and CS- flavor presented in FS solutions.
The percentages of CS+ intake over total intake are denoted above each pair of values.
Significant differences are denoted between CS+/FSQ and CS-/FS intake are denoted (*).
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intakes, rats trained with the highest (0.03%) quinine concentration displayed significantly lower
CS+ intake than CS- intake, indicative of an avoidance of the flavor associated with the FSQ
solution. This effect was transitory in that this group and all other groups failed to display any
differences in CS+ and CS- intakes in Tests 2 and 3 (data not shown). Evaluation of the percent
CS+ intakes failed to reveal any differences among concentrations, tests or their interaction.
Thus, the 29% CS+ percent intake of the 0.03% group was lower, but not significantly so, than
those (48-54%) of the other six quinine groups.
3.2. Pharmacological effects on Quinine-CFA: In the one-bottle training sessions,
overall, CS-/FS intake significantly exceeded CS+/FSQ intake (12.7 vs. 2.0 g/1 h, F(1,60)=
1303.21, p<0.0001), there were significant group differences (F(5,60)= 13.11, p<0.0001), and
there was a significant interaction between groups and CS (F(5,60)= 3.31, p=0.011). CS-/FS
intake for all six groups was significantly higher than CS+/FSQ intake (Figure 2), demonstrating
the ability of quinine at concentrations of 0.03% and 0.06% (VEH.06% group) to reduce intake.
CS-/FS intake was significantly lower in the SCH and NTX groups relative to VEH group; the
MK-801, RAC and VEH groups did not differ significantly in their CS-/FS intakes (Figure 2).
CS+/FSQ intake was significantly lower in MK801, SCH and NTX groups relative to the VEH
group; the RAC and VEH groups did not differ in CS+/FSQ intakes (Figure 2). The CS+/FSQ
intake of the VEH.06% group was significantly lower than that of the VEH group trained with
0.03% quinine (Figure 2).
In the two-bottle choice tests, there were significant differences in the overall CS+ (8.8 g)
and CS- (15.5 g) intakes (F(1,19)= 359.90, p<0.0001), as well as for the interactions between
groups and tests (F(10,120)= 5.12, p<0.043) and tests and CS (F(2,120)= 3.71, p<0.039). Withingroup comparisons revealed that VEH rats consumed more CS- than CS+ only during Test 1

38

Figure 2. (Experiment 2): One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and
CS-/FS solutions during training sessions 30 min following systemic administration of vehicle
(VEH group), MK-801 (MK801 group), SCH23390 (SCH group), raclopride (RAC group) or
naltrexone (NTX group). These groups were trained witih a CS+/FSQ solution containing 0.03%
quinine whereas the VEH.06% group was trained w ith a CS+/FSQ solution containing 0.06%
quinine. Significant differences are denoted between CS+/FSQ and CS-/FS intake are denoted
(*) as are any drug effect relative to VEH (+).
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(Figure 3A), consistent with the results of Experiment 1. In contrast, the MK801, SCH and NTX
groups consumed more CS- than CS+ in all three tests (Figure 3B, C, E), indicating that the
NMDA, DA D1 and opioid antagonists prolonged the CFA effects of quinine. In contrast, the
RAC group, like the VEH group, consumed more CS- than CS+ in Test 1 only (Figure 3D). The
three drug groups (SCH, MK801, NTX) that displayed a persistent CS+ avoidance (Figure
3B,C,E), were the groups that also showed significantly reduced CS+/FSQ intake during training
relative to the VEH group (Figure 2). In contrast, the RAC group was similar to the VEH group
in its training and test intakes. The persistent quinine-induced CFA in rats trained with MK-801,
SCH and NTX was unexpected, and therefore, an additional vehicle control group was added to
determine whether the effects of these drugs were behaviorally and functionally equivalent to
increasing the concentration of quinine during training. This explanation appeared to be plausible
in that the VEH.06% group trained with a 0.06% quinine solution in the CS+/FSQ consumed
significantly more CS- than CS+ in Test 1 and 2 although not in Test 3 (Figure 3F).
Analysis of the percent CS+ intake data revealed significant differences across tests
(F(2,120)= 4.13, p<0.029), but not among groups or for the interaction between groups and
tests. Trends in the data indicate that the avoidance in all five groups were comparable (30-37%)
for the first test pair in animals exposed to the 0.03% quinine solution, and were lower (23%) for
the first test pair in animals exposed to the 0.06% quinine solution (Figure 3). However, whereas
vehicle-trained (43-50%) and RAC-trained (40-46%) rats displayed increasing indifference to
thetwo flavors in the second and third test pairs, rats trained with MK-801 (32-33%), SCH (3536%) and NTX (29-39%) displayed persistent quinine-induced CFA during the second and
thirdtest pairs (Figure 3). Finally, vehicle-treated rats exposed to 0.06% quinine showed a
steadyerosion of the avoidance in the second (34%) and third (40%) test pairs (Figure 3).
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Figure 3. (Experiment 2): Two-bottle choice test intakes (mean +SEM, g/60 min) of the CS+
flavor and CS- flavor presented in fructose+saccharin solutions in Tests 1-3 in groups trained
with vehicle (A), MK-801 (B), SCH23390 (C), raclopride (D), naltrexone (E) or VEH and a
CS+/FSQ solution containing 0.06% quinine (F). The percentages of CS+/FSQ intake over total
intake are denoted above each pair of values. Significant differences are denoted between
CS+/FSQ and CS-/FS intake are denoted (*).
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3.3. Quinine-Induced CFA expressed with Saccharin Solutions: To test the possibility
that the transitory nature of quinine-induced CFA in the VEH group was due to “masking”
effects of the very palatable FS solution used in two-bottle testing, this experiment employed an
identical paradigm in vehicle-trained rats except that the CS+ and CS- flavors were mixed in a
0.2% saccharin solution during the two-bottle test. A SCH group was similarly trained and tested
to determine if the testing with CS flavors in 0.2% saccharin solutions influenced the results
obtained with vehicle and SCH23390 injections. In the one-bottle training sessions, overall, CS/FS intake significantly exceeded CS+/FSQ intake (10.6 vs. 2.5 g/1 h, F(1,9)= 769.41,
p<0.0001), the two groups significantly differed from each other (F(1,9)= 286.26, p<0.0001),
and there was a significant interaction between groups and CS (F(1,9)= 6.31, p=0.033). CS-/FS
intake in both groups was significantly higher than CS+/FSQ intake (Figure 4A). SCH-trained
rats displayed significantly less CS-/FS intake relative to vehicle-trained rats; CS+/FSQ intakes
failed to differ between groups (Figure 4A).
In the two-bottle choice tests, there were significant differences in the overall CS+ (6.3 g)
and CS- (13.9 g) intakes (F(1,9)= 19.03, p<0.002), as well as for the interaction between tests
and CS (F(2,180)= 3.69, p<0.045) but not between groups or for the interaction between groups
and tests. Within-group comparisons revealed that VEH rats consumed significantly more CSthan CS+ only in Test 1(Figure 4B), demonstrating an identical avoidance pattern to that
observed with rats tested with the CS+ and CS- flavors presented in FS solutions in Experiments
1 and 2. In contrast, the SCH rats consumed significantly more CS- than CS+ in all three Tests
(Figure 4C) as observed in Experiment 2. Analysis of the percent CS+ intake data revealed
significant effects across tests (F(2,18)= 4.02, p<0.036), but not between groups and for the
interaction between groups and tests. Trends in the data indicate that the avoidances in the
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Figure 4. (Experiment 3. Panel A): One-bottle training intakes (mean +SEM, g/60 min) of
CS+/FSQ and CS-/FS solutions during training sessions 30 min following systemic
administration of vehicle (VEH group) or SCH23390 (SCH group). Two-bottle choice test
intakes (mean +SEM, g/60 min) of the CS+ flavor and CS- flavor presented in 0.2% saccharin
solutions in Tests 1-3 in VEH group (B) and SCH group (C). The percentages of CS+/FSQ
intake over total intake are denoted above each pair of values. Significant differences are denoted
between CS+/FSQ and CS-/FS intake are denoted (*) as are any drug effect relative to VEH (+).
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vehicle (26%) and SCH (19%) groups were comparable for the first test pair (Figure 4).
However, whereas vehicle-trained rats (40-49%) displayed increasing indifference to the two
flavors in the second and third test pairs, rats trained with SCH displayed persistent quinineinduced CFA during the second (28%) and third (25%) test pairs (Figure 4).
4. Discussion:
The present study examined the roles of DA, NMDA and opioid receptor signaling in
the acquisition of a flavor-taste CFA induced by the bitter taste of quinine added to a flavored
fructose+saccharin solution. This was of interest given that the acquisition of a flavor-taste CFP
induced by the sweet taste of fructose is blocked by systemic or central administration of DA D1,
DA D2, NMDA, but not opioid receptor antagonists (Baker et al., 2003; 2004; Bernal et al.,
2008; 2009; 2010; Golden & Houpt, 2007; Malkusz et al., 2012).
The results of Experiment 1 demonstrated that a CFA could be produced by adulterating
a fructose+saccharin solution with quinine depending upon the concentration of the bitterant. At
very low concentrations (0.001-0.008%), the added quinine failed to reduce CS+FSQ training
intake relative to the CS-FS, and did not produce significant differences in CS+ and CS- intakes
in the two-bottle choice tests. Although adulteration with 0.012% or 0.016% quinine
significantly depressed CS+/FSQ training intake, it was insufficient to produce a CFA in the
two-bottle tests. However, when the quinine concentration was raised to 0.03%, CS+/FSQ intake
was significantly reduced relative to CS-/FS intake in one-bottle training trials, and a quinine
CFA was observed in two-bottle Test 1 but not in Tests 2 and 3. The transitory nature of the
0.3% quinine-induced CFA was also observed in the VEH groups of Experiments 2 and 3 that
were tested with CS flavors presented in fructose+saccharin and saccharin-only solutions,
respectively. The data from Experiment 3 indicates that the transitory quinine CFA observed in
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the first two experiments was not due to the use of palatable fructose+saccharin solutions in the
choice tests. Instead, the quinine CFA was found to be related to the concentration of the bitter
adulterant. The VEH.06% rats trained with a CS+FSQ containing 0.06% quinine consumed less
solution during training and displayed a more persistent CS+ avoidance (Tests 1 and 2) than did
the VEH rats with the CS+FSQ containing 0.03% quinine (Test 1 only), indicating that the
persistence of the quinine CFA could be increased by increasing quinine concentration.
Our observation of a quinine-induced CFA in hungry rats trained with fructose-saccharin
solutions extends a prior report of quinine-induced CFAs in thirsty rats trained with flavored
water using the same grape and cherry CS flavors (Dwyer, 2011). Note that this and prior studies
evaluated quinine-induced CFA in only one or two two-bottle choice sessions (Dwyer, 2011;
Fanselow & Birk, 1982; Harris & Westbrook; 1998) unlike the six test sessions of the present
study, and thus provide no data on the persistence of the CFA in thirsty rats. In studies of
fructose-CFP, the conditioned preference persisted over 6 to 10 two-bottle test sessions which
indicates that at least some forms of flavor-taste learning are resistant to extinction (Baker et al.,
2003; 2004; Bernal et al., 2008; 2009; 2010; Malkusz et al., 2012).
The prior sugar-conditioned flavor-taste preference studies revealed that flavor
conditioning was dependent of upon intact DA D1 and D2 (Baker et al., 2003; Yu et al., 2000a;
2000b) and NMDA (Golden & Houpt, 2007), but not opioid (Baker et al., 2004; Yu et al., 1999)
receptor signaling. That is, systemic administration of SCH23390, raclopride and MK-801, but
not naltrexone, during flavor training reduced or eliminated the learning of the sweet taste based
CS+ preference. This is in marked contrast to the present findings that the same doses of
SCH23390, MK-801, and naltrexone, but not raclopride, enhanced the quinine-CFA as indicated
by the more persistent CS+ avoidance displayed by the SCH, MK801 and NTX groups compared
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to the VEH group. The effects of SCH23390, MK-801 and naltrexone on the quinine-based CFA
were behaviorally similar to that produced by increasing the quinine concentration (from 0.03 to
0.06%) in the CS+FSQ training solution. That is, the rats trained with the 0.06% quinine
adulterated CS+FSQ solution underconsumed the solution to the same degree as the SCH,
MK801, and NTX groups trained with the 0.03% quinine-adulterated CS+FSQ solution, and they
showed a more persistent CS+ avoidance (Tests 1 and 2) approaching that of the drug groups.
Thus it is possible that SCH233890, MK-801, and naltrexone injections enhanced the quinineCFA by increasing the aversiveness of the FSQ training solution, although the mere observation
of behavioral equivalence of the antagonist effects on the one hand, and the increased
concentration effects on the other does not specify that identical mechanisms of action are
involved. Further studies are needed to address this issue.
4.1 DA D1 and D2 Antagonist Effects: In CFP studies, systemic DA D1and D2
antagonists reduce the acquisition of flavor-taste sugar preferences (Baker et al., 2003; Hsiao &
Smith, 1995; Yu et al., 2000a; 2000b), whereas only DA D1 antagonists reduce the acquisition of
flavor-nutrient sugar preferences (Azzara et al., 2001). These DA antagonist effects involve
central sites of action, notably the NAc, AMY and mPFC (Bernal et al., 2008; 2009; Malkusz et
al., 2012; Touzani et al., 2008; 2009a; 2010 ). One interpretation of how DA antagonists block
sugar-based CFPs is that the drugs reduce the reward value of the sweet taste or post-oral actions
of sugars. An extension of this hypothesis would be that DA antagonists also reduce the negative
reward value of aversive tastes or post-oral aversive states. In fact, DA D1 receptor antagonists
administered into either the LH (Caulliez et al., 1996) or shell of the NAc (Fenu et al., 2001)
disrupted the acquisition of a flavor-toxin CFA induced by LiCl in a manner similar to
reductions in the acquisition of flavor-nutrient CFP elicited by IG glucose infusions (Touzani et
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al., 2008; 2009b). The selective effects of SCH23390, but not raclopride injections on quinineinduced CFA is similar to reports that only SCH23390 altered flavor-toxin avoidance produced
by LiCl injections (Fenu et al., 2005; 2009). However, whereas SCH23390 blocked the
development of the LiCl-CFA, the drug enhanced the quinine-CFA in the present study. The
quinine and LiCl conditioning procedures differed in several important respects which
complicate comparisons between the different drug effects. Note, in particular, that in one
experiment, SCH23390 significantly attenuated a LiCl-induced CFA when injected 5 min after
the CS training sessions but not when injected 30 min prior to the CS training sessions as in the
present study (Fenu et al., 2001). Thus, to determine if SCH23390, or other drugs, differentially
influence the learning of a bitter taste (quinine) or toxic drug (LiCl) CFA, it is essential to use
similar training paradigms (drug dose, injection timing, CS flavor, etc.).
Conceivably, DA D1 antagonism may enhance quinine-conditioned flavor avoidance
because it selectively increases the aversiveness of bitter adulterants. However, there is little
evidence concerning the impact of systemic SCH23390 on quinine avoidance; indeed, one study
reported that SCH microinfusions into the ventral pallidum suppressed saccharin, but not quinine
intake (Shimura et al., 2006). In Experiments 2 and 3, SCH23390 reduced the intake of both the
FS and FSQ solutions so the drug effect on quinine avoidance per se cannot be differentiated.
The failure of raclopride injections to alter CS+FSQ training intake or CS+ preference, relative
to the vehicle treatment, is consistent with one report that this DA D2 antagonist did not alter
quinine solution intake in rats (Phillips et al., 1991).
4.2 NMDA Antagonist Effects: In a CFP study, systemic NMDA receptor antagonism
eliminated the acquisition, but not expression of a flavor-taste fructose preference (Golden &
Houpt, 2007). Blockade of NMDA, AMPA and metabotropic glutamate receptors in the AMY,
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but not the LH or parabrachial nucleus, also disrupted a flavor-LiCl CFA (Tucci et al., 1998;
Vales et al.; 2006; Yasoshima et al., 2000), whereas blockade of NMDA receptors in the AMY
eliminated the acquisition of flavor-nutrient-CFP (Touzani et al., 2013). Yet the present study
demonstrated that systemic treatment with MK-801 significantly prolonged the flavor-taste CFA
induced by quinine. During training, MK-801-treated rats displayed significant reductions in
CS+FSQ, but not CS-FS intake as compared to VEH-treated rats, suggesting that it enhanced the
avoidance of the quinine adulterated solution. Yet, a previous study (Vardigan et al., 2010)
reported that systemic MK-801 did not reduce quinine solution intake in thirsty rats. Golden and
Houpt (2007) hypothesized that NMDA receptor signaling mediates the learning process by
which a flavor CS is associated with the reward value of a gustatory US. Thus, it is not clear why
systemic NMDA receptor antagonism with MK-801 blocks a fructose-CFP (Golden & Houpt,
2007), but enhances a quinine-CFA. CFA is induced by MK-801 as well as other NMDA
antagonists (Fowler et al., 2011; Jackson & Sanger, 1989; Traverso et al., 2003; 2012; Turgeon
et al., 2000), and it enhances ethanol-induced CFA (Blenkowski et al., 1998).
4.3 Opioid Antagonist Effects: In CFP studies, neither systemic nor central (NAc) opioid
receptor antagonism altered the acquisition or expression of flavor-taste or flavor-nutrient sugar
preferences (Azzara et al., 2000; Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Yet the
present study demonstrated that NTX significantly prolonged the flavor-taste CFA induced by
quinine. This effect may be related to the finding that opioid antagonism increased quinine
aversion in rats (Cagniard & Murphy, 2013; Le Magnen et al., 1980; Siviy & Reid, 1983),
although this is not a consistent result (Ferraro et al., 2002; Goodwin et al., 2001; Levine et al.,
1982; Parker et al., 1992). Opioid receptor antagonism with naloxone is also reported to enhance
taste aversions elicited by LiCl (Davis et al., 2009; Micelli et al., 1979; Smurthwaite et al.,
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1992). NTX as well as delta-opioid agonists and antagonists produce conditioned flavor
avoidance by themselves (Hutchinson et al., 2000; Kautz et al., 1989; Parker & Rennie, 1992).
Yet, opioid antagonism blocks morphine-induced taste aversions (Fox et al., 2006; Stevenson et
al., 1992).
4.4 Do antagonists prolong flavor-taste quinine CFA by eliciting CFA themselves: The
ability of NTX and MK-801 to induce a CFA when paired with unflavored saccharin or sucrose
raises the question as to whether aversive drug effects contributed to the enhanced quinine-CFA
observed in the present study. However, Golden and Houpt (2007) did not find any evidence
that MK-801 at the dose used in the present study induces a conditioned flavor avoidance. To
our knowledge, there are no reports that systemic SCH23390 conditions sweet taste avoidance;
one study found that systemic SCH failed to produce a saccharin avoidance (Fenu et al., 2001).
It is worth noting the features of the conditioning paradigm used in the present study that differ
from the typical drug-induced CFA procedures. In particular, in the present study, the antagonist
drugs were administered before the presentation of the CS flavor, whereas in standard CFA
studies the drug is administered after the CS flavor is consumed. Nevertheless, it is possible that
taste avoidance can occur in such a "backward" conditioning preparation if the drug onset is slow
enough to functionally occur simultaneous with or after the presentation of the CS flavor. A
second more important difference between the present paradigm and the typical CFA procedure
is that the antagonist drugs were given prior to both the CS- and the CS+ solutions during
training sessions so that both flavors were associated with the aversive effects, if any, of the
drugs. In the typical drug CFA procedure, only CS+ is paired with the drug and the CS- is paired
with a vehicle treatment. The critical importance of this design feature is indicated by early
studies of opioid antagonist effects on sugar-conditioned flavor preferences. In particular, one
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study (Mehiel, 1996) reported that naloxone blocked a sugar CFP when the drug was
administered prior to CS+ training sessions only, whereas other studies reported that naltrexone
did not block a sugar CFP when the drug was administered prior to both CS+ and CS- training
sessions (Azzara et al., 2000; Yu et al., 1999). Thus, it is not certain that drug-induced aversive
effects contributed to the prolonged quinine-CFA observed in the present study, but this issue
certainly requires further analysis.
In summary, whereas DA D1, DA D2 and NMDA, but not opioid receptor antagonism
blocks the acquisition of sweet taste-based CFP, DA D1, NMDA and opioid, but not DA D2
receptor antagonism enhances a bitter taste-based CFA.
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Chapter 4: Muscarinic and nicotinic cholinergic receptor antagonists differentially mediate
acquisition of fructose-conditioned flavor preference and quinine-conditioned flavor
avoidance in rats.
1. Introduction:
Sugar-CFPs are based on learned associations between food flavor elements (flavorflavor conditioning) as well as between flavor and post-ingestive consequences (flavor-nutrient
conditioning) (Sclafani, 1995). Flavor-flavor conditioning has been studied for sucrose in shamfeeding rats (Yu et al., 1999, 2000a, 2000b), and for fructose in real-feeding rats (Baker al.,
2003, 2004) given the inability of fructose to condition preferences after IG administration
(Sclafani and Ackroff, 1994; Sclafani et al., 1993, 1999). In contrast, glucose is capable of
producing CFP following oral and IG administration (Dela Cruz et al., 2014; Sclafani and
Ackroff, 1994; Sclafani et al., 1993, 1999). Previous pharmacological analyses have evaluated
the neurochemical substrates of the acquisition (learning) and expression (maintenance) of the
flavor-flavor component of sugar-CFP. Systemic administration of either DA D1 (SCH23390) or
D2 (raclopride) receptor antagonists eliminated both acquisition and expression of fructose-CFP
in real-feeding, food-restricted rats and sucrose-CFP in sham-feeding, food-restricted rats (Baker
et al., 2003; Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). Central DA receptor mediation of
the acquisition and expression of fructose-CFP is differentially controlled by the NAc, AMY,
mPFC, mOFC, and LH (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012,
2015). Systemic administration of NMDA receptor antagonists (MK-801) eliminated the
acquisition, but not the expression of fructose-CFP (Golden and Houpt, 2007). However,
systemic administration of cannabinoid (CB1) receptor inverse agonists (AM251) reduced the
expression, but not the acquisition of fructose-CFP (Miner et al., 2008). In contrast, systemic and
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NAc administration of NTX reduced sweet intake, but failed to alter flavor-flavor-mediated
sugar-CFP (Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Therefore, DA D1, DA D2,
NMDA and CB1, but not opioid receptor signaling is required for the full learning (acquisition)
and maintenance (expression) of fructose-CFP, apparently in limbic sites associated with reward.
CFA can be induced by either ingested toxins that induce gastrointestinal distress (flavor–
toxin learning; see review: Freeman and Riley, 2009) or by an aversive taste (flavor-taste
learning; e.g., Dwyer, 2011 Fanselow and Birk, 1982). Pharmacological analyses have examined
DA D1, DA D2, NMDA and opioid antagonists in flavor-toxin CFA learning. DA D1, but not
D2 antagonism disrupted the acquisition of a LiCl-induced CFA following systemic
administration, and following central administration into the LH or NAc shell (Caulliez et al.,
1996; Fenu et al., 2001, 2005, 2009). Blockade of NMDA, AMPA and metabotropic glutamate
receptors in the amygdala disrupted LiCl-induced CFA (Yasoshima et al., 2000). Naloxone
enhanced taste aversions elicited by LiCl (Davis et al., 2009; Miceli et al., 1979; Smurthwaite et
al., 1992). Our laboratory (Rotella et al., 2014) previously examined the pharmacological
substrates of flavor-taste CFA learning using a design to match that used in our flavor–flavor
CFP studies. In this case, food-restricted rats were trained with two differently flavored fructose
+ saccharin (FS) solutions with one adulterated with quinine (0.03%: FSQ). In contrast to the
greater persistence of fructose-CFP over a week or more of testing (Baker et al., 2003, 2004),
quinine (0.03%)-CFA typically lasts for one pair of sessions. However, the persistence of
quinine-CFA was significantly enhanced by systemic administration of DA D1, NMDA and
opioid, but not DA D2 receptor antagonists administered during training (Rotella et al., 2014).
Thus, whereas DA D1, DA D2 and NMDA, but not opioid receptor antagonism blocks the
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acquisition of sweet taste-based CFP, DA D1, NMDA and opioid, but not DA D2 receptor
antagonism enhanced the duration of a bitter taste-based CFA.

.

Avena and Rada (2012) have implicated acetylcholine (Ach) in the mediation of food
intake, particularly the “addictive” aspects of excessive sugar intake, by its interactions with
brain DA systems. One Ach-DA neuroanatomical interaction presumably occurs through Ach
inputs from the PPT/LDT nuclei to identified DA cells in the VTA (Holmstrand and Sesack,
2011; Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et al., 1990). The second Ach-DA
interaction presumably occurs through DA terminal innervation of Ach-containing interneurons
in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et al., 2002), although cholinergic
PPT/LDT innervation is found there as well (Dautan et al., 2014). NAc cholinergic-DA
interactions act through local DA D2 receptors (Alcantara et al., 2003), mediate accumbal DA
release that also involves glutamate signaling (Cachope et al., 2012; Chuhma et al., 2014;
Threlfell and Cragg, 2011), and provide feedback control of VTA DA release (Rahman and
McBride, 2002). These interactions are integral in the formulation of central mechanisms
involved in food reward (see reviews: Avena and Rada, 2012; Kelley et al., 2005; Laurent et al.,
2014; Mark et al., 2011; McFadden et al., 2014; Nunes et al., 2013), and suggest that cholinergic
receptor mechanisms may also play a role in acquisition and expression of fructose-CFP
mediated by systemic (Baker et al., 2003; Yu et al., 2000a, 2000b) and accumbal (Bernal et al.,
2008; Malkusz et al., 2012) DA. NAc cholinergic interneurons play a role in regulation of body
weight and metabolism (Hajnal et al., 2000). Food intake increases Ach release in the AMY
(Hajnal et al., 1998) and the NAc (Mark et al., 1992, 1995). Sugar intake under bingeing
conditions potently increases NAc Ach release that is mediated by deprivation, sham intake and
weight of the animals (Avena et al., 2006, 2008a, 2008b, 2008c). Further, VTA Ach and NAc
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DA are concomitantly released by the orexigenic peptide, ghrelin (Jerlhag et al., 2012), and
activity of dorsomedial hypothalamic cholinergic neurons increases following overnight food
deprivation (Groessl et al., 2013). Although food intake was significantly reduced by chronic
nicotine (Dandekar et al., 2011), the nicotinic cholinergic receptor antagonist, MEC suppressed
ghrelin-induced food intake (Dickson et al., 2010), and chronic 18-methoxycoronaridine reduced
long-term sucrose intake (Taraschenko et al., 2011). Pilocarpine, a muscarinic cholinergic
receptor agonist, administered into the NAc core increased chow intake (Nunes et al., 2013).
Muscarinic receptor antagonism with SCOP in the NAc reduced both deprivation-induced
feeding (Pratt and Blackstone, 2009) and NAc DAMGO-induced feeding (Perry et al., 2009),
and NAc sites at which SCOP suppressed feeding and DAMGO induced feeding overlapped
(Perry et al., 2014). DAMGO-induced increases in high-fat feeding were blocked by NTX and
SCOP, but not by antagonists of DA, glutamate or nicotinic receptors (Will et al., 2006).
Muscarinic receptor blockade also mediated cue-related responses to feeding such that SCOP
administered into the VTA disrupted food-related learning (Sharf and Ranaldi, 2006). SCOP
administered into the NAc core induced avoidance to flavor and spatial cues (Pratt et al., 2007).
SCOP administered into the ventral hippocampus impaired memories for socially-transmitted
food preferences (Carballo-Marquez et al., 2009). Thus, these data appear to implicate the
cholinergic receptor system in a limbic circuit that mediates not only food intake per se, but is
also involved in the development of preferences.
Cholinergic receptors have also been previously implicated in certain forms of CFA. In
flavor-toxin CFA learning, SCOP attenuated LiCl-induced CFA without altering aversion to
quinine (Coil et al., 1978). SCOP and nicotine are capable of eliciting flavor-taste CFAs with the
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et
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al., 1986, Ossenkopp and Gugno, 1990). A possible role for cholinergic receptors in flavor-taste
CFA is supported by the ability of quinine to inhibit Ach currents in alpha-9-alpha-10-containing
nicotinic Ach receptors in Xenopus oocytes (Ballestero et al., 2005), and adrenal catecholamine
secretion evoked by Ach stimulation of muscarinic and nicotinic receptors (Jang et al., 2001). In
turn, nicotine depressed quinine-evoked responses in the nucleus tractus solitarius that were
blocked by MEC (Simons et al., 2006). Nicotine and quinine CFA generalized to each other in
three mouse strains (Gyekis et al., 2012), with MEC blocking this ability in behavioral and
electrophysiological assays (Oliveira-Maia et al., 2009). Thus, these data appear to implicate
cholinergic receptor signaling in flavor-taste CFA.
Much of the evidence implicating cholinergic involvement in complex aspects of food
intake appears to be due to activity in a limbic circuit (specifically the VTA and NAc) in which
cholinergic signaling can act directly upon preferences and avoidances either in and of itself, or
through interactions with brain DA. Therefore, the present study investigated the role of
muscarinic and nicotinic cholinergic receptor signaling in mediating the expression and
acquisition of flavor preferences conditioned by fructose in rats. Our previous evaluation of DA
receptor involvement in fructose-CFP initially examined systemic receptor-selective antagonist
effects (Baker et al., 2003; Yu et al., 2000a, 2000b) followed by antagonist administration into
central candidate limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al.,
2012). Hence, the present study initially employed a systemic approach in examining the dosedependent effects of muscarinic (SCOP) or nicotinic (MEC) cholinergic receptor antagonists
upon the expression and acquisition of fructose-CFP. A parallel study then examined whether
systemic SCOP or MEC altered the acquisition of quinine-CFA in a fructose-saccharin solution.
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2. Methods:
2.1 Subjects: Male Sprague-Dawley rats (n=124, 250-275 g), obtained from Charles
River Laboratories (Wilmington, MA), were housed individually in wire mesh cages, maintained
on a 12:12 h light/dark cycle (lights on: 7 AM, lights off: 7 PM) at a constant ambient
temperature of 22°C with chow (5001, PMI Nutrition International, Brentwood, MO) and water
available ad libitum for the first week. All animals were then food-restricted to 85-90% of their
body weight throughout behavioral testing to insure short-latency responses to presentation of
the training and test solutions. Food rations were provided 1 h after the end of daily training and
testing sessions. The experimental protocols were approved by the Queens College Institutional
Animal Care and Use Committee (Protocol 69) certifying that all subjects and procedures are in
compliance with the National Institutes of Health Guide for Care and Use of Laboratory
Animals.
2.2 Fructose-CFP Initial Training and Test Solutions: During initial training in the
fructose-CFP paradigm, rats were trained to drink an unflavored 0.2% sodium saccharin (Sigma
Chemical Co., St. Louis, MO) solution during five daily 1-h sessions to guarantee sampling as
previously described (Baker et al., 2003, 2004); this initial unflavored training solution was the
same concentrations as the flavored CS- solution used in the subsequent conditioning paradigms.
The sipper tube was mounted on the front of the cage held by a taut steel spring, and was
positioned 3-6 cm above the cage floor. Solution measurement (0.1 ml gradations and accuracy)
was insured by using a retrofitted testing sipper tube that has been previously validated (Baker et
al., 2003, 2004; Rotella et al., 2014; Yu et al., 1999, 2000a, 2000b). This training procedure was
repeated daily until all rats approached the sipper tubes with short (< 1 min) latency, typically
within three days. The limited food rations were given 1 h after each training session.
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The two training solutions in the fructose-CFP expression and acquisition studies were a
8% fructose + 0.2% saccharin solution and a saccharin (0.2%) solution, each flavored with
0.05% unsweetened grape or cherry Kool-Aid (General Foods, White Plains, NY). The 8%
fructose + 0.2% saccharin-paired flavor is referred to as the CS+/Fs, and the 0.2% saccharinpaired flavor as the CS-/s (Baker et al., 2003, 2004; Yu et al., 1999, 2000a, 2000b). Half of the
rats in each drug paradigm had the cherry flavor added to the CS+/Fs solution and the grape
flavor added to the CS-/s solution; flavors were reversed for the remaining rats. In all two-bottle
preference choice tests for fructose-CFP, the cherry and grape flavors were presented in 0.2%
saccharin solutions (CS+, CS-). All training and testing in both paradigms took place in the rat’s
home cage during the mid-light phase (~11 AM- 4 PM) of the light:dark cycle.
2.3 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP
Expression: Thirty-one rats were given ten daily 1-bottle training sessions (0.5 h/day) with 16 ml
of the CS+/Fs solution presented on odd-numbered days, and 16 ml of the CS-/s solution
presented on even-numbered days. On days 9 and 10, the rats had access to a second sipper tube
containing water. This familiarized the rats to the presence of two sipper tubes used during the
choice tests; water intake was negligible in these training trials. The left-right position of the CS
and water sipper tubes was counterbalanced over the two days. The order of presentation of the
CS+/Fs first followed by subsequent presentation of the CS-/s solution during training was
identical to that used in our and other previous studies examining the pharmacological substrates
of fructose-CFP in real-feeding rats (Baker et al., 2004; Golden & Houpt, 2007) and sucroseCFP in sham-feeding rats (Yu et al., 2000a, 2000b). Following training, the rats were given eight
2-bottle choice test sessions (0.5 h/day) with unlimited (~45 ml) access to the CS+ and CSflavors mixed in 0.2% saccharin solutions. Solution intakes during training and testing were
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measured by weighing (0.1 g) the bottles before and after the 1 h sessions. The animals were
limited to eight 2-bottle sessions because previous research (Baker et al., 2003, 2004; Yu et al.,
2000a, 2000b) demonstrated that the magnitude of the preference did not change during this
testing interval. Therefore, each animal received vehicle, and three doses of either the muscarinic
or nicotinic cholinergic receptor antagonist. All 31 rats initially received a pair of vehicle
injections that were used to match the animals into muscarinic and nicotinic groups as well as to
match them as a function of receiving three of the five doses. Following vehicle treatment, the
first group of fifteen rats received pairs of three doses of SCOP injections at 0.1 (n=7), 1 (n=7),
2.5 (n=8), 5 (n=8) and 10 (n=15) mg/kg 30 min prior to the two-bottle choice test. Following
vehicle treatment, the second group of sixteen rats received pairs of three doses of MEC
injections at 1 (n=7), 2 (n=7), 4 (n=16), 6 (n=9) and 8 (n=9) mg/kg 30 min prior to the two-bottle
choice test. The 30-min interval for systemic administration of the muscarinic and nicotinic
cholinergic receptor antagonists prior to the experimental condition in this and the other two
paradigms was based on this commonly-used interval in many other systemic studies. Thus, all
groups of rats were tested in two consecutive daily sessions at vehicle and three drug doses with
the left–right position of the CS+ and CS- solutions counterbalanced across sessions to control
for position effects. Half of the rats in each group were tested with an ascending drug dose order,
and the remaining rats were tested with a descending drug dose order.
2.4 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP
Acquisition: Six groups of rats, matched for their intakes of the unflavored 0.2% saccharin
solution prior to training, were given ten 1-bottle training sessions (1 h/day) with 16 ml of the
CS+/Fs solution presented on odd-numbered days, and 16 ml of the CS-/s solution presented on
even-numbered days. The first group (VEH) of eight rats received daily vehicle injections 30
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min prior to each training session. The second (SCOP 1) and third (SCOP 2.5) groups received
daily injections of SCOP at doses of 1 (n=8) and 2.5 (n=8) mg/kg respectively 30 min prior to
each training session. The fourth (MEC 4) and fifth (MEC 6) groups received daily injections of
MEC at doses of 4 (n=8) and 6 (n=7) mg/kg respectively 30 min prior to each training session.
The sixth (n=6) group received daily injections of vehicle 30 min prior to each training session,
but were limited in CS+ and CS- intakes to the reduced levels observed during training in the
drug groups (LMTD VEH). Following training, all groups were given six daily 2-bottle choice
sessions (1 h/day) with unlimited (~45 ml) access to the CS+ and CS- flavors mixed in 0.2%
saccharin solutions; no drugs were administered prior to these sessions. The positions of the CS+
and CS- solutions were counterbalanced across sessions.
2.5 Quinine-CFA Initial Training and Test Solutions: During initial training in the
quinine-CFA paradigm, rats were trained to drink an unflavored 8% fructose (Sigma Chemical
Co.) and 0.2% sodium saccharin solution as previously described (Rotella et al., 2014); this
initial unflavored training solution was the same concentrations as the flavored CS- solution used
in the subsequent conditioning paradigms. Initial training was otherwise identical to the fructoseCFP paradigm. The two training solutions in the quinine-CFA acquisition study were 8%
fructose + 0.2% saccharin with or without quinine (0.03%: Sigma Chemical Co.). Each solution
was flavored with 0.05% unsweetened grape or cherry Kool-Aid (Rotella et al., 2014). Half of
the rats in each group had the cherry flavor added to the fructose + saccharin solution and the
grape flavor added to the fructose + saccharin + quinine solution; the flavors were reversed for
the remaining rats. In the two-bottle choice tests, the cherry and grape flavors were presented in
8% fructose + 0.2% saccharin solutions. The flavored fructose + saccharin + quinine solution is
referred to as the CS+/FSQ, and the flavored fructose + saccharin solution as the CS-/FS; and the
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same flavors used in the two-bottle tests are referred to as CS+ and CS-, respectively (Rotella et
al., 2014). All training and testing in this paradigm took place in the rat’s home cage during the
mid-light phase (~11 AM- 4 PM) of the light:dark cycle.
2.6 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Quinine-CFA
Acquisition: Rats were trained over eight one-bottle training sessions (1 h) to drink 16 ml of the
CS-/FS solution on odd-numbered days, and 16 ml of the CS+/FSQ solution on even-numbered
days. The CS-/FS solution was presented first to minimize potential potent neophobic effects of
the fructose-saccharin solution adulterated by quinine (CS+/FSQ), and encourage intake as
performed previously (Rotella et al., 2014). The eight training trials were divided into four pairs
of sessions with a one-day break between each pair (Rotella et al., 2014). In the first three
training pairs, only one bottle was presented. In the fourth pair of training sessions (days 7 and
8), a second sipper tube containing water was also presented to acclimate the rats to the presence
of two sipper tubes used during the choice tests; water intake was negligible in these training
trials. The left-right position of the CS and water sipper tubes was counterbalanced over the two
days. The first group (VEH) of eighteen rats received daily vehicle injections 30 min prior to
each training session. The second (SCOP 1) and third (SCOP 2.5) groups received daily
injections of SCOP at doses of 1 (n=7) and 2.5 (n=8) mg/kg respectively 30 min prior to each
training session. The fourth (MEC 4) and fifth (MEC 6) groups received daily injections of MEC
at doses of 4 (n=8) and 6 (n=7) mg/kg respectively 30 min prior to each training session.
Because the two SCOP and the two MEC groups displayed comparable CS-/F and CS+/FSQ
intakes during training, an additional limited vehicle group was not employed in this study.
Following training, all groups received six two-bottle sessions with the CS+ and CS- flavors
mixed in 8% fructose + 0.2% saccharin (FS) solutions (unlimited ~45 ml) access). The position

60
of the two bottles were left (L)-right (R)-R-L-L-R in half of the animals, and R-L-L-R-R-L in the
remaining half. Solution intakes during the training and testing were measured by weighing (0.1
g) the bottles before and after the 1 h sessions.
2.7 Statistics: In fructose-CFP expression studies, training intakes were averaged over the
five CS+/Fs and five CS-/s sessions and evaluated by a t-test. Intakes during the two-bottle
preference tests were averaged over the two sessions at each dose and evaluated with two-way
repeated-measures analyses of variance (ANOVA, CS condition vs. Dose) for each group.
Separate ANOVAs evaluated percent CS+/g intakes and total intake as a function of dose for the
three groups. In fructose-CFP acquisition studies, training intakes were averaged over the five
CS+/Fs and CS-/s sessions and were analyzed with a two-way randomized-blocks ANOVA (CS
conditions x Groups). Intakes during the two-bottle preference tests were averaged over sessions
1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A three-way
randomized-blocks ANOVA compared the CS intakes of the six groups (Group x CS x Test). A
separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the six groups
across the three tests. In quinine-CFA acquisition studies, training intakes were averaged over
the four CS+/FSQ and CS-/FS sessions and were analyzed with a two-way randomized-blocks
ANOVA (CS conditions x Groups). Intakes during the preference tests were averaged over
sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3) to control for side position effects. A
three-way randomized-blocks ANOVA compared the CS intakes of the five groups (Group x CS
x Test). A separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the five
groups across the three tests. When main or interaction effects were observed in any ANOVA,
Bonferroni corrected comparisons (p<0.05) detected significant effects. Drug-induced changes
in acquisition or expression preferences were operationally defined as a significant change in

61
percent CS+ intakes relative to vehicle, and/or a failure to observe significant differences
between CS+ and CS- intakes in the two-bottle preference tests.
3. Results:
3.1 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP
Expression: During 1-bottle training, CS+/Fs intake (12.6 g (SEM: +0.3)) significantly exceeded
(t(30)= 3.77, p<0.0005) CS-/s intake (11.1 g (SEM: +0.4)). In the 2-bottle preference tests
conducted following SCOP treatment, overall, CS+ (6.6 g) intakes significantly exceeded CS(1.4 g) intakes (F(1,14)= 102.13, p<0.0001), and intakes significantly differed as functions of
SCOP dose (F(5,70)= 65.29, p<0.0001) and for the interaction between conditions and doses
(F(5,70)= 42.25, p<0.0001). CS+ intake was significantly higher than corresponding CS- intake
following vehicle and all SCOP doses (Figure 5A, *). All SCOP doses significantly reduced
CS+, but not CS- intake relative to vehicle (Figure 5A, +). Percent CS+ preferences significantly
differed (F(5,54)= 5.16, p<0.0006) as a function of SCOP dose with the three highest (2.5 (65%),
5 (65%), 10 (68%) mg/kg) doses significantly reducing percent CS+ preferences relative to
vehicle (90%) (Figure 5A, +). Although significant fructose-CFP preferences were noted across
all SCOP doses after learning of the preference had taken place, these data indicate a dosedependent ability of SCOP to significantly reduce, but not eliminate the magnitude of the
expression of CS+ preferences at the three highest doses.
In the 2-bottle preference tests conducted following MEC treatment, overall, CS+ (7.1 g)
intakes significantly exceeded CS- (1.2 g) intakes (F(1,15)= 570.01, p<0.0001), and intakes
significantly differed as functions of MEC doses (F(5,75)= 197.16, p<0.0001) and for the
interaction between conditions and doses (F(5,75)= 104.40, p<0.0001). CS+ intake was
significantly higher than CS- intake following vehicle and all MEC doses (Figure 5B, *). MEC
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Figure 5. (Cholinergic receptor antagonists and fructose-CFP expression): Intakes (mean +SEM,
g/30 min) of CS+ and CS- solutions in two-bottle preference tests in animals pretreated (30 min)
with systemic scopolamine (Panel A) or mecamylamine (Panel B). Significant differences are
denoted between CS+ and CS- intake within an injection condition (*) as well as drug-induced
effects upon CS+ and CS- intake relative to corresponding vehicle values (+). The percentages of
CS+ intake over total intake are indicated above each pair of values with significant effects
denoted (+).
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doses between 2 and 8 mg/kg, but not 1 mg/kg significantly reduced CS+, but not CS- intake
relative to vehicle (Figure 5B, +). Percent CS+ preferences significantly differed (F(5,58)= 7.75,
p<0.0001) as a function of MEC dose with the three highest (4 (68%), 6 (67%), 8 (73%) mg/kg)
doses significantly reducing percent CS+ preferences relative to vehicle (89%) (Figure 5B. +).
Although significant fructose-CFP preferences were noted across all MEC doses after learning of
the preference had taken place, these data indicate a dose-dependent ability of MEC to
significantly reduce, but not eliminate the magnitude of the expression of CS+ preferences at the
three highest doses.
3.2 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Fructose-CFP
Acquisition: During 1-bottle training, overall CS+/Fs intake (6.0 g) significantly (F(1,7)= 26.58,
p<0.0013) exceeded CS-/s intake (4.1 g), and there were significant differences among groups
(F(5,35)= 21.54, p<0.0001) and for the interaction between groups and conditions (F(5,35)=
3.02, p<0.023). CS+/Fs and CS-/s intakes of the SCOP 1, SCOP 2.5, MEC 4 and MEC 6 groups
were significantly lower than corresponding training intakes of the VEH group (Figure 6, +).
However, training intakes of all drug groups failed to differ from corresponding LMTD VEH
group intakes, except for lower CS-/s intake in the SCOP 2.5 group (Figure 6).
Following training, the rats were given three pairs of two-bottle preference tests without
drug treatment. Significant differences were observed among groups (F(5,35)= 3.42, p<0.013),
among tests (F(2,14)= 4.44, p<0.032), between CS+ and CS- conditions (F(1,7)= 57.24,
p=0.0001), and for the interactions between groups and tests (F(10,70)= 9.59, p<0.017), groups
and conditions (F(5,35)= 5.99, p<0.0004), and among groups, tests and times (F(10,70)= 2.59,
p<0.01), but not for the interaction between tests and conditions (F(2,14)= 1.36, ns). Withingroup comparisons revealed that CS+ intake was significantly greater than CS- intake in
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Figure 6. (Cholinergic receptor antagonists and fructose-CFP acquisition training): Intakes
(mean +SEM, g/60 min) of CS+/Fs and CS-/s solutions during one-bottle training sessions in
animals receiving vehicle (VEH), scopolamine at doses of 1 (SCOP 1) or 2.5 (SCOP 2.5) mg/kg,
mecamylamine at doses of 4 (MEC 4) or 6 (MEC 6) mg/kg, or vehicle, but limited to druginduced intakes (LMTD VEH) 30 min prior to each training session. Significant differences are
denoted in drug-induced effects upon CS+/Fs and CS-/s intake relative to corresponding VEH
intake (+).

65
Tests 1-3 in the VEH (Figure 7A, *), MEC 4 (Figure 7D, *), MEC 6 (Figure 7E, *) and LMTD
VEH (Figure 7F, *) groups. CS+ and CS- intakes failed to differ in any of the tests in the SCOP
1 (Figure 7B) and SCOP 2.5 (Figure 7C) groups. The SCOP 1 group displayed significantly
lower CS+ intake in all three tests and significantly higher CS- intake in the last two tests relative
to VEH (Figure 7B, +), whereas the SCOP 2.5 group displayed significantly lower CS+, but not
CS- intake in the first two tests relative to VEH (Figure 7C, +). Comparisons with the LMTD
VEH group revealed significantly lower CS+ intake across all three tests for the SCOP 1 and
SCOP 2.5 groups, and significantly higher CS- intakes in the last two tests in the SCOP 1 group.
Significant differences in the percent CS+ intake were observed among groups (F(5,35)= 6.48,
p<0.0002) and for the interaction between groups and tests (F(10,70)= 2.98, p<0.035), but not
among tests (F(2,14)= 0.15, ns). The percent CS+ intakes were stable across the three tests in the
VEH (85-92%, Figure 7A), MEC 4 (82-83%, Figure 7D), MEC 6 (67-75%, Figure 7E) and
LMTD VEH (74-88%, Figure 7F) groups. In contrast, the SCOP 1 (40-54%, Figure 7B) and the
SCOP 2.5 (45-58%, Figure 7C) groups displayed significantly lower percent CS+ preferences
across all three tests relative to either the VEH or LMTD VEH groups. Thus, these data indicate
that SCOP, but not MEC, administered during training eliminated the subsequent acquisition of
fructose-CFP.
3.3 Muscarinic and Nicotinic Cholinergic Receptor Antagonists and Quinine-CFA Acquisition:
In the one-bottle training sessions, overall, CS-/FS intake significantly exceeded CS+/FSQ intake
(8.4 vs. 1.7 g/1 h, F(1,17)= 528.14, p<0.0001), there were significant group differences (F(4,68)=
69.44, p<0.0001), and there was a significant interaction between groups and CS (F(4,68)=
18.77, p=0.0001). CS-/FS intake for all five groups was significantly higher than CS+/FSQ
intake (Figure 8A, *), replicating the previously- demonstrated (Rotella et al., 2014) ability of
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Figure 7. (Cholinergic receptor antagonists and fructose-CFP acquisition testing): Intakes (mean
+SEM, g/30 min) of CS+ and CS- solutions in three pairs of two-bottle preference tests
(unlimited (~45 ml) access, Tests 1, 2, 3) in animals that received VEH (Panel A), SCOP 1
(Panel B), SCOP 2.5 (Panel C), MEC 4 (Panel D), MEC 6 (Panel E) or LMTD VEH (Panel F)
during training. Significant differences are denoted between CS+ and CS- intake within an
injection condition (*) as well as drug-induced effects upon CS+ and CS- intake relative to
corresponding vehicle values (+). The percentages of CS+ intake over total intake are denoted
above each pair of values with significant effects denoted relative to VEH (+) and LMTD VEH
(#).
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Figure 8. (Cholinergic receptor antagonists and quinine-CFA acquisition training and testing.
Panel A): One-bottle training intakes (mean +SEM, g/60 min) of CS+/FSQ and CS-/FS solutions
during training sessions in animals receiving systemic administration of VEH, scopolamine at
doses of 1 (SCOP 1) or 2.5 (SCOP 2.5) mg/kg, or mecamylamine at doses of 4 (MEC 4) or 6
(MEC 6) mg/kg 30 min prior to each training session. Animals were given 16 ml of solutions
during training as indicated in the Panel A y-axis. Significant differences are denoted between
CS+/FSQ and CS-/FS intake are denoted (*) as are any drug effect relative to VEH (+). Twobottle choice test intakes (mean +SEM, g/60 min, unlimited (~45 ml) access) of the CS+ and CSflavors presented in fructose+saccharin solutions in Tests 1-3 in groups trained with VEH (Panel
B), SCOP 1 (Panel C), SCOP 2.5 (Panel D), MEC 4 (Panel E) or MEC 6 (Panel F). Significant
differences are denoted between CS+/FSQ and CS-/FS intakes within an injection condition (*)
as well as drug-induced effects upon CS+ and CS- intake relative to corresponding VEH values
(+). The percentages of CS+/FSQ intake over total intake are denoted above each pair of values.
Significant differences are denoted between percent CS+/FSQ intakes relative to VEH (+).

68
quinine at a 0.03% concentration to reduce intake. CS-/FS and CS+/FSQ intakes were
significantly lower in the SCOP 1, SCOP 2.5, MEC 4 and MEC 6 groups relative to the
corresponding VEH group (Figure 8A, +). The SCOP and MEC groups failed to differ from each
other in CS-/FS and CS+/FSQ intakes.
In the two-bottle choice tests, there were significant differences in the overall CS+ (6.4 g)
and CS- (15.4 g) intakes (F(1,17)= 252.39, p<0.0001), as well as significant differences among
groups (F(4,68)= 11.26, p<0.0001), across tests (F(2,34)= 114.71, p<0.0001), and for the
interactions between groups and tests (F(8,136)= 7.63, p<0.013), between groups and conditions
(F(4,68)= 10.07, p<0.0001) and among groups, tests and conditions (F(8,136)= 5.23, p<0.0001),
but not between tests and conditions (F(2,34)= 0.08, ns). Within-group comparisons revealed
that the VEH group consumed significantly more CS- than CS+ only during Test 1 (Figure 8B,
*), consistent with the limited duration of quinine-CFA observed previously (Rotella et al.,
2014). CS- intake was significantly greater than CS+ intake during Tests 1 and 3 in the SCOP 1
group (Figure 8C, *), and during test 2 in the SCOP 2.5 group (Figure 8D, *). CS- intake was
significantly greater than CS+ intake across all three tests in the MEC 4 (Figure 8E, *) and MEC
6 (Figure 8F, *) groups. CS- intake was significantly lower in Test 1 of the SCOP 2.5 group
relative to corresponding VEH (Figure 8D, +). CS+ intake was significantly lower in Test 2 of
the MEC 4 group (Figure 8E, +) and in Tests 1 and 2 of the MEC 6 group (Figure 8F, +).
Analysis of the percent CS+ intake data revealed significant differences among groups (F(4,68)=
11.43, p<0.0001), across tests (F(2,34)= 10.74, p<0.0002), and for the interaction between
groups and tests (F(8,136)= 6.27, p<0.0001). The SCOP 1 group displayed significantly greater
quinine-CFA during Test 1 relative to vehicle (17.0% vs. 33.9%; Figure 8C); all other SCOP
effects failed to differ from the VEH group. In contrast, MEC treatment during training
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significantly enhanced the magnitude of quinine-CFA across all three tests in the MEC 4 (Figure
8E) and MEC 6 (Figure 8F) relative to the VEH group. Thus, these data indicate that MEC, but
not SCOP, administered during training significantly enhanced and prolonged the subsequent
acquisition of quinine-CFA.
4. Discussion:
These experiments indicate that systemic pretreatment with muscarinic and nicotinic
receptor antagonists differentially altered the expression and acquisition of dructose-CFP as well
as the acquisition of quinine-CFA.
4.1 Cholinergic Receptor Antagonism and Fructose-CFP Expression: Expression of
fructose-CFP, defined by significant preferences for the CS+ flavor over the CS- flavor, failed to
be affected by a wide dose range of the muscarinic antagonist, SCOP or the nicotinic antagonist,
MEC. However, the magnitude of fructose-CFP expression, defined by changes in percent CS+
intake, was significantly reduced by high doses of SCOP (2.5-10 mg/kg: 65-68%) and MEC (4-8
mg/kg: 67-73%) relative to vehicle (89-90%). These reductions were accompanied by reductions
in total, and particularly CS+, intake. These intake reductions of saccharin by systemic SCOP
and MEC correspond to previous reductions of sweet intake following systemic nicotinic
receptor antagonism (Taraschenko et al., 2011) and chow intake following systemic of
muscarinic and nicotinic receptor antagonism (Dandekar et al., 2011; Dickson et al., 2010; Perry
et al., 2009; Pratt and Blackstone, 2009; Will et al., 2006). The very limited inhibition of
systemic muscarinic or nicotinic cholinergic receptor antagonism of expression of fructose-CFP
stands in contrast to previously-observed systemic pharmacological effects. Thus, systemic DA
D1 (SCH23390) or D2 (raclopride) receptor antagonists dose-dependently eliminated the
expression of both fructose-CFP in real-feeding rats and sucrose-CFP in sham-feeding rats
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(Baker et al., 2003; Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). Whereas a CB1 receptor
inverse agonist (AM-251) reduced expression of fructose-CFP (Miner et al., 2008), neither
NMDA (MK-801) nor opioid (naltrexone) receptor antagonism affected expression of fructoseCFP (Baker et al., 2004; Bernal et al., 2010; Golden and Houpt, 2007). Thus, muscarinic or
nicotinic cholinergic receptor santagonism plays a minimal role in the maintenance of an
already-acquired CFP for fructose.
4.2 Cholinergic Receptor Antagonism and Fructose-CFP Acquisition: Acquisition of
fructose-CFP was eliminated by systemic muscarinic (SCOP), but not nicotinic (MEC)
cholinergic receptor antagonists administered during training. This was demonstrated by the
failure of two-bottle CS+ and CS- intakes to differ in rats receiving SCOP during training. The
magnitude of fructose-CFP observed in vehicle-trained (85-92%) rats was eliminated in SCOPtrained rats receiving 1 (40-54%) and 2.5 (45-58%) mg/kg doses, effects indicative of
indifference. Because these SCOP doses significantly reduced CS+/Fs and CS-/s intakes during
training, it is possible that this loss of preference could be alternatively due to specific primary
actions of muscarinic cholinergic receptor antagonism or to secondary actions of reducing the
opportunities to learn the preference due to reduced intake per se. The addition of the LMTD
VEH group receiving vehicle injections, but limited in comparable CS+ and CS- intakes to those
of the drug groups controlled for this second possibility, and displayed comparable, significant
fructose-CFP preferences relative to vehicle-trained rats. These data strongly suggest that the
inability of SCOP-trained rats to display preferences was thus due to its cholinergic receptor
antagonism. Further, the SCOP doses (1-2.5 mg/kg) capable of eliminating fructose-CFP
acquisition were incapable of affecting fructose-CFP expression. In contrast, MEC-trained rats
displayed significant preferences with CS+ intake significantly higher than CS- intake, and
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comparable percent CS+ intake preferences following the 4 (82-83%) and 6 (67-75%) mg/kg
doses relative to vehicle- (85-92%) and LMTD VEH- (74-88%) trained groups. This failure of
systemic nicotinic receptor antagonism to affect fructose-CFP acquisition occurred despite
MEC’s significant reductions in CS+/Fs and CS-/s intakes during training to levels observed for
SCOP. Hence, systemic muscarinic (SCOP), but not nicotinic (MEC) receptor antagonism
administered during training eliminated fructose-CFP acquisition. These data extend the
circumstances under which muscarinic receptor blockade mediated other cue-related feeding
responses, including disruptions in food-related learning following VTA administration (Sharf
and Ranaldi, 2006), avoidance to flavor and spatial cues following NAc core administration
(Pratt et al., 2007), and memories for socially-transmitted food preferences following ventral
hippocampal administration (Carballo-Marquez et al., 2009). These effects are also consistent
with the ability of food, and especially sugars, to increase Ach release in the AMY and the NAc
(Avena et al., 2006, 2008a, 2008b, 2008c; Hajnal et al., 1998; Mark et al., 1992, 1995). The
systemic SCOP-induced elimination of fructose-CFP acquisition is similar in magnitude to the
abilities of systemic DA D1, DA D2 and NMDA receptor antagonists to eliminate fructose-CFP
acquisition in real-feeding rats (Baker et al., 2003; Golden and Houpt, 2007; Hsiao and Smith,
1995) and sucrose-CFP acquisition in sham-feeding rats (Yu et al., 2000a, 2000b).
4.3 Cholinergic Receptor Antagonism and Quinine-CFA Acquisition: Systemic
administration of nicotinic (MEC), but not muscarinic (SCOP) cholinergic receptor antagonism
significantly enhanced and prolonged the acquisition of quinine-CFA. Vehicle-trained rats
displayed a significant, transitory quinine-CFA as demonstrated by a significant aversion
observed after the first (34%), but not second (48%) or third (47%) pairs of tests. Systemic
nicotinic cholinergic antagonism significantly increased the magnitude and duration of quinine-
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CFA as indicated by rats trained with the 4 (18-24%) and 6 (11-13%) mg/kg MEC doses. In
contrast, the SCOP 1 group displayed a significant aversion after the first test pair (17%), but
failed to differ from vehicle-trained rats thereafter, whereas the SCOP 2.5 group failed to display
quinine-CFA after any preference test. It should be noted that both systemic SCOP and MEC
significantly reduced CS-/FS intake and CS+/FSQ intake during training relative to vehicle. This
raises the possibility that the greater subsequent avoidance responses could be due to nonspecific malaise brought about by pairing the antagonist with the flavored solutions during
training. Both LiCl-induced conditioned taste aversions and attenuation of neophobic responses
were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al., 2002;
Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et al.,
2006), but not when SCOP was administered after the presentation of the new taste. Although
nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine, an
acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors,
reduced nicotine seeking without producing malaise (Hopkins et al., 2012). These data suggest
that systemic nicotinic, but not muscarinic receptor antagonism, enhances and prolongs quinineCTA by acting on its specific cholinergic signaling mechanism, and not through non-specific
malaise-induced effects. Further studies altering the timing of cholinergic antagonist injections
are necessary to completely rule out participation by this non-specific effect. These effects
extend our previous (Rotella et al., 2014) findings demonstrating that the persistence of quinineCFA was significantly enhanced by systemic administration of DA D1, NMDA and opioid, but
not DA D2 receptor antagonists administered prior to training. Thus, systemic nicotinic, DA D1,
NMDA and opioid, but not muscarinic, or DA D2 receptor antagonists administered during
training enhanced and prolonged the acquisition of quinine-CFA. The inability of SCOP to affect
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quinine-CFA acquisition is consistent with its previously-described inability to alter quinine
aversion while attenuating LiCl-induced CFA (Coil et al., 1978). Although systemic SCOP
elicited a flavor-taste CFA (Ossenkopp et al., 1986), the present data indicate that SCOP- and
quinine-CFA fail to synergize. The ability of MEC to enhance and prolong quinine-CFA is
consistent with previous observations that nicotine depressed quinine-evoked responses in the
nucleus tractus solitarius that were blocked by MEC (Simons et al., 2006), and CFAs induced by
nicotine and quinine generalized to each other in mice (Gyekis et al., 2012) that were blocked by
MEC (Oliveira-Maia et al., 2009). However, the ability of MEC to enhance and prolong quinineCFA appears specific to this type of “inhibitory” learning. Recent studies demonstrated that
chronic co-treatment with systemic MEC prevented the occurrence of depressive-like behavior
elicited by chronic restraint stress as measured by the forced swim test, sucrose preference and
body weight control (Aboul-Fotouh, 2015). Moreover, whereas nicotine facilitated a version of
“inhibitory” learning called negative occasion setting, systemic MEC co-treatment extended the
number of training sessions to elicit this behavior (Meyer et al., 2015).
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Chapter 5: Baclofen differentially mediates fructose-conditioned flavor preference and
quinine-conditioned flavor avoidance in rats.
1. Introduction:
GABA or its agonists administered into limbic and hypothalamic sites increase food
intake (e.g., Arnt et al., 1979; Echo et al., 2002; Grandison and Guidotti, 1977; Soderpalm and
Berridge, 2000; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993). Feeding
elicited by the GABAB agonist, BAC is mediated through GABA receptor interactions between
the VTA and NAc (Miner et al., 2010). Indeed, brain dopamine and cholinergic systems
modulate medium spiny NAc GABA output and VTA dopamine output (see reviews: Avena &
Rada, 2012; Hoebel et al., 2007). Although peripheral BAC increased rodent chow and fat intake
under specific dose regimens and intake conditions (e.g., Bains and Ebenezer, 2013; Ebenezer
and Patel, 2011), it decreased food intake in diabetic and diet-induced obese mice (Sato et al.,
2007). Peripheral BAC also selectively reduced fat intake under normal, limited-access and
“binge-type” conditions (; as well as intakes of pure fat or a sugar-fat mixture (Avena et al.,
2014; Berner et al., 2009; Buda-Levin et al., 2005; Corwin et al., 2009; Rao et al., 2008;
Wojnicki et al., 2006; Wong et al., 2009 but see Covelo et al., 2014). Given the complex effects
of GABAB receptor signaling on feeding, the present study investigated whether systemic BAC
mediated expression and acquisition of fructose-CFP as well as quinine-CFA in rats.
2. Methods:
2.1 Subjects: Male Sprague-Dawley rats (n=74, 250-275 g), obtained from Charles River
Laboratories (Wilmington, MA), were housed individually in wire mesh cages, maintained on a
12:12 h light/dark cycle (lights on: 7 AM, lights off: 7 PM) at a constant ambient temperature of
22°C with chow (5001, PMI Nutrition International, Brentwood, MO) and water available ad
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libitum for the first week. All animals were then food-restricted to 85-90% of their body weight
throughout behavioral testing to insure short-latency responses to presentation of the training and
test solutions. Food rations were provided 1 h after the end of daily training and testing sessions.
The experimental protocols were approved by the Queens College Institutional Animal Care and
Use Committee certifying that all subjects and procedures are in compliance with the National
Institutes of Health Guide for Care and Use of Laboratory Animals.
2.2 Fructose-CFP Initial Training and Test Solutions: During initial training in the
fructose-CFP paradigm, rats were trained to drink an unflavored 0.2% sodium saccharin (Sigma
Chemical Co., St. Louis, MO) solution during five daily 1-h sessions to guarantee sampling as
previously described (Baker et al., 2003, 2004); this initial unflavored training solution was the
same concentration as the flavored CS- solutions used in the subsequent conditioning paradigms.
The sipper tube was mounted on the front of the cage held by a taut steel spring, and was
positioned 3-6 cm above the cage floor. Solution measurement (0.1 ml gradations and accuracy)
was insured by using a retrofitted testing sipper tube that has been previously validated (Baker et
al., 2003, 2004; Rotella et al., 2014, 2015; Yu et al., 1999, 2000a). This training procedure was
repeated daily until all rats approached the sipper tubes with short (< 1 min) latency, typically
within three days. The limited food rations were given 1 h after each training session.
The two training solutions in the fructose-CFP expression and acquisition studies were
an 8% fructose + 0.2% saccharin solution and a saccharin (0.2%) solution, each flavored with
0.05% unsweetened grape or cherry Kool-Aid (General Foods, White Plains, NY). The 8%
fructose + 0.2% saccharin-paired flavor is referred to as the CS+/Fs, and the 0.2% saccharinpaired flavor as the CS-/s. Half of the rats in each drug paradigm had the cherry flavor added to
the CS+/Fs solution and the grape flavor added to the CS-/s solution; flavors were reversed for
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the remaining rats. In all two-bottle preference choice tests for fructose-CFP, the cherry and
grape flavors were presented in 0.2% saccharin solutions (CS+, CS-). All training and testing in
both paradigms took place in the rat’s home cage during the mid-light phase (~11 AM- 4 PM) of
the light/dark cycle.
2.3 BAC and Fructose-CFP Expression: Seventeen rats were given ten daily 1-bottle
training sessions (0.5 h/day) with 16 ml of the CS+/Fs solution presented on odd-numbered days,
and 16 ml of the CS-/s solution presented on even-numbered days. On days 9 and 10, the rats had
access to a second sipper tube containing water. This familiarized the rats to the presence of two
sipper tubes used during the choice tests; water intake was negligible in these training trials. The
left-right position of the CS and water sipper tubes was counterbalanced over the two days. The
order of presentation of the CS+/Fs first followed by subsequent presentation of the CS-/s
solution during training was identical to that used in our and other previous studies examining
the pharmacological substrates of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007).
Following training, the rats were given eight 2-bottle choice test sessions (0.5 h/day) with
unlimited (~45 ml) access to the CS+ and CS- flavors mixed in 0.2% saccharin solutions.
Solution intakes during training and testing were measured by weighing (0.1 g) the bottles before
and after the sessions. The animals were limited to eight 2-bottle sessions because previous
research (Baker et al., 2003, 2004; Yu et al., 2000) demonstrated that the magnitude of the
preference did not change during this testing interval. Therefore, each animal received VEH, and
three BAC doses. All 17 rats initially received a pair of VEH injections that were used to match
the animals across subsequent pairs of BAC doses of 0.5 (n=14), 1.5 (n=15), 3 (n=14) and 5
(n=8) mg/kg 30 min prior to the two-bottle choice test. The 30-min interval for systemic BAC
administration prior to the experimental condition in this and the other two paradigms was based
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on this commonly-used interval in many other systemic studies. Thus, all groups of rats were
tested in two consecutive daily sessions at VEH and three drug doses with the left–right position
of the CS+ and CS- solutions counterbalanced across sessions to control for position effects. To
control for drug dose order effects, half of the rats in each group were tested with an ascending
dose order, and the remaining rats were tested with a descending dose order.
2.4 BAC and Fructose-CFP Acquisition: Three groups of rats, matched for their intakes
of the unflavored 0.2% saccharin solution prior to training, were given ten 1-bottle training
sessions (1 h/day) with 16 ml of the CS+/Fs solution presented on odd-numbered days, and 16
ml of the CS-/s solution presented on even-numbered days. The first group (VEH) of eight rats
received daily VEH injections 30 min prior to each training session. The second (BAC 3) and
third (BAC 5) groups received daily injections of BAC at doses of 3 (n=7) and 5 (n=7) mg/kg
respectively, 30 min prior to each training session. Following training, all groups were given six
daily 2-bottle choice sessions (1 h/day) with unlimited (~45 ml) access to the CS+ and CSflavors mixed in 0.2% saccharin solutions; no drugs were administered prior to these sessions.
The positions of the CS+ and CS- solutions were counterbalanced across sessions.
2.5 Quinine-CFA Initial Training and Test Solutions: During initial training in the
quinine-CFA paradigm, rats were trained to drink an unflavored 8% fructose (Sigma Chemical
Co.) and 0.2% sodium saccharin solution as previously described (Rotella et al., 2014, 2015);
this initial unflavored training solution was the same concentrations as the flavored CS- solution
used in the subsequent conditioning paradigms. Initial training was otherwise identical to the
fructose-CFP paradigm. The two training solutions in the quinine-CFA acquisition study were
8% fructose + 0.2% saccharin with or without quinine (0.03%: Sigma Chemical Co.). Each
solution was flavored with 0.05% unsweetened grape or cherry Kool-Aid (Rotella et al., 2014).
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Half of the rats in each group had the cherry flavor added to the fructose + saccharin solution and
the grape flavor added to the fructose + saccharin + quinine solution; the flavors were reversed
for the remaining rats. In the two-bottle choice tests, the cherry and grape flavors were presented
in 8% fructose + 0.2% saccharin solutions. The flavored fructose + saccharin + quinine solution
is referred to as the CS+/FSQ, and the flavored fructose + saccharin solution as the CS-/FS; and
the same flavors used in the two-bottle tests are referred to as CS+ and CS-, respectively (Rotella
et al., 2014). All training and testing in this paradigm took place in the rat’s home cage during
the mid-light phase (~11 AM- 4 PM) of the light/dark cycle.
2.6 BAC and Quinine-CFA Acquisition: Rats were trained over eight one-bottle training
sessions (1 h) to drink the CS-/FS solution (16 ml) on odd-numbered days, and the CS+/FSQ
solution (16 ml) on even-numbered days. The CS-/FS solution was presented first to minimize
potential potent neophobic effects of the fructose-saccharin solution adulterated by quinine
(CS+/FSQ), and encourage intake as performed previously (Rotella et al., 2014, 2015). The eight
training trials were divided into four pairs of sessions with a one-day break between each pair. In
the first three training pairs, only one bottle was presented. In the fourth pair of training sessions
(days 7 and 8), a second sipper tube containing water was also presented to acclimate the rats to
the presence of two sipper tubes used during the choice tests; water intake was negligible in these
training trials. The left-right position of the CS and water sipper tubes was counterbalanced over
the two days. The first group (VEH) of eighteen rats received daily VEH injections 30 min prior
to each training session. The second (BAC 3) and third (BAC 5) groups received daily injections
of BAC at doses of 3 (n=8) and 5 (n=9) mg/kg respectively, 30 min prior to each training
session. Following training, all groups received six two-bottle sessions with the CS+ and CSflavors mixed in 8% fructose + 0.2% saccharin (FS) solutions (unlimited (~45 ml) access). The
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left–right position of the CS+ and CS- solutions were counterbalanced across sessions to control
for position effects. Solution intakes during training and testing were measured by weighing (0.1
g) the bottles before and after the 1 h sessions.
2.7 Statistics: In fructose-CFP expression studies, training intakes were averaged over the
five CS+/Fs and five CS-/s sessions and evaluated by a t-test. Intakes during the two-bottle
preference tests were averaged over the two sessions (test pairs) at each dose and evaluated with
two-way repeated-measures analyses of variance (ANOVA, CS condition vs. Dose). Separate
ANOVAs evaluated percent CS+/g intakes and total intake as a function of dose. In fructoseCFP acquisition studies, training intakes were averaged over the five CS+/Fs and CS-/s sessions
and were analyzed with a two-way randomized-blocks ANOVA (CS conditions x Groups).
Intakes during the two-bottle preference tests were averaged over sessions 1-2, 3-4, and 5-6
(referred to as Tests 1, 2, and 3) to control for bottle position effects. A three-way randomizedblocks ANOVA compared the CS intakes of the three groups (Group x CS x Test). A separate
two-way ANOVA evaluated percent CS+ intakes and total intakes of the three groups across the
three tests. In quinine-CFA acquisition studies, training intakes were averaged over the four
CS+/FSQ and CS-/FS sessions and were analyzed with a two-way randomized-blocks ANOVA
(CS conditions x Groups). Intakes during the preference tests were averaged over sessions 1-2, 34, and 5-6 (referred to as Tests 1, 2, and 3) to control for bottle position effects. A three-way
randomized-blocks ANOVA compared the CS intakes of the three groups (Group x CS x Test).
A separate two-way ANOVA evaluated percent CS+ intakes and total intakes of the three groups
across the three tests. When main or interaction effects were observed in any ANOVA,
Bonferroni corrected comparisons (P<0.05) detected significant effects. Drug-induced changes
in acquisition or expression preferences were operationally defined as a significant change in
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percent CS+ intakes relative to VEH, and/or a failure to observe significant differences between
CS+ and CS- intakes in the two-bottle preference tests.
3. Results:
3.1 BAC and Fructose-CFP Expression: Training intakes of CS+/Fs (11.3 g) and CS(10.5 g) failed to differ (t(16)= 1.19). In the 2-bottle preference tests, overall, CS+ (11.8 g)
intakes significantly exceeded CS- (3.5 g) intakes (F(1,16)= 349.59, P<0.0001), and intakes
significantly differed for the interaction between conditions and doses (F(4,64)= 2.88, P<0.03),
but not among BAC doses (F(4,64)= 0.85). CS+ intake was significantly higher than
corresponding CS- intake following VEH and all BAC doses (Fig. 9). Percent CS+ preferences
significantly differed (F(4,64)= 3.22, P<0.02) across BAC doses with the 3.0 mg/kg (66%) dose
significantly reducing percent CS+ preferences relative to VEH (87%) (Fig. 9). Total saccharin
intake failed to differ (F(4,64)= 0.31) among the 0.0 (15.7 g), 0.5 (14.6 g), 1.5 (16.1 g), 3.0 (15.7
g) and 5.0 (14.2 g) BAC doses.
3.2 BAC and Fructose-CFP Acquisition: Significant differences in training intakes failed
to occur among groups (F(2,14)= 0.66), between CS+/Fs and CS-/s conditions (F(1,7)= 5.08) or
for the interaction between groups and conditions (F(2,14)= 3.10): VEH (CS+/Fs: 12.0 g; CS-/s:
10.0 g), BAC 3 (CS+/Fs: 13.7 g; CS-/s: 10.5 g) and BAC 5 (CS+/Fs: 12.4 g; CS-/s: 12.5 g). The
two-bottle preference tests produced significant differences among groups (F(2,14)= 3.96,
P<0.04), among tests (F(2,14)= 3.74, P<0.05), between CS+ and CS- conditions (F(1,7)= 81.99,
P=0.0001), but not for any of the two-way and three-way interactions. Fig. 10 illustrates the
similar pattern of effects in CS+ and CS- intakes across the three tests in the VEH (Panel A),
BAC 3 (Panel B) and BAC 5 (Panel C) groups. Significant differences in percent CS+ intake
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Figure 9. (Baclofen effects upon fructose-CFP expression): Intakes (mean ±SEM, g/30 min) of
CS+ and CS- solutions in two-bottle preference tests in animals pretreated (30 min) with
systemic BAC. The percentages of CS+ intake over total intake are indicated above each pair of
values. Significant differences are denoted between CS+ and CS- intake (*) as are significant
BAC effects relative to vehicle (+).
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Figure 10. (Baclofen effects upon fructose-CFP acquisition): Intakes (mean ±SEM, g/30 min) of
CS+ and CS- solutions in three pairs of two-bottle preference tests (unlimited (~45 ml) access,
Tests 1, 2, 3) in animals that received vehicle (VEH: Panel A) or baclofen at doses of 3 (BAC 3:
Panel B) or 5 (BAC 5: Panel C) mg/kg during training. The percentages of CS+ intake over total
intake are denoted above each pair of values.
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failed to occur among groups (F(2,14)= 2.31), among tests (F(2,14)= 0.19) or for the interaction
between groups and tests (F(4,28)= 1.18) (Fig. 10). Total saccharin intake significantly differed
among groups (F(2,14)= 3.95, P<0.04) and among tests (F(2,14)= 3.77, P<0.05), but not for the
interaction between groups and tests (F(4,28)= 1.82). Total saccharin intake in the third test was
significantly higher in the BAC 5 (23.8 g) relative to the VEH (16.2 g) group.
3.3 BAC and Quinine-CFA Acquisition: In one-bottle training, CS-/FS intake
significantly exceeded CS+/FSQ intake (14.1 vs. 2.8 g/1 h, F(1,17)= 1650.40, P<0.0001); there
were also significant differences among groups (F(2,34)= 18.62, P<0.0001) and for the
interaction between groups and CS (F(2,34)= 5.53, P=0.008). CS-/FS intake for all groups was
significantly higher than CS+/FSQ intake (Fig. 11A). CS+/FSQ intake was significantly lower in
the BAC 5 relative to the VEH group (Fig. 11A). In two-bottle choice tests, there were
significant differences between CS+ (8.2 g) and CS- (15.9 g) intakes (F(1,17)= 65.47, P<0.0001)
as well as among groups (F(2,34)= 7.17, P<0.003), across tests (F(2,34)= 97.95, p<0.0001), and
for the interactions between groups and tests (F(4,68)= 7.54, P<0.01), between groups and
conditions (F(2,34)= 7.06, P<0.003) and among groups, tests and conditions (F(4,68)= 6.29,
P<0.0002), but not between tests and conditions (F(2,34)= 0.17). Within-group comparisons
revealed that the VEH-trained group consumed significantly more CS- than CS+ only during
Test 1 (Fig. 11B), consistent with the limited duration of quinine-CFA observed previously
(Rotella et al., 2014, 2015). The BAC 3-trained group consumed significantly more CS- than
CS+ during Test 3, and this pattern approached significance in Tests 1 and 2 (Fig. 11C). In
contrast, CS- intake was significantly higher than CS+ intake across all three tests in the BAC 5trained group (Fig. 11D). CS+ intake in the BAC 5-trained group was significantly lower than
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Figure 11. (Baclofen effects upon quinine-CFA acquisition): One-bottle training intakes (mean
±SEM, g/60 min) of CS+/FSQ and CS-/FS solutions during training sessions (16 ml limit) in
animals receiving systemic vehicle or baclofen at doses of 3 or 5 mg/kg 30 min prior to each
training session (Panel A). Significant differences are denoted between CS+/FSQ and CS-/FS
intake (*) as well as BAC effects relative to vehicle (+). Two-bottle choice test intakes (mean
+SEM, g/1 h, unlimited (~45 ml) access) of the CS+ and CS- flavors presented in fructose +
saccharin solutions in Tests 1-3 in groups trained with VEH (Panel B), BAC 3 (Panel C) BAC 5
(Panel D). The percentages of CS+/FSQ intake over total intake are denoted above each pair of
values. Significant differences are denoted between CS- and CS+ intakes (*) as well as BACinduced effects relative to corresponding VEH (+).
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CS+ intake of the VEH-trained group across all three tests (Fig. 11B, 11D). Significant
differences in percent CS+ intake were observed among groups (F(2,34)= 10.41, P<0.0003),
among tests (F(2,34)= 6.51, P<0.004) and for the interaction between groups and tests (F(4,68)=
2.71, P<0.04). Percent CS+ intakes were significantly lower across all three tests in the BAC 5
(Fig. 11D) relative to the VEH (Fig. 11B) group. The lower percent CS+ intakes in Tests 2 and 3
in the BAC 3 group did not differ from VEH (Fig. 11B, 11C). Total fructose and saccharin intake
significantly differed among groups (F(2,34)= 7.20, P<0.003), among tests (F(2,34)= 98.09,
P<0.0001) and for the interaction between groups and tests (F(4,68)= 7.58, P<0.0001). Total
fructose and saccharin intake in the first test was significantly lower in the BAC 3 (20.0 g) and
BAC 5 (15.6 g) groups relative to the VEH (24.5 g) group.
4. Discussion
The present study examined whether GABAB receptor activation with systemic BAC
would alter the expression and acquisition of fructose-CFP or the acquisition of quinine-CFA.
GABA or its agonists administered into limbic and hypothalamic sites increase food intake (e.g.,
Arnt et al., 1979; Echo et al., 2002; Grandison and Guidotti, 1977; Miner et al., 2010; Soderpalm
and Berridge, 2000; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993).
Further, whereas peripheral BAC administration increased chow and fat intake in non- deprived
rats and mice (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), it decreased food
intake in diabetic and diet-induced obese mice (Sato et al., 2007). Moreover, peripheral BAC
reduced fat relative to chow intake under normal, limited-access and “binge-type” conditions in
rats (e.g., Buda-Levin et al., 2005; Rao et al., 2008; Wojnicki et al., 2006), particularly intakes of
pure fat or a sugar-fat mixture (e.g., Avena et al., 2014; Berner et al., 2009; Corwin et al., 2009;
Wong et al., 2009).
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Although the present study focused on the role of BAC in sugar preference and quinine
avoidance, BAC effects upon total intake could be analyzed for saccharin intake in the fructoseCFP expression 2-bottle testing paradigm, for fructose + saccharin and saccharin intake in the
fructose-CFP 1-bottle training paradigm, and for fructose + saccharin and quinine + fructose +
saccharin intake in the quinine-CFA acquisition 1-bottle training paradigm. In the fructose-CFP
expression paradigm, systemic BAC failed to alter total saccharin intake across the 0.5-5 mg/kg
BAC dose range. In the fructose-CFP acquisition paradigm, neither the 3 nor 5 mg/kg doses of
BAC administered during training significantly altered fructose + saccharin or saccharin intake
relative animals receiving VEH. The inability of systemic BAC to alter saccharin intake per se is
in contrast to the ability of the same dose range to impair gustatory discrimination of 0.3% and
0.6% saccharin solutions (Wilson et al., 2011). In the quinine-CFA paradigm, fructose +
saccharin intake was similar among the three training groups, but quinine-adulterated fructose
and saccharin intake was significantly lower in the rats receiving the 5 mg/kg BAC dose during
training. It should be noted that animals in all three conditioning paradigms were food-restricted
and received multiple injections of systemic BAC, factors that alter BAC-induced orexigenic
actions on chow intake (e.g., Patel and Ebenezer, 2008). Thus, these data are in agreement with
the general failure to observe differences in sweet intake per se following systemic BAC (Avena
et al., 2014; Berner et al., 2009; Corwin and Wojnicki, 2009).
4.1 GABAB Receptor Agonism and Fructose-CFP Expression: In the fructose-CFP
expression paradigm, CS+ intake was significantly higher than corresponding CS- intake in the
two-bottle preference tests following VEH and all (0.5-5 mg/kg) BAC doses. The magnitude of
the fructose-CFP measured by percent CS+ preference was significantly, but marginally lowered
by the 3 mg/kg BAC dose (66%) relative to VEH; lower (0.5, 1.5) and higher (5.0) BAC doses
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failed to exert effects. This marginal reduction in fructose-CFP expression following systemic
GABAB receptor activation was similar and comparable to that observed following systemic
administration of AM-251, a cannabinoid CB1 receptor inverse agonist (Miner et al., 2008) and
muscarinic (scopolamine) and nicotinic (mecamylamine) cholinergic antagonists (Rotella et al.,
2015). In contrast, systemic administration of dopamine D1 (SCH23390) or D2 (raclopride)
receptor antagonists eliminated expression of fructose-CFP in real-feeding rats and sucrose-CFP
in sham-feeding rats (Baker et al., 2003; Yu et al., 2000). Further, neither systemic NMDA (MK801) nor opioid (naltrexone) receptor antagonism affected expression of fructose-CFP in realfeeding rats or sucrose-CFP in sham-feeding rats (Baker et al., 2004; Golden and Houpt, 2007;
Yu et al., 1999).
4.2 GABAB Receptor Agonism and Fructose-CFP Acquisition: In the fructose-CFP
acquisition paradigm, the patterns of CS+ and CS- intake in all three two-bottle preferences tests
were similar in rats receiving VEH or the two (3 or 5 mg/kg) BAC doses during training.
Correspondingly, the magnitude of fructose-CFP measured by percent CS+ intake failed to differ
among these groups. The inability of systemic GABAB receptor activation to alter the acquisition
(learning) of fructose-CFP stands in marked contrast to the abilities of systemic administration of
DA D1, DA D2, NMDA or muscarinic receptor antagonists to eliminate acquisition of fructoseCFP in real-feeding rats and/or sucrose-CFP in sham-feeding rats (Baker et al., 2003; Golden and
Houpt, 2007; Rotella et al., 2015; Yu et al., 2000). Rather, the effects of systemic BAC in failing
to affect fructose-CFP acquisition were similar to that observed following NTX (Baker et al.,
2004; Yu et al., 1999), AM-251 (Miner et al., 2008) or MEC (Rotella et al., 2015).
4.3 GABAB Receptor Agonism and Quinine-CFA Acquisition: In the quinine-CFA
paradigm, systemic BAC dose-dependently enhanced and prolonged the magnitude of quinine-
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CFA with rats receiving the 5 mg/kg BAC dose during training eliciting significantly higher CSthan CS+ intake across all three tests. As observed previously (Rotella et al., 2014, 2015), the
VEH-trained group consumed significantly more CS- than CS+ only during Test 1. The BAC 3trained group consumed significantly more CS- than CS+ during Test 3, and this pattern
approached significance in Tests 1 and 2. Consequently, the magnitudes of quinine-CFA as
measured by percent CS+ intake takes were significantly lower across all three tests in rats
trained with the 5 mg/kg BAC dose (15-20-25%) relative to VEH-trained rats (34-48-47%). The
dose-dependent ability of systemic GABAB receptor activation to enhance and prolong quinineCFA is similar to that observed following systemic dopamine D1, NMDA, opioid or nicotinic,
but not dopamine D2 or muscarinic antagonists (Rotella et al., 2014, 2015). A role for GABAB
receptor systems in conditioned aversions is supported by the ability of the GABAB agonist,
BAC, but not the GABAB antagonist, saclofen, to suppress saccharin-induced drinking following
pairing (Echo et al., 2002; Wilson et al., 2011). However, another study using a similar dose
range found that systemic BAC failed to induce an aversion or affect ethanol-induced aversions
(Chester and Cunningham, 1999). Further, although systemic BAC failed to alter operant
responding to quinine-adulterated solutions (Petry and Heyman, 1997), it did enhance the
discriminative abilities of D-amphetamine in a conditioned taste aversion procedure (Miranda et
al., 2009). The present findings that systemic BAC enhanced and prolonged quinine-CFA
extends the role of GABAB receptor signaling in both orosensory and post-ingestive processes
related to avoidance and aversion, respectively.
In conclusion, these data implicate GABAB receptor signaling in the acquisition of
quinine avoidance with minimal or no effects upon fructose preferences. Further studies
investigating systemic BAC effects upon fat-CFP are warranted given the reductions in fat intake
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following systemic administration of GABAB receptor agonists (e.g., Avena et al., 2014; Berner
et al., 2009; Buda-Levin et al., 2005; Corwin et al., 2009; Rao et al., 2008; Wojnicki et al., 2006;
Wong et al., 2009).
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Chapter 6: Muscarinic, nicotinic and GABAergic receptor signaling differentially
mediate fat-conditioned flavor preferences in rats.
1. Introduction:
The pharmacological substrates of the acquisition and expression of sugar- and fat-CFP
have been examined for DA, opioid and NMDA receptor systems. Systemic administration of
DA D1 (SCH23390) or D2 (raclopride), but not opioid (naltrexone), receptor antagonists
eliminated the acquisition and expression of flavor-flavor conditioning studies elicited by
sucrose in sham-feeding rats (Yu et al., 1999, 2000a, 2000b) or fructose in real-feeding rats
(Baker et al., 2003, 2004), implicating both DA receptor families, but not opioids in both the
learning and maintenance of these responses. Yet DA D1, but not D2 or opioid receptor
antagonists eliminated acquisition, and to a lesser degree, reduced expression of flavor-nutrient
conditioning elicited by IG sucrose infusions (Azzara et al., 2000, 2001), implicating only the
DA D1 receptor in the learning of this response. In contrast, fat (CO)-CFP acquisition and
expression was only attenuated by DA D2, but not D1 or opioid receptor antagonists (Dela Cruz
et al., 2012a, 2012b), indicating that combined flavor-flavor and flavor-nutrient mechanisms
reduce the effectiveness of DA antagonism to affect the response. The non-competitive NMDA
receptor antagonist, MK-801 eliminated the acquisition, but not expression of CFP induced by
fructose (Golden and Houpt, 2007) or CO (Dela Cruz et al., 2012a), implicating glutamatergic
signaling in the learning of this response. The more limited pharmacological effects on CO-CFP
is similar to that observed following glucose that also activates both flavor-flavor and flavornutrient processes. Thus, oral glucose-CFP was significantly though marginally attenuated in
expression studies by DA D1, DA D2 or NMDA receptor antagonism (Dela Cruz et al., 2014).
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Cholinergic muscarinic and nicotinic receptor signaling and GABAB receptor signaling
have been recently implicated in the mediation of fructose-CFP (Rotella et al., 2015, 2016).
Fructose-CFP expression was significantly reduced by systemic administration of muscarinic
(SCOP: 2.5-10 mg/kg: 65-68%) and nicotinic (MEC: 4-8 mg/kg: 67-73%) cholinergic receptor
antagonists, but only at doses that reduced total saccharin intake. However, this occurred
despite the fact that CS+ preference intakes were significantly higher than CS- preference
intakes, indicating minimal actions of cholinergic signaling on expression of this response.
Further, fructose-CFP acquisition was eliminated by SCOP at doses of 1 (40-54%) and 2.5 (4558%) mg/kg, and was accompanied by a failure to observe CS+ and CS- intake differences. On
the other hand, MEC failed to alter fructose-CFP acquisition, indicating a critical role for
muscarinic cholinergic receptors in the learning of this response. In contrast, MEC, but not
SCOP enhanced the magnitude and persistence of quinine-induced conditioned flavor avoidance
for a fructose solution (Rotella et al., 2015), indicating different cholinergic receptor mechanisms
in preference and avoidance responses. Whereas systemic administration of the GABAB receptor
agonist, BAC minimally reduced the expression, but not the acquisition of fructose-CFP, the
magnitude and persistence of quinine-induced conditioned flavor avoidance for a fructose
solution was enhanced (Rotella et al., 2016), indicating a limited role for GABAB signaling in
expression of this response.
Cholinergic receptor signaling has also been implicated in the mediation of food and fat
intake. Food increases Ach release in the AMY and the NAc (Avena et al., 2006, 2008a, 2008b,
2008c; Hajnal et al., 1998; Mark et al., 1992, 1995). Consumption of a high-fat diet for one week
reduced acetylcholinesterase activity in the frontal cortex, hypothalamus and midbrain, as well as
increased both β2-nAChR binding in the medial prefrontal cortex and substantia nigra, in
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addition to α7-nAChR binding in the lateral and ventromedial hypothalamus (Morganstern et al.,
2012). MEC blocked the enhancements in exploratory and novelty-seeking behaviors induced by
high-fat consumption (Morganstern et al., 2012). Chronic nicotine reduced body weight in mice,
particularly those maintained on a high-fat diet, an effect blocked by MEC co-treatment
(Mangubat et al., 2012). Accumbal microinjections of SCOP markedly reduced fat intake elicited
by accumbal administration of the mu-opioid receptor agonist, DAMGO, and also reduced food
intake in food-deprived rats (Perry et al., 2009; Will et al., 2006). However, accumbal SCOP
failed to affect fat intake itself (Will et al., 2006).
GABAB receptor signaling has also been implicated in the mediation of fat intake. BAC
administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et al., 1979;
Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al., 1993), and
was reported to be mediated through GABA receptor interactions between the ventral tegmental
area and nucleus accumbens (Miner et al., 2010). Systemic BAC increased fat intake under
normal conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), but suppressed fat
intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al.,
2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al., 2009).
Therefore, the present study examined whether systemic administration of muscarinic (SCOP)
and nicotinic (MEC) cholinergic receptor antagonists and a GABAB receptor agonist (BAC)
would alter expression and acquisition of fat-CFP elicited ingestion of a flavor (e.g., cherry)
paired with a higher (3.5%) CO concentration relative to a flavor (e.g., grape) paired with a
lower (0.9%) CO concentration.
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2. Methods:
2.1 Subjects: Male Sprague-Dawley rats (260-300 g, Charles River Laboratories,
Wilmington, MA) were housed individually in wire mesh cages and maintained on a 12:12 h
light/dark cycle with chow (5001, PMI Nutrition International, Brentwood, MO) and water
available ad libitum, except as noted below. The experimental protocols were approved by the
Queens College Institutional Animal Care and Use Committee certifying that all subjects and
procedures are in compliance with the National Institutes of Health Guide for Care and Use of
Laboratory Animals.
2.2 Test Solutions: The training fluids consisted of 3.5% and 0.9% corn oil (CO: Sigma
Chemical Co., St. Louis, MO) flavored with 0.05% unsweetened grape or cherry Kool-Aid
(General Foods, White Plains, NY) and prepared as suspensions using 0.3% xanthan gum
(Sigma) as described previously (Dela Cruz et al., 2012a, 2012b). Half of the rats in each group
had the cherry flavor added to the 3.5% CO and the grape flavor added to the 0.9% CO; the
flavors were reversed for the remaining rats. In the two-bottle preference tests, the 0.05% cherry
and grape flavors were each presented in similar 0.9% CO + 0.3% xanthan gum suspensions. The
CO + Kool-Aid + gum mixtures with the flavored training solutions are hereafter referred to as
CS+/3.5% CO and CS-/0.9% CO, and the flavored 0.9% CO two-bottle test solutions are
referred to as CS+ and CS-. All testing took place in the rat’s home cage during the mid-light
phase of the light:dark cycle. In the two weeks prior to testing, the rats were placed on a food
restriction schedule that maintained their body weights at 85-90% of their ad libitum level to
increase approach behavior to the solutions. This procedure has been consistently applied in all
of our and other prior CFP studies using oral intake or intragastric infusions of sugars and fats
(e.g., Azzara et al., 2000, 2001; Baker et al., 2003, 2004; Dela Cruz et al., 2012a, 2012b; 2014;
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Golden and Houpt, 2007; Rotella et al., 2015, 2016; Yu et al., 199, 2000a, 2000b). It is important
to note that examination of these effects in food-deprived rats not only increases motivation to
drink, but also produces an energy deficit. Many prior studies have explored both taste and
consumption of palatable diets under both sated and deprived conditions, and have found
dissociable behavioral and neurochemical processes. In other words, distinct hedonic and
homeostatic processes can govern approach and consumption, and can presumably differentially
alter preference for flavored solutions (see review: Baldo et al., 2013). For instance,
administration of naloxone into the basolateral nucleus of the amygdala blocked increased fat
intake induced by accumbal administration of DAMGO, but not increased fat intake induced by
food deprivation (Parker et al., 2010). In contrast, administration of naloxone into the central
nucleus of the amygdala blocked food deprivation-induced increases in fat intake, but not fat
intake induced by accumbal DAMGO (Parker et al., 2014). Further, whereas intra-accumbal
DAMGO increased c-Fos activation within the hypothalamic perifornical area that was blocked
by baso-lateral amygdala inactivation, inta-accumbal DAMGO increased c-Fos activation in the
ventral tegmental area that was unaffected by baso-lateral amygdala inactivation (Parker et al.,
2015). Our laboratory (Yu et al., 1999) performed one CFP study that tested the ability of
naltrexone to affect acquisition and expression of sucrose intake in sham-feeding rats under sated
and deprived conditions. We found that the feeding condition failed to alter naltrexone’s inability
to reduce acquisition or expression of sucrose-CFP in sham-feeding rats. Thus, the fact that these
studies were done under food restriction should serve as a caveat.
The rats were initially adapted to drink an unflavored 0.2% saccharin solution from
sipper tubes during daily 2-h sessions. The sipper tube was mounted on the front of the cage held
by a taut steel spring, and was positioned 3-6 cm above the cage floor. This training procedure
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was repeated daily until all rats approached the sipper tubes with short (< 1 min) latency,
typically within three days. The limited food rations were given 30 min after each training
session.
2.3 Experiment 1: SCOP, MEC and BAC CO-CFP: Expression Study: Twenty-four male
rats were given ten 1-bottle training sessions (2 h/day) with 24 ml of the CS+/3.5% CO solution
presented on odd-numbered days, and 24 ml of the CS-/0.9% CO solution presented on evennumbered days. On days 9 and 10, the rats had access to a second sipper tube containing water.
This familiarized the rats to the presence of two sipper tubes used during the choice tests; water
intake was negligible in these training trials. The left-right position of the CS and water sipper
tubes was counterbalanced over the two days. Following training, all rats were given eight daily
two-bottle choice test sessions (2 h/day) with the CS+ (45 ml) and CS- (45 ml) solutions. Thirty
min prior to the first two sessions, all rats were given vehicle injections (1 ml 0.9% saline/kg
body weight, intraperitoneally (ip)). The animals were then divided into three equal (n=8) groups
matched for the magnitude of their CO preferences observed following vehicle treatment. The
SCOP group received three doses (1, 5 and 10 mg/kg, ip, Sigma Chemical Co., St. Louis, MO)
prior to the remaining six sessions; half of the rats were tested with an ascending dose order, and
the remaining rats were tested with a descending dose order. The rats were tested in two
consecutive daily sessions at each drug dose with the left-right position of the CS+ and CSsolutions counterbalanced across sessions to control for bottle position effects. The MEC group
received three doses (1, 6 and 8 mg/kg, ip, Sigma Chemical Co.), and the BAC group received
three doses (1.5, 3 and 5 mg/kg, ip, Sigma Chemical Co.) prior to the remaining six sessions The
dose ranges were similar to those used in our prior conditioning studies with sugars (Rotella et
al., 2015, 2016). Care was taken to minimize spillage due to the fact that some of the effects
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could be potentially small. After initially weighing each bottle, it was gently shaken to insure
appropriate flow of the viscous CO solutions. Any effluent from the bottle (~ 0.5-1.0 g) was
collected and appropriate spillage adjustments were made to obtain an accurate pre-weight
measurement. The taut steel spring prevented movement of the bottles during the sessions.
Visual inspection of the bottles during the study revealed minimal if any spillage because of the
viscosity of the solutions. The session length of 2 h was identical to that previously used in
assessing fructose-CFP (Baker et al., 2003, 2004), and CO-CFP (Dela Cruz et al., 2012a, 2012b).
2.4 Experiment 2: SCOP, MEC and BAC and CO-CFP: Acquisition Study. Eight groups
of naïve male rats were matched for their intakes of an unflavored 0.2% saccharin solution prior
to training. The rats were given ten 1-bottle training sessions (2 h/day, 24 ml) with the CS+/3.5%
CO solution presented on odd-numbered sessions, and the CS-/0.9% CO solution presented on
even-numbered sessions, and all intraperitoneal (ip) injections were administered 30 min prior to
each training session. Seven of the eight groups received vehicle (VEH, n=11, 1 ml 0.9% saline/
kg body weight), SCOP at doses of 1 (SCOP1, n=10) and 2.5 (SCOP2.5, n=8) mg/kg, MEC at
doses of 4 (MEC4, n=8) and 6 (MEC6, n=11) mg/kg, BAC at doses of 3 (BAC3, n=8) and 5
(BAC5, n=8) mg/kg. Because some of the drugs reduced overall CS intakes, an eighth group
(Limited VEH, n=10) received vehicle injections, and their intakes were limited to approximate
the reduced intakes observed in the different drug dose groups. These doses were similar to those
employed in acquisition studies with sugars (Rotella et al., 2015, 2016). Following training, all
eight groups were given six daily two-bottle choice sessions (2 h/day) with unlimited access to
the CS+ (45 ml) and CS- (45 ml) solutions; no drugs were administered prior to these sessions.
The positions of the CS+ and CS- solutions were counterbalanced across sessions.
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2.5 Data analysis: In the expression studies, training intakes were averaged over the five
CS+/3.5% CO and five CS-/0.9% CO sessions and evaluated by t-tests. Intakes during the
preference tests were averaged over the two sessions at each dose and evaluated with two-way
repeated-measures analyses of variance (ANOVA, CS condition vs. Dose) for the SCOP, MEC
and BAC groups, respectively. Separate ANOVAs evaluated percent CS+ intakes and total
intakes as a function of drug doses. In the acquisition study, training intakes were averaged over
the five CS+/3.5% CO and CS-/0.9% CO sessions, and were analyzed separately in a two-way
randomized-blocks ANOVA (CS x Groups). Intakes during the preference tests were averaged
over sessions 1-2, 3-4, and 5-6 (referred to as Tests 1, 2, and 3). A three-way randomized-blocks
ANOVA compared the CS intakes of the drug and control groups (Group x CS x Test). Separate
two-way ANOVAs evaluated percent CS+ intakes and total intakes of the groups. When main or
interaction effects were found, Bonferroni corrected comparisons (p<0.05) detected significant
effects.
3. Results:
3.1 SCOP, MEC and BAC and expression of CO-CFP: The mean 1-bottle training intake
of the CS+/3.5% CO (21.8 ±0.3 g/2 h) was significantly greater (t(23)= 4.03, p<0.0005) than the
CS-/0.9% CO (18.2 ±1.0 g/2 h). In the two-bottle choice tests in SCOP-tested rats, CS+ was
consumed significantly more (F(1,28)= 72.06, p<0.0001) than CS-, and significant differences
were observed among doses (F(3,28)= 17.94, p<0.0001) and for the CS x Dose interaction
(F(3,28)= 22.24, p<0.0001). CS+ intakes significantly exceeded CS- intakes following VEH and
the 1 and 10, but not the 5 mg/kg SCOP doses (Figure 12A). Rats consumed significantly less
CS+ at all SCOP doses compared to VEH, whereas CS- intakes failed to be significantly affected
(Figure 12A). Total intake (g/2 h) significantly (F(3,24)= 24.75, p<0.0001) declined following
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Figure 12. (Expression Study): Intakes (mean (g/2 h), ±SEM) of CS+ and CS− flavored 0.9%
corn oil (CO) solutions in two-bottle preference tests in animals receiving systemic injections of
the muscarinic cholinergic antagonist, scopolamine (SCOP: Panel A), the nicotinic cholinergic
antagonist, mecamylamine (MEC, Panel B) or the GABAB receptor agonist, baclofen (BAC:
Panel C) 30 min prior to testing. Significant differences are denoted between CS+ and CS−
intake within an injection condition (*) and between CS+ intake following a drug dose relative to
vehicle treatment (+). The percentages of CS+ intake over total intake are denoted above each
pair of values with significant differences relative to vehicle treatment (+) noted.

99
the 1 (11.3 ±3.5 g), 5 (6.0 ±1.4 g) and 10 (4.6 ±1.3 g) mg/kg SCOP doses relative to VEH (27.6
±3.3 g). Significant differences in the percent CS+ intakes were observed (F(3,21)= 5.00,
p<0.009), and the 70% preference at the 5 mg/kg SCOP dose was significantly lower than the
98% preference following VEH (Figure 12A). Preferences at the 1 (84%) and 10 (82%) mg/kg
SCOP doses were intermediate, but did not differ from the VEH test.
In the two-bottle choice tests in MEC-tested rats, CS+ was consumed significantly more
(F(1,28)= 229.44, p<0.0001) than CS-, and significant differences were observed among doses
(F(3,28)= 21.52, p<0.0001) and for the CS x Dose interaction (F(3,28)= 30.05, p<0.0001). CS+
intakes significantly exceeded CS- intakes following VEH and all three MEC doses (Figure
12B). Rats consumed significantly less CS+ at the two higher MEC doses compared to VEH,
whereas CS- intakes were not affected (Figure 12B). Total intake (g/2 h) significantly (F(3,21)=
43.17, p<0.0001) declined following the 6 (8.4 ±1.3 g) and 8 (8.8 ±1.2 g) mg/kg MEC doses
relative to VEH (31.8 ±4.0 g). Significant differences in the percent CS+ intakes were observed
(F(3,21)= 4.62, p<0.01), and the 85% preference at the 8 mg/kg MEC dose was significantly
lower than the 97% preference following VEH (Figure 12B). Preferences at the 1 (95%) and 6
(91%) mg/kg MEC doses were intermediate, and did not differ from the VEH test.
In the two-bottle choice tests in BAC-tested rats, CS+ was consumed significantly more
(F(1,28)= 37.71, p<0.0001) than CS-, but no differences were observed among doses (F(3,28)=
0.24) or for the CS x Dose interaction (F(3,28)= 1.08). CS+ intakes significantly exceeded CSintakes following VEH and the 1.5 and 5, but not the 3 mg/kg BAC doses (Figure 12C). BACinduced CS+ and CS- intakes did not differ from VEH values (Figure 12C). Total intake (g/2 h)
also did not differ (F(3,21)= 1.03) across the VEH and BAC conditions. The percent CS+
intakes approached significance (F(3,21)= 2.68, p=0.073), and a post-hoc comparison revealed

100
that the 74% preference at the 3 mg/kg BAC dose was significantly lower than the 97%
preference following VEH (Figure 12C). Preferences at the 1.5 (85%) and 5 (86%) mg/kg BAC
doses were intermediate, and did not differ from the VEH test.
3.2 SCOP, MEC and BAC and acquisition of CO-CFP: During 1-bottle training, overall
CS+/3.5% CO intake (13.7 g/2 h) significantly (F(1,132)= 4.23, p<0.0001) exceeded CS-/0.9%
CO intake (11.6 g/2 h), and significant differences were observed among groups (F(7,132)=
12.07, p<0.0001) but not for the Group x CS interaction (F(7,132)= 0.31). Total training intakes
(2 h/g) were significantly greater in the VEH group (20.3 g) than the LMTD VEH (8.6 g),
SCOP1 (12.8 g), SCOP2.5 (9.4 g), MEC4 (8.7 g) and MEC6 (6.9 g), but not the BAC3 (18.3 g)
and BAC5 (16.2 g) groups (Figure 13A). Intakes of the SCOP and MEC groups did not differ
from the LMTD VEH group. CS+/3.5% CO and CS-/0.9%CO intakes of the SCOP2.5, MEC4,
MEC6 LMTD VEH groups were significantly lower than the corresponding VEH animals,
whereas CS+/3.5%CO intake of the SCOP1 group was significantly lower than corresponding
VEH animals. However, CS+/3.5% CO and CS-/0.9% CO intakes of these groups did not differ
from those of the LMTD VEH group. In the two-bottle preference tests, overall, rats consumed
significantly more (F(1,396)= 538.31, p<0.0001) CS+ than CS- solution, and significant
differences were observed among the eight groups (F(7,396)= 2.51, p<0.016), and for the Groups
x CS interaction (F(7,396)= 11.59, p<0.0001), but not among tests (F(2,396)= 0.58) or for the
Groups x Tests (F(14,128)= 0.42), Tests x CS (F(2,396)= 1.89) and Groups x Tests x CS
(F(14,396)= 0.52) interactions. CS+ intakes significantly exceeded CS- intakes across all three
tests in the VEH (Figure 13B), Limited VEH (Figure 13C), SCOP1 (Figure 13D), MEC4 (Figure
13F), MEC6 (Figure 13G), BAC3 (Figure 13H) and BAC5 (Figure 13I) groups. In contrast, CS+
and CS- intakes did not differ across any test in the SCOP2.5 group (Figure 13E). Significant
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Figure 13. (Acquisition Study): Training intakes (mean (g/2 h), ±SEM) of rats exposed to ten 1bottle sessions of flavored 3.5% corn oil solutions (CS+/3.5% CO, Days 1, 3, 5, 7, 9) or 0.9%
corn oil solutions (CS-/0.9% CO, Days 2, 4, 6, 8, 10) 30 min following systemic injections of
vehicle (VEH), a limited vehicle (LTD VEH) control, scopolamine at doses of 1 (SCOP1) or 2.5
(SCOP2.5) mg/kg, mecamylamine at doses of 4 (MEC4) or 6 (MEC6) mg/kg or baclofen at
doses of 3 (BAC3) or 5 (BAC5) mg/kg. Significant differences are denoted between CS+/3.5%
CO or CS-/0.9% CO intake following a drug dose relative to VEH (+) treatment (Panel A).
Intakes (mean (g/2 h), ±SEM) of CS+ and CS− flavored 0.9% CO solutions in three two-bottle
preference tests in the VEH (Panel B), LTD VEH (Panel C), SCOP1 (Panel D), SCOP2.5 (Panel
E), MEC4 (Panel F), MEC6 (Panel G), BAC3 (Panel H) or BAC5 (Panel I) groups. Significant
differences (*) are denoted between CS+ and CS−intake within each test and each group, and for
percent CS+ intake in a given drug group relative to VEH (+) conditions.
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differences in the percent CS+ intakes were observed among groups (F(7,198)= 19.16,
p<0.0001), but not among tests (F(2,198)= 2.0), or for the interaction between Groups x Tests
(F(14,198)= 0.41). Percent CS+ intake were significantly lower in the SCOP2.5 (Figure 13E)
relative to the VEH group (Figure 13B) in tests 1 (59% vs. 88%), 2 (55% vs. 87%) and 3 (41%
vs. 84%). All other groups did not differ from VEH values across tests in percent CS+ intake.
Significant differences in total intake were observed among groups (F(7,198)= 2.36, p<0.024),
but not among tests (F(2,198)= 0.56), or for the interaction between Groups x Tests (F(14,198)=
0.39). Whereas total intake was typically similar for most groups relative to the VEH group,
significant reductions were noted in the first two tests in the MEC6 group and in the third test in
the LMTD VEH group.
4. Discussion:
The present study examined whether muscarinic (SCOP) or nicotinic (MEC) cholinergic
receptor antagonism or GABAB (BAC) receptor activation would alter expression and
acquisition of fat (CO)-CFP. Using percent CS+ intake as a measure of the magnitude of a
preference, expression of CO-CFP was significantly, but marginally reduced by the 5 mg/kg
SCOP dose (70%), by the 8 mg/kg MEC dose (85%) and by the 3 mg/kg BAC dose (74%)
relative to comparable vehicle values (97-98%). These mild reductions in CO-CFP expression
occurred despite sizable dose-dependent reductions in total CS intake following SCOP and
MEC, but not BAC. Acquisition of CO-CFP was selectively and dose-dependently eliminated by
administration of SCOP, but not MEC or BAC during one-bottle training. Training intakes of the
CS+ and CS- CO solutions were significantly lower in groups receiving SCOP and MEC, but not
BAC. To control for the non-specific actions of reduced solution consumption during training, an
additional Limited VEH group had their intakes limited to approximate the reduced intakes
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observed in drug groups. In contrast to the robust CO-CFP observed across the three tests in the
VEH (86%) and Limited VEH (95%) groups, the SCOP2.5 group failed to display differences
between CS+ and CS- intakes across tests, and their overall percent CS+ intake approached
indifference (52%). Whereas total intake during the preference tests failed to differ among the
VEH, Limited VEH and SCOP2.5 groups, the CS+ and CS- intakes respectively decreased and
increased across preference tests in the SCOP2.5 group, demonstrating a selective loss of the
salience of the CS+ solution. In contrast, a lower dose of SCOP (SCOP1 group) failed to affect
the significant CS+ preferences demonstrated by analyses of CS+ and CS- intakes and percent
CS+ intake (78%). Moreover, neither MEC at doses of 4 or 6 mg/kg nor BAC at doses of 3 or 5
mg/kg administered during training affected CO-CFP acquisition in analyses of either CS+ and
CS- intakes or percent CS+ intake. The following sections examine cholinergic and GABAB
receptor involvement in preference conditioning and palatable intake.
4.1 Muscarinic and Nicotinic Cholinergic and GABAB Receptor Involvement in Fat-CFP
Expression: Expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015) was
minimally affected only at certain doses over a wide dose range of either SCOP (fructose-CFP:
65-68% (2.5-10 mg/kg; CO-CFP: 70% (5 mg/kg)) or MEC (fructose-CFP: 67-73% (4-8 mg/kg);
CO-CFP: 80% (8 mg/kg)). In both paradigms, these reductions were accompanied by reductions
in total, and particularly CS+, intake following SCOP and MEC, but not BAC. The intake
reductions of saccharin CS solutions in the fructose-CFP paradigm by SCOP and MEC are
similar to reductions of sweet intake following systemic nicotinic receptor antagonism
(Taraschenko et al., 2011). The intake reductions of 0.9% corn oil CS solutions in the CO-CFP
paradigm by SCOP and MEC differ from the inability of accumbal SCOP to affect fat intake
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(Will et al., 2006), but correspond to the finding that accumbal SCOP microinjections reduced
fat intake elicited by accumbal DAMGO administration (Perry et al., 2009; Will et al., 2006).
Coincidentally, expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2016),
was minimally affected only at one dose (3 mg/kg) over a wide dose range of BAC (fructoseCFP: 66%; CO-CFP: 74%). The inability of the BAC dose range to alter total fat intake in the
present study stands in contrast to its previously-reported increases in fat intake under normal adlibitum conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), and suppression
of fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin
et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al.,
2009). This may be due to the fact that animals in the present study were chronically foodrestricted to encourage short latency sampling of the solutions during the preference paradigm.
The patterns of very limited inhibition of expression of CO-CFP by muscarinic or
nicotinic cholinergic receptor antagonism or GABAB receptor agonism are similar to DA D1, DA
D2, opioid and NMDA receptor antagonism of CO-CFP expression (Dela Cruz et al., 2012a,
2012b). Despite evaluating a wide dose range (50-800 nmol/kg) of SCH23390 and raclopride,
CO-CFP expression was reduced only by intermediate (200 nmol/kg) DA D1 (56%) and DA D2
(61%) antagonist doses. Similarly, despite evaluating a wide naltrexone dose range (0.1-5
mg/kg), CO-CFP expression was modestly reduced by only the 0.1 (69%) and 1 mg/kg (71%)
doses. Further, despite evaluating a wide MK-801 dose range (50-200 µg/kg), the loss of
preference (49%) following the highest NMDA antagonist dose was accompanied by dramatic
decreases in total fat intake. Antagonist effects upon fructose-CFP are more striking in that
SCH23390 or raclopride dose-dependently eliminated the expression of both fructose-CFP in
real-feeding rats and sucrose-CFP in sham-feeding rats (Baker et al., 2003; Hsiao and Smith,
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1995; Yu et al., 2000a, 2000b). In contrast, neither NMDA nor opioid receptor antagonism
affected expression of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007). It is important
to note that whereas glucose and sucrose are capable of conditioning flavor preferences through
both flavor-flavor and flavor-nutrient processes, fructose elicits flavor preferences through
flavor-flavor, but not flavor-nutrient processes in short-term tests (Sclafani and Ackroff, 1994;
Sclafani et al., 1993, 1999). Therefore, comparisons of the present limited cholinergic and
GABAB receptor signaling effects on CO-CFP with sugar-CFP may be more pertinent for oral
glucose-CFP because, like CO, glucose activates both flavor-flavor and flavor-nutrient
processes. Rats displayed a robust oral glucose-CFP (94-95%) which was significantly though
marginally attenuated in expression studies by SCH23390 (67-70%), raclopride (77%) or MK801 (70%) at doses that also markedly reduced overall CS intake (Dela Cruz et al., 2014). Given
the imperfection of direct fructose and oil comparisons and given that parallel glucose data using
the present agents is not yet available, other future studies need to address this issue as well as
others examining oral only and oral + post-ingestive mechanisms. Finally, other future studies
should address whether the oral effects of fat are more important in these procedures than fatrelated post-ingestive effects by examining whether pharmacological manipulation of
preferences elicited by short-term exposure to intragastric oil are similar to or different from that
of the present data.
4.2 Muscarinic and Nicotinic Cholinergic and GABAB Receptor Involvement in Fat-CFP
Acquisition: Acquisition of CO-CFP was selectively and dose-dependently eliminated by
administration of SCOP, but not MEC during one-bottle training despite the fact that both
antagonists lowered training intakes. The SCOP2.5 group failed to display differences between
CS+ and CS- intakes across tests, and their overall percent CS+ intake approached indifference
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(52%). CS+ and CS- intakes respectively decreased and increased across preference tests in the
SCOP2.5 group, demonstrating a selective loss of the salience of the CS+ solution. Further, the
SCOP dose (2.5 mg/kg) capable of eliminating CO-CFP acquisition is lower than the dose (5
mg/kg) that only mildly reduced CO-CFP expression. In contrast, the SCOP1, MEC4 and MEC6
groups failed to display changes in CO-CFP acquisition. The pattern of selective muscarinic, but
not nicotinic cholinergic receptor involvement parallels the ability of SCOP, but not MEC to
eliminate fructose-CFP acquisition (Rotella et al., 2015). The selective actions by which
muscarinic, but not nicotinic cholinergic receptor blockade blocks both CO- and fructose-CFP
acquisition (Rotella et al., 2015) are similar to other previously-cited cue-related feeding
responses (Carballo-Marquez et al., 2009; Pratt et al., 2007; Sharf and Ranaldi, 2006). It does not
appear that SCOP is eliminating fat- and fructose-CFP acquisition through some aversive
quality. Reasons include that the doses necessary to eliminate acquisition of these responses are
far lower than the SCOP doses that marginally reduce the maintenance of these responses in
expression studies. Second, and more importantly, whereas SCOP, but not MEC blocks the
acquisition of fructose-CFP, MEC, but not SCOP enhances the conditioned flavor avoidance
induced by quinine adulteration (Rotella et al., 2015). Finally, acquisition of CO-CFP was
unaffected by administration of BAC at doses of 3 or 5 mg/kg during one-bottle training, and
these doses also failed to affect training intakes. The inability of GABAB receptor agonism to
affect CO-CFP acquisition parallels its inability to alter fructose-CFP acquisition (Rotella et al.,
2016). This failure by BAC to affect acquisition of sugar- or fat-CFP stands in contrast to its
ability to enhance and prolong the magnitude of quinine-CFA (Rotella et al., 2016).
The elimination of acquisition of CO-CFP by muscarinic cholinergic antagonism is
similar to NMDA receptor antagonist effects (Dela Cruz et al., 2012a), and is more potent than
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DA D1 and D2 receptor antagonist effects (Dela Cruz et al., 2012b). In contrast, the inability of
nicotinic cholinergic receptor antagonism or GABAB receptor agonism to alter CO-CFP
acquisition is similar to the relative lack of opioid antagonist effects (Dela Cruz et al., 2012a).
That GABAB agonists and opioid antagonists similarly fail to affect CO-CFP acquisition stand in
contrast to the ability of BAC and naltrexone to strongly suppress fat intake under “binge-eating”
and other similar conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al., 2005;
Corwin and Wojnicki, 2009; Rao et al., 2008; Wang et al., 2011; Wong et al., 2009). Thus, it
would appear that the regulatory processes underlying opioid and GABAB regulation of “bingeeating” is unrelated to the lack of involvement of these systems in the learning of these strong fat
preferences.
The present and previous (Rotella et al., 2015, 2016) data indicate that whereas SCOP,
MEC and BAC minimally affect fat-CFP expression, SCOP, but not MEC or BAC effectively
eliminates the acquisition of fructose-CFP and fat-CFP. The use of systemic cholinergic receptor
antagonist treatment or GABAB agonist treatment in examining fructose- and fat-CFP followed
our previous strategy of initial systemic evaluation of DA receptor involvement in fructose- and
fat-CFP (Baker et al., 2003; Dela Cruz et al., 2012a, 2012b Yu et al., 2000a, 2000b) followed by
DA antagonist administration into central candidate limbic sites for fructose-CFP (Amador et al.,
2014; Bernal et al., 2008, 2009; Malkusz et al., 2012). Much of the evidence implicating
cholinergic involvement in complex aspects of food intake appears to be due to activity in a
limbic circuit (specifically the VTA and NAc) in which cholinergic signaling can act directly
upon sweet preferences and avoidances either in and of itself, or through interactions with brain
DA. Sweet solutions appear to affect both DA and Ach release, particularly in the NAc and
related sites. In addition to the ability of general food intake to increase DA and Ach in the NAc
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shell (Mark et al., 1992), daily bingeing on sugar repeatedly and initially released NAc shell DA
followed by Ach NAc shell release (Rada et al., 2005). Whereas real-feeding sucrose increased
NAc DA and Ach, sucrose intake in sham-drinking rats displayed the DA, but not the Ach
elevations in the NAc (Avena et al., 2006). Correspondingly, increases in NAc DA were
observed in normal-weight and underweight rats, whereas NAc Ach was increased in the former,
but not the latter group (Avena et al., 2008c). In contrast, animals trained to binge on a sucrose
solution display increased Ach and decreased DA release in the NAc shell following food
deprivation (Avena et al., 2008a). Consistent with the ability of sugars to produce greater CFP
relative to saccharin, sucrose-predictive cues evoked greater NAc DA release than saccharinpredictive cues (McCutcheon et al., 2012). Administration of morphine, the mu-opioid agonist,
DAMGO or galanin into the paraventricular nucleus of the hypothalamus increased DA and
decreased Ach in the NAc shell (Rada et al., 1998, 2010). A parallel system might be proposed
for mediation of fat-CFP given the present data, and that accumbal microinjections of SCOP
markedly reduced fat intake elicited by accumbal administration of the mu-opioid receptor
agonist, DAMGO, and also reduced food intake in food-deprived rats (Perry et al., 2009; Will et
al., 2006). However, accumbal SCOP failed to affect fat intake itself (Will et al., 2006).
Given these relationships, a central site of action at which muscarinic receptor
antagonism might reduce sugar- and fat-CFP and interact with brain DA is the NAc shell. Such
Ach-DA interactions would presumably occur through DA terminal innervation of Achcontaining interneurons in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et al., 2002),
although cholinergic PPT/LDT innervation is found there as well (Dautan et al., 2014). NAc
cholinergic-DA interactions act through local DA D2 receptors (Alcantara et al., 2003), mediate
accumbal DA release that also involves glutamate signaling (Cachope et al., 2012; Chuhma et
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al., 2014; Threlfell and Cragg, 2011), and provide feedback control of VTA DA release (Rahman
and McBride, 2002). Further studies with accumbal cholinergic receptor antagonists are
necessary to confirm this hypothesis for fat-CFP.
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Chapter 7: General Discussion
The final chapter will briefly summarize the effects of muscarinic and nicotinic
cholinergic receptor antagonism on the acquisition and expression of fructose-CFP or CO-CFP
(e.g., Specific Aims 1 and 2) as well as the effects of GABAB receptor agonism (e.g., Specific
Aims 3 and 4). Our novel flavor avoidance paradigm (quinine-CFA) will then be reviewed in
terms of the effects of DA D1, DA D2, opioid and NMDA receptor antagonism (Specific Aim 5)
and muscarinic and nicotinic cholinergic receptor antagonism and GABAB receptor agonism
(Specific Aim 6) on the acquisition of quinine-CFA. Finally, there will be a general discussion
of the following topics: A) what is the relationship between preference and avoidance, and how
theoretically would receptor antagonists affect the two forms of learning, B) future directions on
the proposed research as well as C) implications of animal based CFP and CFA investigations
for human consumption behaviors and pathology.
1A. Summary of Muscarinic and Nicotinic Cholinergic Receptor Antagonism: Fructoseand Fat-CFP (Specific Aims 1 & 2)
The expression of fructose-CFP failed to be affected by a wide dose range of the
muscarinic antagonist, SCOP or the nicotinic antagonist, MEC. However, the magnitude of
fructose-CFP expression, defined by changes in percent CS+ intake, was significantly reduced by
high doses of SCOP (2.5-10 mg/kg: 65-68%) and MEC (4-8 mg/kg: 67-73%) relative to VEH
(89-90%). These reductions were accompanied by reductions in total, and particularly CS+,
intake. These intake reductions of saccharin by systemic SCOP and MEC correspond to previous
reductions of sweet intake following systemic nicotinic receptor antagonism (Taraschenko et al.,
2011) and chow intake following systemic of muscarinic and nicotinic receptor antagonism
(Dandekar et al., 2011; Dickson et al., 2010; Perry et al., 2009; Pratt and Blackstone, 2009; Will
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et al., 2006). The very limited inhibition of systemic muscarinic or nicotinic cholinergic receptor
antagonism of expression of fructose-CFP stands in contrast to previously-observed systemic
pharmacological effects. Thus, systemic DA D1 (SCH23390) or D2 (raclopride) receptor
antagonists dose-dependently eliminated the expression of both fructose-CFP in real-feeding rats
and sucrose-CFP in sham-feeding rats (Baker et al., 2003; Hsiao and Smith, 1995; Yu et al.,
2000a, 2000b). Whereas a CB1 receptor inverse agonist (AM-251) reduced expression of
fructose-CFP (Miner et al., 2008), neither NMDA (MK-801) nor opioid (naltrexone) receptor
antagonism affected expression of fructose-CFP (Baker et al., 2004; Bernal et al., 2010; Golden
and Houpt, 2007). Thus, muscarinic or nicotinic cholinergic receptor antagonism plays a
minimal role in the maintenance of an already-acquired CFP for fructose.
In contrast, acquisition of fructose-CFP was eliminated by systemic SCOP, but not MEC
administered during training and the magnitude of fructose-CFP relative to VEH-trained (8592%) rats was eliminated in SCOP-trained rats receiving 1 (40-54%) and 2.5 (45-58%) mg/kg
doses, effects indicative of indifference. However, these SCOP doses significantly reduced
CS+/Fs and CS-/s intakes during training, lending to the possiblity that this loss of preference
could be due to specific primary actions of muscarinic cholinergic receptor antagonism or to
secondary actions of reducing the opportunities to learn the preference due to reduced intake per
se. To control for this second possibility, the addition of the LMTD VEH group receiving
vehicle injections, but limited in comparable CS+ and CS- intakes to those of the drug groups,
displayed comparable, significant fructose-CFP preferences relative to vehicle-trained rats
suggesting that the inability of SCOP-trained rats to display preferences was thus due to its
cholinergic receptor antagonism. Further, while lower SCOP doses eliminated fructose-CFP
acquisition, they failed to affect fructose-CFP expression. In contrast, MEC-trained rats
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continued to display significant preferences with CS+ intake significantly higher than CS- intake
despite MEC resulting in significant reductions in CS+/Fs and CS-/s intakes during training to
levels observed for SCOP. Hence, systemic muscarinic, but not nicotinic receptor antagonism
administered during training eliminated fructose-CFP acquisition. The systemic SCOP-induced
elimination of fructose-CFP acquisition is similar in magnitude to the abilities of systemic DA
D1, DA D2 and NMDA receptor antagonists to eliminate fructose-CFP acquisition in realfeeding rats (Baker et al., 2003; Golden and Houpt, 2007; Hsiao and Smith, 1995) and sucroseCFP acquisition in sham-feeding rats (Yu et al., 2000a, 2000b).
Given the similar, albeit weaker effects of DA D1, DA D2, and NMDA receptor
antagonists on the acquisition and expression of CO-CFP relative to fructose-CFP (Dela Cruz et
al., 2012a, 2012b) in addition to the research suggesting interactions amongst these systems and
the cholinergic system in the mediation of reward and learning (Avena & Rada, 2012), it was
hypothesized and addressed in Specific Aim 2 that blockade of muscarinic and nicotinic
cholinergic receptors would also influence the acquisition and expression of CO-CFP, and that
these effects would be smaller in magnitude relative to the effects observed for fructose-CFP.
The expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015) was minimally
affected only at certain doses over a wide dose range of either SCOP (fructose-CFP: 65-68%
(2.5-10 mg/kg; CO-CFP: 70% (5 mg/kg)) or MEC (fructose-CFP: 67-73% (4-8 mg/kg); COCFP: 80% (8 mg/kg)). In both paradigms, these reductions were accompanied by reductions in
total, and particularly CS+, intake following SCOP and MEC. The intake reductions of saccharin
CS solutions in the fructose-CFP paradigm by SCOP and MEC are similar to reductions of sweet
intake following systemic nicotinic receptor antagonism (Taraschenko et al., 2011). The patterns
of very limited inhibition of expression of CO-CFP by muscarinic or nicotinic cholinergic

113
receptor antagonism is similar to DA D1, DA D2, opioid and NMDA receptor antagonism of
CO-CFP expression (Dela Cruz et al., 2012a, 2012b). Despite evaluating a wide dose range (50800 nmol/kg) of SCH23390 and raclopride, CO-CFP expression was reduced only by
intermediate (200 nmol/kg) DA D1 (56%) and DA D2 (61%) antagonist doses. Similarly, despite
evaluating a wide NTX dose range (0.1-5 mg/kg), CO-CFP expression was modestly reduced by
only the 0.1 (69%) and 1 mg/kg (71%) doses. Further, despite evaluating a wide MK-801 dose
range (50-200 µg/kg), the loss of preference (49%) following the highest NMDA antagonist dose
was accompanied by dramatic decreases in total fat intake. Antagonist effects upon fructose-CFP
are more striking in that SCH23390 or raclopride dose-dependently eliminated the expression of
both fructose-CFP in real-feeding rats and sucrose-CFP in sham-feeding rats (Baker et al., 2003;
Hsiao and Smith, 1995; Yu et al., 2000a, 2000b). In contrast, neither NMDA nor opioid receptor
antagonism affected expression of fructose-CFP (Baker et al., 2004; Golden and Houpt, 2007). It
is important to note that whereas glucose and sucrose are capable of conditioning flavor
preferences through both flavor-flavor (orosensory) and flavor-nutrient (post-ingestive)
processes, fructose elicits flavor preferences through flavor-flavor, but not flavor-nutrient
processes in short-term tests (Sclafani and Ackroff, 1994; Sclafani et al., 1993, 1999). Therefore,
comparisons of the present limited cholinergic receptor signaling effects on CO-CFP with sugarCFP may be more pertinent for oral glucose-CFP because, like CO, glucose activates both
flavor-flavor and flavor-nutrient processes. Rats displayed a robust oral glucose-CFP (94-95%)
which was significantly though marginally attenuated in expression studies by SCH23390 (6770%), raclopride (77%) or MK-801 (70%) at doses that also markedly reduced overall CS intake
(Dela Cruz et al., 2014). Given the imperfection of direct fructose and oil comparisons and given
that parallel glucose data using the present agents is not yet available, other future studies need to
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address this issue as well as others examining oral only and oral + post-ingestive mechanisms.
Finally, other future studies should address whether the oral effects of fat are more important in
these procedures than fat-related post-ingestive effects by examining whether pharmacological
manipulation of preferences elicited by short-term exposure to intragastric oil are similar to or
different from that of the present data.
Acquisition of CO-CFP was selectively and dose-dependently eliminated by
administration of SCOP, but not MEC during one-bottle training despite the fact that both
antagonists lowered training intakes. The SCOP2.5 group failed to display differences between
CS+ and CS- intakes across tests, and their overall percent CS+ intake approached indifference
(52%). CS+ and CS- intakes respectively decreased and increased across preference tests in the
SCOP2.5 group, demonstrating a selective loss of the salience of the CS+ solution. Further, the
SCOP dose (2.5 mg/kg) capable of eliminating CO-CFP acquisition is lower than the dose (5
mg/kg) that only mildly reduced CO-CFP expression. In contrast, the SCOP1, MEC4 and MEC6
groups failed to display changes in CO-CFP acquisition. The pattern of selective muscarinic, but
not nicotinic cholinergic receptor involvement parallels the ability of SCOP, but not MEC to
eliminate fructose-CFP acquisition (Rotella et al., 2015). The selective actions by which
muscarinic, but not nicotinic cholinergic receptor blockade blocks both CO- and fructose-CFP
acquisition (Rotella et al., 2015) are similar to other previously-cited cue-related feeding
responses (Carballo-Marquez et al., 2009; Pratt et al., 2007; Sharf and Ranaldi, 2006). It does not
appear that SCOP is eliminating fat- and fructose-CFP acquisition through some aversive
quality. Reasons include that the doses necessary to eliminate acquisition of these responses are
far lower than the SCOP doses that marginally reduce the maintenance of these responses in
expression studies. Second, and more importantly, whereas SCOP, but not MEC blocks the
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acquisition of fructose-CFP, MEC, but not SCOP enhances the conditioned flavor avoidance
induced by quinine adulteration (Rotella et al., 2015).
The elimination of acquisition of CO-CFP by muscarinic cholinergic antagonism is
similar to NMDA receptor antagonist effects (Dela Cruz et al., 2012a), and is more potent than
DA D1 and D2 receptor antagonist effects (Dela Cruz et al., 2012b). Thus in relation to Specific
Aim 2, whereas both SCOP and MEC partially mediate fat-CFP expression, only SCOP is
involved in the acquisition of fat-CFP.
1B. Summary of GABAB Receptor Agonism: Fructose- and Fat-CFP (Specific Aims 3 & 4)
Although the present study focused on the role of BAC in sugar preference, BAC effects
upon total intake could be analyzed for saccharin intake in the fructose-CFP expression 2-bottle
testing paradigm, for fructose + saccharin and saccharin intake in the fructose-CFP 1-bottle
training paradigm. In the fructose-CFP expression paradigm, systemic BAC failed to alter total
saccharin intake across the 0.5-5 mg/kg BAC dose range. In the fructose-CFP acquisition
paradigm, neither the 3 nor 5 mg/kg doses of BAC administered during training significantly
altered fructose + saccharin or saccharin intake relative animals receiving VEH. The inability of
systemic BAC to alter saccharin intake per se is in contrast to the ability of the same dose range
to impair gustatory discrimination of 0.3% and 0.6% saccharin solutions (Wilson et al., 2011). It
should be noted that animals in these conditioning paradigms were food-restricted and received
multiple injections of systemic BAC, factors that alter BAC-induced orexigenic actions on chow
intake (e.g., Patel and Ebenezer, 2008). Thus, these data are in agreement with the general failure
to observe differences in sweet intake per se following systemic BAC (Avena et al., 2014;
Berner et al., 2009; Corwin and Wojnicki, 2009).

116
In the fructose-CFP expression paradigm, CS+ intake was significantly higher than
corresponding CS- intake in the two-bottle preference tests following VEH and all (0.5-5 mg/kg)
BAC doses. The magnitude of the fructose-CFP was significantly, but marginally lowered by the
3 mg/kg BAC dose (66%) relative to VEH; lower (0.5, 1.5) and higher (5.0) BAC doses failed to
exert effects. This marginal reduction in fructose-CFP expression following systemic GABAB
receptor activation was similar and comparable to that observed following systemic
administration of AM-251, a cannabinoid CB1 receptor inverse agonist (Miner et al., 2008) and
muscarinic (scopolamine) and nicotinic (mecamylamine) cholinergic antagonists (Rotella et al.,
2015). In contrast, systemic administration of dopamine D1 (SCH23390) or D2 (raclopride)
receptor antagonists eliminated expression of fructose-CFP in real-feeding rats and sucrose-CFP
in sham-feeding rats (Baker et al., 2003; Yu et al., 2000). Further, neither systemic NMDA (MK801) nor opioid (naltrexone) receptor antagonism affected expression of fructose-CFP in realfeeding rats or sucrose-CFP in sham-feeding rats (Baker et al., 2004; Golden and Houpt, 2007;
Yu et al., 1999).
In the fructose-CFP acquisition paradigm, the patterns of CS+ and CS- intake in all three
two-bottle preferences tests were similar in rats receiving VEH or the two (3 or 5 mg/kg) BAC
doses during training. Correspondingly, the magnitude of fructose-CFP measured by percent
CS+ intake failed to differ among these groups. The inability of systemic GABAB receptor
activation to alter the acquisition of fructose-CFP stands in marked contrast to the abilities of
systemic administration of dopamine D1, dopamine D2, NMDA or muscarinic receptor
antagonists to eliminate acquisition of fructose-CFP in real-feeding rats and/or sucrose-CFP in
sham-feeding rats (Baker et al., 2003; Golden and Houpt, 2007; Rotella et al., 2015; Yu et al.,
2000). Rather, the effects of systemic BAC in failing to affect fructose-CFP acquisition were
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similar to that observed following NTX (Baker et al., 2004; Yu et al., 1999), AM-251 (Miner et
al., 2008) or MEC (Rotella et al., 2015). Thus in relation to Specific Aim 3, while BAC
marginally reduced fructose-CFP expression, it failed to block fructose-CFP acquisition.
The expression of CO-CFP, like that of fructose-CFP (Rotella et al., 2015), was
minimally affected only at one dose (3 mg/kg) over a wide dose range of BAC (fructose-CFP:
66%; CO-CFP: 74%). The inability of the BAC dose range to alter total fat intake in these series
of studies stands in contrast to its previously-reported increases in fat intake under normal adlibitum conditions (e.g., Bains and Ebenezer, 2013; Ebenezer and Patel, 2011), and suppression
of fat intake under “binge-type” conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin
et al., 2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wojnicki et al., 2014; Wong et al.,
2009). This may be due to the fact that animals in the present study were chronically foodrestricted to encourage short latency sampling of the solutions during the preference paradigm.
The patterns of very limited inhibition of expression of CO-CFP by GABAB receptor agonism
are similar to DA D1, DA D2, opioid, NMDA, muscarinic or nicotinic cholinergic receptor
antagonism on CO-CFP expression (Dela Cruz et al., 2012a, 2012b). It is important to note that
whereas glucose and sucrose are capable of conditioning flavor preferences through both flavorflavor (orosensory) and flavor-nutrient (post-ingestive) processes, fructose elicits flavor
preferences through flavor-flavor, but not flavor-nutrient processes in short-term tests (Sclafani
and Ackroff, 1994; Sclafani et al., 1993, 1999). Therefore, comparisons of the present limited
GABAB receptor signaling effects on CO-CFP with sugar-CFP may be more pertinent for oral
glucose-CFP because, like CO, glucose activates both flavor-flavor and flavor-nutrient
processes. Rats displayed a robust oral glucose-CFP (94-95%) which was significantly though
marginally attenuated in expression studies by SCH23390 (67-70%), raclopride (77%) or MK-
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801 (70%) at doses that also markedly reduced overall CS intake (Dela Cruz et al., 2014). Given
the imperfection of direct fructose and oil comparisons and given that parallel glucose data using
the present agents is not yet available, other future studies need to address this issue as well as
others examining oral only and oral + post-ingestive mechanisms. Finally, other future studies
should address whether the oral effects of fat are more important in these procedures than fatrelated post-ingestive effects by examining whether pharmacological manipulation of
preferences elicited by short-term exposure to intragastric oil are similar to or different from that
of the present data.
The acquisition of CO-CFP was unaffected by administration of BAC at doses of 3 or 5
mg/kg during one-bottle training, and these doses also failed to affect training intakes. The
inability of GABAB receptor agonism to affect CO-CFP acquisition parallels its inability to alter
fructose-CFP acquisition (Rotella et al., 2016). This failure by BAC to affect acquisition of
sugar- or fat-CFP stands in contrast to its ability to enhance and prolong the magnitude of
quinine-CFA (Rotella et al., 2016).
That GABAB agonists and opioid antagonists similarly fail to affect CO-CFP acquisition
stand in contrast to the ability of BAC and NTX to strongly suppress fat intake under “bingeeating” and other similar conditions (Avena et al., 2014; Berner et al., 2009; Buda-Levin et al.,
2005; Corwin and Wojnicki, 2009; Rao et al., 2008; Wang et al., 2011; Wong et al., 2009). Thus,
it would appear that the regulatory processes underlying opioid and GABAB regulation of
“binge-eating” is unrelated to the lack of involvement of these systems in the learning of these
strong fat preferences.
The inability of nicotinic cholinergic receptor antagonism or GABAB receptor agonism to
alter CO-CFP acquisition is similar to the relative lack of opioid antagonist effects (Dela Cruz et

119
al., 2012a), but differs from the ability of muscarinic cholinergic (Rotella et al., 2016b) and
NMDA receptor antagonist effects (Dela Cruz et al., 2012a). Thus, in relation to Specific Aim
4, these data indicate that BAC minimally affects fat-CFP expression and fails to effectively
eliminate the acquisition of fructose-CFP and fat-CFP.
1C. Summary of the Pharmacology of Quinine-CFA (Specific Aims 5 & 6)
Under an evolutionary perspective, it could be said that the activation of certain taste
receptors for sweets and fats and the following “pleasant” perceptions aided in the survival of
man and many species and thus were selected for and subsequently passed to following
generations due to the energy and nutrients these substances provided. By contrast, it could be
said that the activation of certain taste receptors for bitter toxins and the following “unpleasant”
perceptions aided in the survival of man and many species and thus were selected for and
subsequently passed to following generations due to the harm or death that was prevented.
Those failing to learn to avoid these toxic substances presumably did not survive and the genes
coding for the taste receptors and underlying neurochemical substrates mediating this learning
were also not passed down. Therefore, not only is important to understand the neurochemical
and/or neuroanatomical substrates mediating these adaptive approach behaviors, but it is equally
important to understand the same processes underlying adaptive avoidant behaviors. As such,
another primary goal of this dissertation was to determine whether the same neurotransmitter
systems mediating the learning and maintenance of preferences conditioned by primary rewards
(e.g. sugars and fats) also mediated the underlying learning processes of avoidances conditioned
by primary aversive stimuli (e.g. bitter taste of quinine).
In order to assess the proposed effects on Specific Aim 5, we first demonstrated that a
CFA could be produced by adulterating a fructose+saccharin solution with quinine depending
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upon the concentration of the bitterant. At very low concentrations (0.001-0.008%), the added
quinine failed to reduce CS+FSQ training intake relative to the CS-FS, and did not produce
significant differences in CS+ and CS- intakes in the two-bottle choice tests. Although
adulteration with 0.012% or 0.016% quinine significantly depressed CS+/FSQ training intake, it
was insufficient to produce a CFA in the two-bottle tests. However, when quinine concentration
was raised to 0.03%, CS+/FSQ intake was significantly reduced relative to CS-/FS intake in onebottle training trials, and a quinine-CFA was observed in two-bottle Test 1 but not in Tests 2 and
3. The transitory nature of the 0.3% quinine-induced CFA was also observed in the VEH groups
of Experiments 2 and 3 that were tested with CS flavors presented in fructose+saccharin and
saccharin-only solutions, respectively. The data from Experiment 3 indicates that the transitory
quinine CFA observed in the first two experiments was not due to the use of palatable
fructose+saccharin solutions in the choice tests. Instead, the quinine-CFA was found to be
related to the concentration of the bitter adulterant. The VEH.06% rats trained with a CS+FSQ
containing 0.06% quinine consumed less solution during training and displayed a more persistent
CS+ avoidance (Tests 1 and 2) than did the VEH rats with the CS+FSQ containing 0.03%
quinine (Test 1 only), indicating that the persistence of the quinine-CFA could be increased by
increasing quinine concentration.
In CFP studies, systemic DA D1and D2 antagonists reduce the acquisition of flavor-taste
sugar preferences (Baker et al., 2003; Hsiao & Smith, 1995; Yu et al., 2000a; 2000b), whereas
only DA D1 antagonists reduce the acquisition of flavor-nutrient sugar preferences (Azzara et
al., 2001). One interpretation of how DA antagonists block sugar-based CFPs is that the drugs
reduce the reward value of the sweet taste or post-oral actions of sugars. An extension of this
hypothesis would be that DA antagonists also reduce the negative reward value of aversive tastes
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or post-oral aversive states. In fact, DA D1 receptor antagonists administered into either the
lateral hypothalamus (Caulliez et al., 1996) or shell of the NAc (Fenu et al., 2001) disrupted the
acquisition of a flavor-toxin CFA induced by LiCl in a manner similar to reductions in the
acquisition of flavor-nutrient CFP elicited by IG glucose infusions (Touzani et al., 2008; 2009b).
The selective effects of SCH23390, but not raclopride injections on quinine-induced CFA is
similar to reports that only SCH23390 altered flavor-toxin avoidance produced by LiCl
injections (Fenu et al., 2005; 2009). However, whereas SCH23390 blocked the development of
the LiCl-CFA, the drug enhanced the quinine-CFA in the present study. The quinine and LiCl
conditioning procedures differed in several important respects which complicate comparisons
between the different drug effects. Note, in particular, that in one experiment, SCH23390
significantly attenuated a LiCl-induced CFA when injected 5 min after the CS training sessions
but not when injected 30 min prior to the CS training sessions as in the present study (Fenu et al.,
2001). Thus, to determine if SCH23390, or other drugs, differentially influence the learning of a
bitter taste (quinine) or toxic drug (LiCl) CFA, it is essential to use similar training paradigms
(drug dose, injection timing, CS flavor, etc.).
Conceivably, DA D1 antagonism may enhance quinine-conditioned flavor avoidance
because it selectively increases the aversiveness of bitter adulterants. However, there is little
evidence concerning the impact of systemic SCH23390 on quinine avoidance; indeed, one study
reported that SCH microinfusions into the ventral pallidum suppressed saccharin, but not quinine
intake (Shimura et al., 2006). In Experiments 2 and 3, SCH23390 reduced the intake of both the
FS and FSQ solutions so the drug effect on quinine avoidance per se cannot be differentiated.
The failure of raclopride injections to alter CS+FSQ training intake or CS+ preference, relative
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to the vehicle treatment, is consistent with one report that this DA D2 antagonist did not alter
quinine solution intake in rats (Phillips et al., 1991).
In a CFP study, systemic NMDA receptor antagonism eliminated the acquisition, but not
expression of a flavor-taste fructose preference (Golden & Houpt, 2007). Yet the present study
demonstrated that systemic treatment with MK-801 significantly prolonged the flavor-taste CFA
induced by quinine. During training, MK-801-treated rats displayed significant reductions in
CS+FSQ, but not CS-FS intake as compared to VEH-treated rats, suggesting that it enhanced the
avoidance of the quinine adulterated solution. Yet, a previous study (Vardigan et al., 2010)
reported that systemic MK-801 did not reduce quinine solution intake in thirsty rats. Golden and
Houpt (2007) hypothesized that NMDA receptor signaling mediates the learning process by
which a flavor CS is associated with the reward value of a gustatory US. Thus, it is not clear why
systemic NMDA receptor antagonism with MK-801 blocks a fructose-CFP (Golden & Houpt,
2007), but enhances a quinine-CFA. CFA is induced by MK-801 as well as other NMDA
antagonists (Fowler et al., 2011; Jackson & Sanger, 1989; Traverso et al., 2003; 2012; Turgeon
et al., 2000), and it enhances ethanol-induced CFA (Blenkowski et al., 1998).
In CFP studies, neither systemic nor central (NAc) opioid receptor antagonism altered the
acquisition or expression of flavor-taste or flavor-nutrient sugar preferences (Azzara et al., 2000;
Baker et al., 2004; Bernal et al., 2010; Yu et al., 1999). Yet the present study demonstrated that
NTX significantly prolonged the flavor-taste CFA induced by quinine. This effect may be related
to the finding that opioid antagonism increased quinine aversion in rats (Cagniard & Murphy,
2013; Le Magnen et al., 1980; Siviy & Reid, 1983), although this is not a consistent result
(Ferraro et al., 2002; Goodwin et al., 2001; Levine et al., 1982; Parker et al., 1992). Opioid
receptor antagonism with naloxone is also reported to enhance taste aversions elicited by LiCl
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(Davis et al., 2009; Micelli et al., 1979; Smurthwaite et al., 1992). NTX as well as delta-opioid
agonists and antagonists produce conditioned flavor avoidance by themselves (Hutchinson et al.,
2000; Kautz et al., 1989; Parker & Rennie, 1992). Yet, opioid antagonism blocks morphineinduced taste aversions (Fox et al., 2006; Stevenson et al., 1992).
In relation to Specific Aim 6, the last set of studies addressed the roles of muscarinic,
nicotinic or GABAB receptor signaling in the acquisition of quinine-CFA.
Systemic administration of nicotinic (MEC), but not muscarinic (SCOP) cholinergic
receptor antagonism significantly enhanced and prolonged the acquisition of quinine-CFA.
VEH-trained rats displayed a significant, transitory quinine-CFA as demonstrated by a
significant aversion observed after the first (34%), but not second (48%) or third (47%) pairs of
tests. Systemic nicotinic cholinergic antagonism significantly increased the magnitude and
duration of quinine-CFA as indicated by rats trained with the 4 (18-24%) and 6 (11-13%) mg/kg
MEC doses. In contrast, the SCOP 1 group displayed a significant aversion after the first test pair
(17%), but failed to differ from VEH-trained rats thereafter, whereas the SCOP 2.5 group failed
to display quinine-CFA after any preference test. It should be noted that both systemic SCOP and
MEC significantly reduced CS-/FS intake and CS+/FSQ intake during training relative to VEH.
This raises the possibility that the greater subsequent avoidance responses could be due to nonspecific malaise brought about by pairing the antagonist with the flavored solutions during
training. Both lithium chloride-induced conditioned taste aversions and attenuation of neophobic
responses were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al.,
2002; Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et
al., 2006), but not when SCOP was administered after the presentation of the new taste.
Although nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine,
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an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors,
reduced nicotine seeking without producing malaise (Hopkins et al., 2012).
The inability of SCOP to affect quinine-CFA acquisition is consistent with its previouslydescribed inability to alter quinine aversion while attenuating LiCl-induced CFA (Coil et al.,
1978). Although systemic SCOP elicited a flavor-taste CFA (Ossenkopp et al., 1986), the present
data indicate that SCOP- and quinine-CFA fail to synergize. The ability of MEC to enhance and
prolong quinine-CFA is consistent with previous observations that nicotine depressed quinineevoked responses in the nucleus tractus solitarius that were blocked by MEC (Simons et al.,
2006), and CFAs induced by nicotine and quinine generalized to each other in mice (Gyekis et
al., 2012) that were blocked by MEC (Oliveira-Maia et al., 2009). However, the ability of MEC
to enhance and prolong quinine-CFA appears specific to this type of “inhibitory” learning.
Recent studies demonstrated that chronic co-treatment with systemic MEC prevented the
occurrence of depressive-like behavior elicited by chronic restraint stress as measured by the
forced swim test, sucrose preference and body weight control (Aboul-Fotouh, 2015). Moreover,
whereas nicotine facilitated a version of “inhibitory” learning called negative occasion setting,
systemic MEC co-treatment extended the number of training sessions to elicit this behavior
(Meyer et al., 2015).
These data suggest that systemic nicotinic, but not muscarinic receptor antagonism,
enhances and prolongs quinine-CTA by acting on its specific cholinergic signaling mechanism,
and not through non-specific malaise-induced effects. These effects extend our previous
(Rotella et al., 2014) findings demonstrating that the persistence of quinine-CFA was
significantly enhanced by systemic administration of DA D1, NMDA and opioid, but not DA D2
receptor antagonists administered prior to training. Thus, systemic nicotinic, DA D1, NMDA and
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opioid, but not muscarinic, or DA D2 receptor antagonists administered during training enhanced
and prolonged the acquisition of quinine-CFA.
In the quinine-CFA paradigm, systemic BAC dose-dependently enhanced and prolonged
the magnitude of quinine-CFA with rats receiving the 5 mg/kg BAC dose during training
eliciting significantly higher CS- than CS+ intake across all three tests. As observed previously
(Rotella et al., 2014, 2015), the VEH-trained group consumed significantly more CS- than CS+
only during Test 1. The BAC 3-trained group consumed significantly more CS- than CS+ during
Test 3, and this pattern approached significance in Tests 1 and 2. Consequently, the magnitudes
of quinine-CFA as measured by percent CS+ intake takes were significantly lower across all
three tests in rats trained with the 5 mg/kg BAC dose (15-20-25%) relative to VEH-trained rats
(34-48-47%). The dose-dependent ability of systemic GABAB receptor activation to enhance and
prolong quinine-CFA is similar to that observed following systemic dopamine D1, NMDA,
opioid or nicotinic, but not dopamine D2 or muscarinic antagonists (Rotella et al., 2014, 2015).
A role for GABAB receptor systems in conditioned aversions is supported by the ability of the
GABAB agonist, BAC, but not the GABAB antagonist, saclofen, to suppress saccharin-induced
drinking following pairing (Echo et al., 2002; Wilson et al., 2011). However, another study using
a similar dose range found that systemic BAC failed to induce an aversion or affect ethanolinduced aversions (Chester and Cunningham, 1999). Further, although systemic BAC failed to
alter operant responding to quinine-adulterated solutions (Petry and Heyman, 1997), it did
enhance the discriminative abilities of D-amphetamine in a conditioned taste aversion procedure
(Miranda et al., 2009). The present findings that systemic BAC enhanced and prolonged quinineCFA extends the role of GABAB receptor signaling in both orosensory and post-ingestive
processes related to avoidance and aversion, respectively. These data implicate GABAB receptor
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signaling in the acquisition of quinine avoidance and extend our findings to that of systemic
nicotinic, DA D1, NMDA and opioid, but not muscarinic, or DA D2 receptor antagonism, as
demonstrated by the enhancement and prolonged duration of the acquisition of quinine-CFA.
2A. CFP and CFA: Theoretical Perspective of Pharmacological Effects
The series of studies conducted for this dissertation involved the pharmacological
substrates of both the learning and maintenance of two forms of food-related preference learning
in rats, fructose-CFP and corn oil-CFP, as well as the learning of a form of food-related
avoidance, quinine-CFA. Much evidence supports the roles of the D1, D2 and NMDA receptor
antagonism in the acquisition and expression of both fructose- and corn oil-CFP and the present
series of studies provide even further elucidation of the pharmacology of these learned foodrelated preferences. By contrast, the pharmacological substrates of learned food-related
avoidances are far less studied, and as a result the series of studies conducted for this dissertation
extended the pharmacology of learned preferences to learned avoidances, demonstrating stark
behavioral and pharmacological differences between the two. These findings are summarized in
Table 1.
With respect to learned food-related preferences (fructose-CFP and fat-CFP), we show
that muscarinic receptor signaling is involved in the associative learning phase of both foodrelated preferences that were under investigation, but not the expression phase of this learning:.
We reported that systemic administration of SCOP eliminated the acquisition of both fructoseand corn oil-CFP acquisition, with slightly more robust effects for fructose-CFP (40-54%
indifference) than CO-CFP (41%-59% indifference). These results lend behavioral support for a
cholinergic hypothesis of learning and memory (Hasselmo, 1999, 2006; Hasselmo et al., 2002;
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Table 1
Summary of systemic pharmacological findings in the fructose-conditioned flavor preference (CFP) expression and acquisition,
quinine-conditioned flavor avoidance (CFA) acquisition and corn oil-CFP acquisition and expression paradigms.
Paradigm
Neurotransmitter system
Effect
Effect
Reference
Expression
Receptor sub-type: drug
Acquisition
Dose
A. Fructose-CFP Dopamine
Blocked*
Baker et al., 2003
DA D1 antagonist (SCH)
Blocked
DA D2 antagonist (RAC)
Blocked
Blocked*
Baker et al., 2003

B. Quinine-CFA

B. Corn oil-CFP

Glutamate
NMDA antagonist (MK801) Blocked

No Effect

Golden & Houpt, 2007

Opioid
General antagonist (NTX)

No Effect

No Effect

Baker et al., 2004

Acetylcholine
mACh antagonist (SCOP)
nACh antagonist (MEC)

Blocked
No Effect

Attenuated
Attenuated

Rotella et al., 2015
Rotella et al., 2015

GABA
GABAB agonist (BAC)

No Effect

Attenuated

Rotella et al., 2016a

Dopamine
DA D1 antagonist (SCH)
DA D2 antagonist (RAC)

Enhanced/prolonged
No Effect

n/a
n/a

Rotella et al., 2014
Rotella et al., 2014

Glutamate
NMDA antagonist (MK801) Enhanced/prolonged

n/a

Rotella et al., 2014

Opioid
General antagonist (NTX)

Enhanced/prolonged

n/a

Rotella et al., 2014

Acetylcholine
mACh antagonist (SCOP)
nACh antagonist (MEC)

No Effect
Enhanced/prolonged

n/a
n/a

Rotella et al., 2015
Rotella et al., 2015

GABA
GABAB agonist (BAC)

Enhanced/Prolonged

n/a

Rotella et al., 2016a

Dopamine
DA D1 antagonist (SCH)
DA D2 antagonist (RAC)

Attenuated
Attenuated

Blocked
Blocked

Dela Cruz et al., 2012a
Dela Cruz et al., 2012a

Glutamate
NMDA antagonist (MK801) Blocked

Attenuated

Dela Cruz et al., 2012b

Opioid
General antagonist (NTX)

Attenuated

Attenuated

Dela Cruz et al., 2012b

Acetylcholine
mACh antagonist (SCOP)
nACh antagonist (MEC)

Blocked
No Effect

Attenuated
Attenuated

Rotella et al., 2016b
Rotella et al., 2016b

GABA
GABAB agonist (BAC)
No Effect
Attenuated
Rotella et al., 2016b
DA: dopamine; NMDA: N-methyl-D-aspartate; SCH; SCH23390; RAC: raclopride; MK801: MK-801; NTX: naltrexone;
SCOP: scopolamine; MEC: mecamylamine, BAC: baclofen.
Blocked: Significant %CS effect present (≈ 50%) absent of significant differences in CS+ and CS- intakes.
Attenuated: Significant %CS effect present (≈ 50%) including significant differences in CS+ and CS- intakes.
* Very low CS intakes at higher doses
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Hasselmo & McGaughy, 2004; Klinkenberg & Blokland, 2010; Meeter et al., 2004). This
hypothesis proposes that oscillations in cholinergic activity within a network including the
entorhinal cortex, dentate gyrus, CA3, CA1 and medial septum (Meeter et al., 2004) shifts to
allow optimal levels of information encoding, consolidation and retrieval, where decreases in
cholinergic activity would impair encoding and increases would impair consolidation and
retrieval. Our findings lend support to this hypothesis in that SCOP administration differentially
blocked the acquisition (encoding) phase of fructose- and CO-CFP. These findings are similar to
that of other studies demonstrating these effects on learning and memory using SCOP (Winters
et al., 2007, 2006, 2008; Young et al., 1995); however, theses studies demonstrated that
consolidation could even be enhanced by SCOP administration, which would suggest an
enhanced expression of CFP. Although we failed to demonstrate significant blockade or
enhacement of expression of CFP in these studies, it could be due to methodological differences
between the studies.
Interestingly, these effects on acquisition were also seen for systemic blockade of DA and
NMDA receptors in rats. In contrast, nicotinic receptor antagonism or GABAB receptor agonism
failed to affect either type of preference acquisition. Given this, it could be hypothesized that
muscarinic receptor signaling is required for acquiring a food-related association. However,
preferences are not the only form of associative learning animals and humans may acquire,
avoidances are also possible. Thus, it could be said that if muscarinic blockade simply interferes
with all forms of food-related learning, it would also block learned food-related avoidances. The
current series of studies found a contrasting effect, in which systemically administered SCOP
failed to affect the acquisition of quinine-CFA. Therefore, the ability of SCOP to block the
learning of a food-related association transcends the nutrient used to condition the behavior, but
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may be related to the hedonic valence of the stimulus used to condition the behavior, where
fructose and CO act as appetitive stimuli with positive hedonic valence and quinine acts an
avoidant stimulus with negative hedonic valence.
Given these effects, it may be hypothesized that the pharmacological agents administered
eliminate or reduce the salience of the stimulus used to condition the behavior, leading to
indifference during extinction testing. For example, with respect to CFPs, the positive hedonic
qualities (e.g. sweet taste of fructose or fatty taste/texture of CO) play a role in their ability to
condition flavor preferences, resulting in significant % CS+ preferences relative to CS-. The
current findings support the role of SCOP to eliminate the positive hedonic salience of fructose
and CO given that administration of the drug blocked their acquisition as measured by
indifference (about 50% CS+ relative to CS- intake) during two-bottle testing. If this hypothesis
were true of food-learning despite hedonic salience, the same would hold for avoidances, leading
a taste avoidance to shift to indifference. With respect to quinine-CFA, the negative hedonic
quality (e.g. bitter taste of quinine) plays a role in its ability to condition a flavor avoidance,
resulting in significant %CS+ avoidances relative to CS-. By contrast, the current findings fail to
support the role of SCOP in its ability to eliminate the negative hedonic salience of quinine by
shifting the learned avoidance to indifference, given its failure to eliminate quinine-CFA
acquisition. Therefore it would seem that the effects of SCOP on food-related learning are
restricted to conditioning occurring through the pairing of stimuli of positive hedonic salience.
Another interesting result was that nicotinic and GABAB receptor signaling, despite
failing to mediate the acquisition of fructose- and CO-CFP, were found to significantly affect the
acquisition of quinine-CFA, demonstrating a pharmacological and behavioral distinction
between these and muscarinic signaling. Here, we report that systemically administered MEC
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and BAC significantly prolonged the duration of quinine-CFA. If the above hypothesis were to
hold true, it would be assumed that the acquisition of quinine-CFA would be eliminated rather
than prolonged. As a result, the totality of our findings does NOT support this hypothesis
relating to the elimination of the salience of the stimulus used to condition the behavior.
A more encompassing hypothesis to the findings reported in this dissertation would be
that the pharmacological agents administered serve to shift the acquired association in the
negative direction, such that taste preferences would shift to indifferences and taste avoidances
would become more avoided. The results of SCOP administration provide support for this
hypothesis in that systemic SCOP lead to %CS+ indifference for both fructose- and CO-CFP
acquisition, also supported by similar effects reported for DA and glutamatergic NMDA receptor
blockade, but not nicotinic, GABAB or opioid receptor blockade. On the other hand, while
systemic MEC or BAC administration caused an already avoided solution to become more
avoided or avoided for longer periods of time, similar to opioid, DA and glutamatergic NMDA
receptor blockade, muscarinic receptor blockade failed to affect quinine-CFA acquisition. Thus
although not all pharmacological agents administered affected the learning of these behaviors,
most served to shift the acquired association in the negative direction, leading preferences to
indifference and avoidances to become more avoided or for increased duration.
2B. Future Directions of Research
Cholinergic Effects: The present data indicate that whereas systemic muscarinic (SCOP)
and nicotinic (MEC) cholinergic receptor antagonism minimally affects fructose- and fat-CFP
expression, systemic muscarinic, but not nicotinic cholinergic receptor antagonism effectively
eliminates the acquisition of fructose- and fat-CFP. In contrast, systemic nicotinic, but not
muscarinic cholinergic receptor antagonism enhanced and prolonged the acquisition of quinine-
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CFA. The use of systemic cholinergic receptor antagonist treatment followed our previous
strategy of initial systemic evaluation of DA receptor involvement in fructose-CFP (Baker et al.,
2003; Yu et al., 2000a, 2000b) followed by antagonist administration into central candidate
limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012). Thus, we
propose the central candidate sites for muscarinic receptor antagonist effects on fructose- and fatCFP acquisition and nicotinic receptor antagonists for quinine-CFA acquisition.
Muscarinic Acetylcholine Effects: Much of the evidence implicating cholinergic
involvement in complex aspects of food intake appears to be due to activity in a limbic circuit
(specifically the VTA and NAc) in which cholinergic signaling can act directly upon preferences
and avoidances either in and of itself, or through interactions with brain DA. Sweet solutions
appear to affect both DA and Ach release. One Ach-DA neuroanatomical interaction
presumably occurs through Ach inputs from the PPT/LDT nuclei to identified DA cells in the
VTA (Holmstrand and Sesack, 2011; Maskos, 2008; Omelchenko and Sesack, 2005; Woolf et
al., 1990). The second Ach-DA interaction presumably occurs through DA terminal innervation
of Ach-containing interneurons in the NAc (de Rover et al., 2002; Witten et al., 2010; Zhou et
al., 2002), although cholinergic PPT/LDT innervation is found there as well (Dautan et al.,
2014). NAc cholinergic-DA interactions act through local DA D2 receptors (Alcantara et al.,
2003), mediate accumbal DA release that also involves glutamate signaling (Cachope et al.,
2012; Chuhma et al., 2014; Threlfell and Cragg, 2011), and provide feedback control of VTA
DA release (Rahman and McBride, 2002).
In addition to the ability of general food intake to increase DA and Ach in the NAc shell
(Mark et al., 1992), daily bingeing on sugar repeatedly and initially released NAc shell DA
followed by Ach NAc shell release (Rada et al., 2005). Whereas real-feeding sucrose increased
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NAc DA and Ach, sucrose intake in sham-drinking rats displayed the DA, but Ach elevations in
the NAc (Avena et al., 2006). Correspondingly, increases in NAc DA were observed in normalweight and underweight rats, whereas NAc Ach was increased in the former, but not the latter
group (Avena et al., 2008c). In contrast, animals trained to binge on a sucrose solution display
increased Ach and decreased DA release in the NAc shell following food deprivation (Avena et
al., 2008a). Consistent with the ability of sugars to produce greater CFP relative to saccharin,
sucrose-predictive cues evoked greater NAc DA release than saccharin-predictive cues
(McCutcheon et al., 2012). Administration of morphine, a mu-opioid agonist, DAMGO or
galanin into the paraventricular nucleus of the hypothalamus increased DA and decreased Ach in
the NAc shell (Rada et al., 1998, 2010). VTA Ach and NAc DA are concomitantly released by
the orexigenic peptide, ghrelin (Jerlhag et al., 2012). Given these relationships, a central site of
action at which muscarinic receptor antagonism might reduce fructose- and fat-CFP and interact
with brain DA is the NAc shell.
Furthermore, multiple studies implicate the VTA as a potential site in which muscarinic
antagonist effects may block the acquisition of CFPs, given not only the interaction of DA and
Ach here, but also NMDA receptors. NMDA receptor antagonism by MK-801 was found to
block both fructose- (Golden & houpt, 2007) and fat-CFP (Dela Cruz et al., 2012b) and (2R)amino-5-phosphonopentanoate (AP-5) in the VTA impaired acquisition of lever pressing for
food, but not when injected dorsal to the VTA suggesting region specificty (Zellner et al., 2009).
Further, VTA NMDA receptor stimulation is necessary for both the acquisition of reward-related
learning and acquisition by the CS to activate dopamine terminal regions, as measured by c-fos
expression in forebrain structures such as prefrontal cortex area 2, nucleus accumens core and
shell as well as medial and lateral caudate (Ranaldi et al., 2011). It has also been reported that
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primary rewarding UCSs activate VTA DA neurons and NSs associated with these UCSs acquire
the ability to act as CSs since they also come to acquire the ability to activate VTA DA neurons
through NS-UCS associations (Zellner & Ranaldi, 2010), as measured by c-fos activity in the
VTA (Kest et al., 2012).
This dissertation reported that systemic antagonism of muscarinic cholinergic receptors
blocks the acquisition of both fructose- and corn oil-CFP, but failed to affect the acquisition of
quinine-CFA suggesting that SCOP primarily interferes with reward-related learning. These
effects are support by studies demonstrating that SCOP in the VTA blocks the acquisition of
reward-related learning in the absence of performance deficits (Galaj et al., 2017). Similar
effects were reported for the ability of VTA SCOP to block the acquisition of food-related
learning (Sharf & Ranaldi, 2006) or the acquisition of food-rewarded operant responding, but not
the performance of the task in rats as measured by a failure to affect lever pressing break points
under a progressive ratio schedule of reinforcement (Sharf et al., 2006). Taken together, these
findings suggest that SCOPs ability to block acquisition of fructose- and corn oil-CFP may be
due to interfering with the ability of the NSs to acts as CSs by preventing the CS to either
activate VTA DA on its own or to prevent NMDA-dependent VTA DA activation. Thus,
muscarinic cholinergic receptor activation is necessary for a NS to acquire the ability to act as a
CS through associating with a UCS in the absence of performance deficits.
Given the pronounced effects of muscarinic cholinergic receptor antagonism on the
acquisition of fructose-CFP, the process whereby these effects occurred may be discussed in
relation to whether SCOP blocked the rewarding effects of fructose, or whether SCOP blocked
the learned association. A recent study reported that SCOP significantly reduced intakes of both
a more preferred 16% sucrose solution as well as a less preferred 0.2% saccharin solution in
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C57BL/6 and BALB/c mice, but not SWR mice (Olsson et al., 2017), suggesting not only a
genetic difference in the extent to which muscarinic cholinergic receptor blockade influences
sweet intake, but more importantly that SCOPs effects on intake did not depend on the rewarding
quality of the stimulus in C57BL/6 and BALB/c mice. Additionally, whereas SCOP dosedependently reduced the expression of sucrose-CFP in C57BL/6 and BALB/c mice it failed to
affect expression in SWR mice, and while SCOP dose-dependently reduced the acquisition of
sucrose-CFP in BALB/c mice it marginally affected acquisition in C57BL/6 and SWR mice
(Bourie et al., 2017). Therefore, the reductions induced by SCOP on acquisition and expression
of sugar-CFP particularly in SWR mice appear due to interferrcnce with the associative process
underlying the behavior (Bourie et al., 2017), and not the inherent reward value of the UCS
(Olsson et al., 2017). Further studies are necessary to examine this “reward” vs. “learning” issue.
Nicotinic Acetylcholine Effects: With respect to avoidances, DA D1, but not D2
antagonism disrupted the acquisition of a LiCl-induced CFA following systemic administration,
and following central administration into the LH or NAc shell (Caulliez et al., 1996; Fenu et al.,
2001, 2005, 2009), sites also involved in preference–related learning. Blockade of NMDA,
AMPA and metabotropic glutamate receptors in the AMY disrupted LiCl-induced CFA
(Yasoshima et al., 2000). SCOP and nicotine are capable of eliciting flavor-taste CFAs with the
former abolished and the latter enhanced by lesions placed in the area postrema (Ossenkopp et
al., 1986, Ossenkopp and Gugno, 1990). Further, nicotine depressed quinine-evoked responses in
the nucleus tractus solitarius that were blocked by MEC (Simons et al., 2006). Given these
relationships, central sites of action at which nicotinic receptor antagonism might enhance
quinine-CFA is through either by mediation of brain DA reward circuitry, acting within the NAc
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shell, or by mediation of medullary toxin-detecting structures, acting within the area postrema or
solitary nucleus.
It is possibile that the greater subsequent avoidance responses could be due to nonspecific malaise brought about by pairing the antagonist with the flavored solutions during
training. Both LiCl-induced conditioned taste aversions and attenuation of neophobic responses
were blocked by central SCOP pretreatment into the insular cortex (Ferreira et al., 2002;
Gutierrez et al., 2003a, 2003b; Naor and Dudai, 1996) and NAc shell (Ramirez-Lugo et al.,
2006), but not when SCOP was administered after the presentation of the new taste. Although
nicotinic receptor antagonists have not been evaluated in this paradigm, galantamine, an
acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic Ach receptors,
reduced nicotine seeking without producing malaise (Hopkins et al., 2012). These data suggest
that systemic nicotinic, but not muscarinic receptor antagonism enhances and prolongs quinineCTA by acting on its specific cholinergic signaling mechanism, and not through non-specific
malaise-induced effects. Further studies altering the timing of cholinergic antagonist injections
are necessary to completely rule out participation by this non-specific effect.
GABAB Effects: The present data indicate that whereas systemic BAC administration
failed to significantly affect fructose- and fat-CFP, it enhanced and prolonged the acquisition of
quinine-CFA. The use of systemic GABAB receptor agonist treatment followed our previous
strategy of initial systemic evaluation of DA receptor involvement in fructose-CFP (Baker et al.,
2003; Yu et al., 2000a, 2000b) followed by antagonist administration into central candidate
limbic sites (Amador et al., 2014; Bernal et al., 2008, 2009; Malkusz et al., 2012). Thus, we
propose the central candidate central sites for GABAB receptor agonist effects for quinine-CFA
acquisition.
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BAC administered into limbic and hypothalamic sites increased food intake (e.g., Arnt et
al., 1979; Echo et al., 2002; Stratford and Kelley, 1997; Ward et al., 2000; Wirtshafter et al.,
1993), and was reported to be mediated through GABA receptor interactions between the VTA
and NAc (Miner et al., 2010). Feeding elicited by the GABAB agonist, BAC is mediated through
GABA receptor interactions between the VTA and NAc (Miner et al., 2010). Indeed, brain DA
and cholinergic systems modulate medium spiny NAc GABA output and VTA DA output (see
reviews: Avena & Rada, 2012; Hoebel et al., 2007). Given these relationships, a central site of
action at which GABAB receptor agonism might enhance quinine-CFA is the VTA. A summary
of the proposed neuroanatomical system mediating sugar-CFP is presented in Figure 14.
2C. Clinical Implications
Food-Related Pathology: Although the etiology of obesity is complex, including both
environmental and genetic factors, obesity in humans tends to occur where cheap, highly
palatable, and energy-dense foods are readily available (Dragone, 2009). Furthermore, it has
been proposed that the apparent bias in favor of weight gain rather than weight loss may be a
result of not the body’s energy homeostasis sysems, but instead due to a bias towards meal
initiation as a result of learning, sensory and emotional cues as well as certain societal variables
(Saper et al., 2002; Schwartz et al., 2003). As such, sensory, emotional and societal stimuli
associated with palatable foods can activate potent reward systems that can override the
homestatic energy system and lead to over-consumption. Thus, understanding of the behavioral
pharmacology of learned food preferences and avoidances may be translatable to human
ingestive studies with the goal of determining the correct drug targets for therapeutic intervention
in indiviuals with obesity or other food-related behavioral pathology. Accordingly, muscarinic
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Figure 14

Figure 14. A model neuroanatomical system of a “distributed brain network” mediating the
pharmacological effects of sugar-CFP. The model system begins with the ventral tegmental area
(VTA) and its two major dopamine (DA) projections through the meso-limbic and meso-cortical
pathways. In this model, the meso-limbic DA projection terminates in the nucleus accumbens
(NAC) and amygdala (AMY) both of which possess DA D1 and D2 receptors (D1/2 R). The
meso-cortical DA projection terminates in the medial prefrontal cortex (mPFC) and medial
orbital frontal cortex (MOFC) both of which possess D1/2 R. The NAC sends GABA projections
to the mPFC and MOFC, and in turn receives glutamate (Glu) projections from those cortical
sites. Major Glu projections reciprocally innervate the AMY with the mPFC and MOFC. Further,
mixed GABA/Glu projections reciprocally innervate 5the NAC and AMY. Finally, the VTA
receives input from the NAC through the ventral pallidum (VP), from the AMY through a GLU
pathway, and from the lateral hypothalamus (LH) through an orexin (Or) projection that is in
turn innervated by a DA pathway originating in the zona incerta.
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receptor antagonists such as SCOP may be used to help reduce the associations made between
unhealthy foods or their associated environmental cues and their rewarding flavors in patients
diagnosed with pre-diabetic symptoms. Further, nicotinic receptor antagonists and GABAB
receptor agonists may be used to help enhance the negative qualities or environmental cues
associated with binge- or over-eating, effectively combatting the development of diabetes.
Food and Addictions: Animal models of consumption have shown that high-fat and/or
high-sugar foods lead to neurobiological and behavioral changes that are similar to those due to
consumption of addictive drugs including their associations with reward dysfunction (Gearhardt
et al., 2011; Davis et al., 2013) and behavioral factors such as craving and impulsivity (Murphy
et al., 2014; Meule & Kubler, 2012; Meule & Gearhardt, 2014). Accordingly, although the
behaviors assessed in this dissertation involved primarily orosensory properties, similar
associative processes play a role in the development of various addictions, for example,
alcholism. BAC (Colombo et al., 2004) or GABAB positive allosteric modulators (Maccioni et
al., 2015) were reported to suppress the acquisition and maintenance of alchol self-administration
in rats by reducing their reinforcing properties. Further, BAC has been reported to be effective
in reducing the craving aspect of alcohol addiction in a clinical study of men (Rozatkar et al.,
2016). In our studies, we found that while BAC administration failed to affect preference
learning, it significantly enhanced and prolonged quinine-CFA, suggesting its role was to
increase quinine’s avoidant properties. Given this, perhaps this dissertation research can help
explain BAC’s effectiveness in reducing alchol self-administration by means of enhancing
avoidance to the negative and toxic qualities of alcohol.
With respect to nicotine addiction, MEC has been reported to increase cessation rates in
smokers most effectively when combined with a nicotine patch (Lancaster & Stead, 2000). We
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report here that while MEC administration failed to affect preference learning, it significantly
enhanced and prolonged quinine-CFA, demonstrating the pharmacological difference between
cholinergic receptor subtype on behavior type. Our results suggest that MEC’s role was to
increase quinine’s avoidant properties, thus enhancing and prolonging the avoidance. Together
these findings suggest that MEC is a potential pharmacological agent to aid in smoking cessation
during periods of reduced intake and that this behavioral result could be also due to MEC
enhancing the negative and toxic qualities of nicotine when paired with a nicotine patch, such
that it may act to enhance the actions of the nicotine patch without having to apply it as often or
in higher doses.
In addition, a recent study reported that ADX71441, a novel GABAB receptor positive
allosteric modulator, decreased alcohol self-administration preferentially in alcohol-dependent
versus non-dependent rats and further blocked cue- and stress- induced relapse (Augier et al.,
2017), which are a result of underlying associative processes with alcohol consumption. In
comparison to BAC, ADX71441 achieved these effects in the absence of significant secondary
non-specific effects. Given the similaries in the effects of BAC versus ADX71441 in alcoholrelated behaviors, but the benefit of ADX71441’s lack of secondary non-specific effects, it
would be interesting to see how ADX71441 influences the orosensory learning procedures we
evaluated in this dissertation. If the secondary non-specific effects of BAC were interfereing
with its central effects on learning, use of ADX71441 may help to rule out this issue.
In conclusion, the results from our series of studies suggest that whereas muscarinic
cholinergic receptor signaling mediates acquisition of preferences associated with sweet and
fatty tastants, nicotinic cholinergic receptor signaling mediates acquisition of avoidances
associated with bitter tastants, in addition to GABAB receptor signaling. These results expand on
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previous literature supporting the roles of DA D1, D2 and NMDA receptor signaling in the
acquisition of preferences associated with sweet and fatty tastants and the roles of DA D2,
NMDA and opioid receptor signaling in the acquisition of avoidances associated with bitter
tastants, ultimately lending support for theories proposing the interaction of these major
neurotransmitter systems in the development of food-related learning behaviors. Interestingly,
none of the antagonists administered significantly affected the expression of these preferences or
avoidances, similar to more sparse effects for DA, glutamate and opioid systems, suggesting that
the maintenance of these learned effects maybe be more isolated with respect to neurochemistry.
Although these series of studies are limited in the extent that they examined pharmacological
effects rather than anatomical effects, they do provide support for future studies in which
anatomical substrates may be targeted. Much of the underlying processes of learning and
memory remain unclear, but it can be thought that these processes are mediated by a distributed
neural network (Figure 14), and the results of these series of studies add yet another piece to this
puzzle.
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